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SUMMARY 
 
Disorders of iron metabolism account for some of the most common human diseases, such 
as anemias and hemochromatosis. To maintain physiological iron balance, homeostatic 
mechanisms are normally in place both at the systemic and the cellular level. Cellular iron 
homeostasis is secured by Iron Regulatory Proteins (IRP) −1 and −2 through their binding to cis-
regulatory iron-responsive elements (IRE) in target mRNAs encoding proteins with key functions 
in iron metabolism. In turn, the IRE−binding activity of the two IRPs is feedback regulated by the 
cellular labile iron pool. Mouse models with IRP deficiency have contributed valuable insights 
into the in vivo roles of the IRP/IRE system as well as mammalian iron biology. However, the 
physiological consequences of gain of IRP function have so far remained unexplored. 
To investigate the importance of adequate IRP expression in vivo, we have generated a 
mouse model allowing conditional gain of IRP function using Cre/Lox technology. This new line 
expresses a flag-tagged IRP1 mutant (IRP1*), which escapes iron-mediated regulation, being 
constitutively active in its IRE binding form.  
Systemic expression of the IRP1* transgene from the Rosa26 locus yields viable animals 
with gain of IRE-binding activity in all organs that were analyzed. IRP1* alters the expression of 
IRP target genes and is accompanied by abnormal body iron distribution. Furthermore, mice 
display macrocytic erythropenia with decreased hematocrit and hemoglobin levels. Flow 
cytometric analysis of bone marrow-derived erythroid precursors also revealed impaired erythroid 
differentiation. Under standard laboratory conditions, broad spectrum phenotyping of IRP1* mice 
revealed that gain of IRP1 function does not affect their general health status. Yet, when 
challenged, mice displayed mildly altered motor coordination and reduced endurance as well as 
impaired neuromuscular transmission, suggesting a potential role of appropriate IRP activity in 
maintenance of neuromuscular function. Ex vivo, iron challenged bone marrow-derived 
macrophages showed that IRP1* expression alters the cellular response to fluctuations in iron 
levels. However, when IRP1* mice were pharmacologically administered with iron or crossed 
with a mouse model of chronic iron overload, IRP1* expression did not produce any overt 
abnormalities in the animal response to the iron challenges. 
In conclusion, this work describes the first model of gain of IRP1 function in a mammalian 
organism. This new mouse model further highlights the importance of appropriate IRP regulation 
in central organs of iron metabolism as well as for general physiology. Moreover, it opens novel 
avenues for study of diseases associated with abnormally high IRP activity, such as Parkinson’s 
disease or Friedreich ataxia. 
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ZUSAMMENFASSUNG 
 
Ein neues Mausmodell mit erhöhter Aktivität des Iron Regulatory Protein 1 
 
Störungen des Eisenstoffwechsels sind für einige der häufigsten Krankheiten des 
Menschen verantwortlich, wie etwa der Anämie und der Hämochromatose. Um eine 
physiologische Eisenbalance zu gewährleisten, spielen homöostatische Mechanismen sowohl auf 
der systemischen wie auch auf der zellulären Ebene eine wichtige Rolle. Dabei wird die zelluläre 
Eisenhomöostase durch zwei Proteine, Iron Regulatory Proteins (IRP -1 und -2), vermittelt. Dies 
geschieht durch IRP-Bindung an cis-regulatorische Elemente, iron responsive elements (IRE), in 
mRNAs die für Proteine kodieren, die ihrerseits Schlüsselfunktionen im Eisenstoffwechsel 
einnehmen. Gleichzeitig wird die IRE-bindende Aktivität der beiden IRPs mittels eines feedback 
Mechanismus durch den verfügbaren Eisenpool der Zelle reguliert. IRP-defizente Mausmodelle 
konnten bereits wertvolle Einblicke in die Rolle des IRP/IRE Systems in vivo und in die RNA-
Biologie von Säugetieren geben. Auf der anderen Seite blieben die physiologischen 
Konsequenzen einer erhöhten IRP Aktivität bislang weitgehend unbekannt. 
Zur Erforschung des Einflusses einer adäquaten IRP Expression in vivo haben wir ein 
Mausmodell generiert, das eine konditional erhöhte IRP Aktivität durch Cre/Lox Technologie 
ermöglicht. Diese neue Mauslinie exprimiert eine mit dem Flag Peptid versehene IRP1 Mutante 
(IRP1*), die unabhängig vom Eisenstatus konstitutiv in ihrer IRE bindenden Form vorliegt. 
Systemische Expression des in den Rosa26 Locus integrierten IRP1* Transgen führt zur 
Überexpression IRE-bindender Aktivität in allen analysierten Organen. IRP1* verändert die 
Expression von IRP regulierten Genen und führt zu einer anomalen Verteilung des Eisens im 
Körper. Ausserdem zeigen diese Mäuse eine makrozytäre Erythropenie mit erniedrigten 
Hämatokrit- und Hämoglobinwerten. Durch analytische Durchflusszytrometrie von 
Erythrozytenvorläufern aus Knochenmarksgewebe entdeckten wir ausserdem eine Einschränkung 
der Erythrozytendifferenzierung. Unter Standardlaborbedingungen zeigte eine  weitangelegte 
Phänotypisierung der IRP1* Mäuse dass die zusätzliche IRP1* Aktivität keinen generellen Effekt 
auf ihre Gesundheit hat. Allerdings fanden sich unter Belastungsbedingungen eine leicht 
verminderte motorische Koordination sowie reduzierte Ausdauer und gestörte neuromuskuläre 
Signalweiterleitung, was auf eine mögliche Rolle adäquater IRP-Aktivität bei der 
Aufrechterhaltung von neuromuskulären Funktionen hindeutet. Ex vivo zeigten aus Kochenmark 
gewonnene und mit Eisen oder Eisenchelatoren behandelte Makrophagen, dass die IRP1* 
Expression die zelluläre Antwort auf Schwankungen der Eisenverfügbarkeit verändert. Allerdings 
ZUSAMMENFASSUNG
   
konnten wir beobachten, dass IRP1* Mäuse die IRP1* Expression weder nach pharmakologischer 
Gabe von Eisen noch nach Kreuzung mit einem Mausmodell chronischer Eisenüberladung zu 
irgendwelchen offenkundigen Abnormalitäten bei der Reaktion auf wechselnde 
Eisenkonzentrationen führte. 
Zusammenfassend beschreibt diese Arbeit das erste Modell gesteigerter IRP1 Aktivität bei 
einem Säugetier. Dieses neue Mausmodell unterstreicht die Bedeutung der IRP Regulation in 
zentralen Organen des Eisenstoffwechsels sowie für die generelle Physiologie. Es eröffnet neue 
Möglichkeiten Krankheiten zu untersuchen, die mit anomal hoher IRP Aktivität verbunden sind, 
wie zum Beispiel Morbus Parkinson oder die Friedreichsche Ataxie. 
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1. INTRODUCTION 
 
 
1.1 Iron biology 
 
1.1.1 The light and dark side of iron biochemistry 
Iron is the second most abundant metal in the earth’s crust and is also an essential 
micronutrient for life. The high incidence of human diseases caused by imbalances of iron 
homeostasis demonstrates the biological importance (Fleming and Ponka, 2012). 
As a transition metal, iron can adopt different oxidation states of which the most common 
are ferrous (Fe2+) and ferric (Fe3+) ion forms. The ability of iron to readily accept and donate 
electrons makes iron an essential cofactor for electron transfer while its flexible coordination 
chemistry is key to its versatility in binding to biological ligands. Iron plays part in a wide range 
of biological processes either as cofactor or more often as part of prosthetic groups, for instance 
as heme and Fe-S clusters (Ponka, 1997; Sheftel et al., 2010). Hemoproteins are implicated in 
diverse biological functions such as oxygen transport (hemoglobin and myoglobin), electron 
transfer along the mitochondrial respiratory chain (cytochromes) and antioxidant defense 
(superoxide dismutase, peroxidase and catalase) (Ponka, 1997). Fe-S proteins are involved in 
electron transfer reactions as well as DNA/RNA synthesis, nucleotide metabolism, citric acid 
cycle and regulation of iron homeostasis (Rouault and Tong, 2008). 
Paradoxically, the same chemical properties that make iron biologically essential also 
underlie the toxicity of iron excess. Ferrous iron can in fact react with hydrogen peroxide and 
generate highly reactive hydroxyl radicals via Fenton chemistry (Merkofer et al., 2006): 
 
Fe2+ + H2O2  Fe3+ OH- + OH• 
 
Reactive oxygen species readily attack nucleic acids, proteins and lipid membranes leading to 
damage and eventually cell death and organ injury (Galaris and Pantopoulos, 2008). 
Hence, due to its dual nature, iron levels must be maintained in a tight physiological range 
to avoid the detrimental consequences of both iron deficiency and excess. 
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 1.1.2 Disorders of iron metabolism 
Iron mismanagement belongs to some of the most common human diseases worldwide. 
Iron deficiency mostly causes anemia, which is a major public health problem affecting billions 
of people around the globe (WHO, 2005). Commonly, insufficient dietary iron intake or heavy 
blood loss results in iron deficiency. It disproportionally affects individuals with marginal basal 
iron levels (or higher iron requirements), such as young children and menstruating or pregnant 
women (WHO, 2005). Genetic defects involving crucial iron-managing proteins are also 
recognized as causes of various forms of anemia (Andrews, 2008). 
Unlike iron deficiency, the etiology of iron-overload disorders is typically genetic, although 
environmental factors can contribute to the manifestation of the disease as in the case of 
hemochromatosis. Systemic iron accumulation typically results in unrestricted access of iron into 
organs, such as liver, heart and endocrine glands with ensuing severe tissue damage (Fleming and 
Ponka, 2012). 
At the interface between iron deficiency and iron overload is a series of pathologies 
characterized by defects of iron distribution. This can lead to iron loading in certain tissues, 
coexisting with iron deficiency in other organs. Iron mislocalization can also occur intracellularly 
where it results in abnormal iron distribution in different intracellular compartments, such as 
cytosol and mitochondria. Examples of disorders of systemic iron distribution are the acquired 
anemia of chronic disease and the inherited iron-refractory iron deficiency anemia. Both disorders 
are characterized by iron retention in the reticulo-endothelial system and iron shortage in 
interstitial fluids and plasma (Weiss and Goodnough, 2005; Finberg, 2009). Deficiency in 
proteins responsible for intracellular iron utilization leads to iron misdistribution between the 
cytoplasmic and mitochondrial compartments thereby causing degenerative diseases like 
Friedreich Ataxia (Ye and Rouault, 2010). Furthermore, localized iron accumulation has also 
been associated with and implicated in the pathogenesis of neurological disorders such as 
neurodegeneration with brain iron accumulation as well as Alzheimer’s and Parkinson’s diseases 
(Youdim, 2008; Gregory and Hayflick, 2011; Batista-Nascimento et al., 2012). 
Inadequate iron management is a common denominator of a wide spectrum of 
hematological, metabolic and neurodegenerative human diseases. To avoid the pathological 
consequences of iron imbalance, homeostatic mechanisms have evolved to tightly regulate body 
iron levels. 
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1.2 Systemic iron metabolism 
 
1.2.1 Systemic iron fluxes 
Each cell in an organism requires iron for fundamental metabolic processes. A network of 
iron fluxes exists between the sites of iron absorption (the small intestine), utilization 
(erythroblasts in the bone marrow), recycling (macrophages of the spleen) and storage (the liver) 
(Fig. 1.1). 
Primary sites of dietary iron absorption are the duodenal enterocytes. Although heme is the 
most bioavailable source of iron, the mechanism of dietary heme absorption is still ill understood 
(Hallberg, 1981). By contrast, the mechanism of inorganic iron absorption is well characterized. 
Upon reduction of dietary ferric iron by the membrane-bound ferric reductase DcytB (duodenal 
cytochrome B) (Latunde-Dada et al., 2002), ferrous iron is transported across the apical side of 
duodenal enterocytes through the transmembrane divalent metal iron transporter (DMT1) 
(Gunshin et al., 2001). On the basolateral side of the absorptive cell, iron is exported to the blood 
stream through the (sole) iron exporter ferroportin (FPN) (Abboud and Haile, 2000; Donovan et 
al., 2000; McKie et al., 2000). This step requires iron oxidization back to its ferric form by the 
multi-copper ferroxidase hephaestin (Vulpe et al., 1999). In all other cells, FPN-mediated iron 
export is assisted by the ferroxidase ceruloplasmin, which is synthetized in the liver and released 
into circulation (Harris et al., 1999). 
Once in the blood stream, iron typically circulates through the body bound to the divalent 
glycoprotein transferrin, which buffers it in a soluble and non-toxic form (Bartnikas, 2012). In 
pathological states when plasma iron exceeds the total iron binding capacity (TIBC) of serum 
transferrin, iron starts to accumulate in the form of non-transferrin bound iron (NTBI) (Brissot et 
al., 2012). All cells and tissues in the body take up iron-bound transferrin through the 
ubiquitously expressed transferrin receptor 1 (TfR1) (Cheng et al., 2004). 
About 10% of total body iron is contained within the skeletal muscle, where iron is mainly 
located in myoglobin. This hemoprotein is involved in oxygen storage and diffusion from 
capillaries to mitochondria, where cellular respiration generates the energy necessary to fuel the 
contractile activity of the muscle (Ordway and Garry, 2004). However, the majority of body iron 
(~75%) is used for hemoglobinisation of nascent red blood cells within the bone marrow (Hentze 
et al., 2004). Of note, the amount of iron used for erythropoiesis greatly exceeds the iron that is 
absorbed from the diet (Fig. 1.1); therefore iron recycling is essential to sustain the high 
erythropoietic iron needs. Continuously, senescent and damaged erythrocytes are engulfed by 
macrophages of the reticulo-endothelial system, present in the spleen, liver and bone marrow 
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(Knutson et al., 2003). In the macrophages, heme oxygenase extracts iron contained in the heme 
(Poss and Tonegawa, 1997), which is then recycled and returned to plasma transferrin. While 
macrophages of the liver, spleen and bone marrow normally hold a transient fraction of iron, the 
body iron excess is safely stored in liver hepatocytes within ferritin shells and is ready to be 
mobilized upon demand (Pantopoulos et al., 2012). 
A controlled physiological mechanism of iron excretion from the body does not exist and 
iron is normally only lost through cell shedding and minor bleeding (Hentze et al., 2010). To 
compensate for the iron losses, duodenal iron absorption must be tightly controlled to ensure that 
erythroid iron demand is met and hepatic iron stores are replete. 
 
 
Figure 1.1 Systemic iron fluxes. Schematically depicted is the distribution of total body iron content 
among tissues. Central organs of iron metabolism are represented, including the site of iron absorption (the 
duodenum), usage (erythocytes), recycling (macrophages) and storage (the liver). Values correspond to the 
approximate tissue iron content and daily fluxes of iron of an adult person. (Fe3+)2-Tf: diferric-transferrin. 
Picture modified from Hentze et al., 2004.  
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1.2.2 Systemic regulation of iron homeostasis: hepcidin 
Central coordinator of systemic iron fluxes is hepcidin, a small peptide hormone primarily 
produced in the liver. Upon synthesis, hepcidin is secreted into the blood stream where it targets 
FPN, mainly on the surface of enterocytes, macrophages and hepatocytes. Hepcidin binding to 
FPN induces its internalization and lysosomal degradation (Nemeth et al., 2004), thus directly 
inhibiting iron release into the circulation from the sites of iron absorption, recycling and storage. 
Therefore, hepcidin expression catalyzes a systemic response to reduce iron fluxes into 
circulation in iron-replete conditions. Convincing evidence of the primary importance of hepcidin 
for systemic iron balance was offered by targeted deletion of hepcidin in mice. Animals 
completely lacking hepcidin expression suffered from severe iron overload in multiple organs, 
which was concurrent with iron depletion in spleen macrophages (Lesbordes-Brion et al., 2006).   
Hepcidin production must respond to various body signals to coordinate iron absorption 
from the diet and release from the reticulo-endothelial system and the hepatic stores (Fig 1.2). 
Physiologically, hepcidin expression is modulated by systemic iron availability as both elevated 
transferrin saturation and high hepatic iron stores have been implicated in direct activation of 
hepcidin expression (Ramos et al., 2011). Conversely, erythropoietic activity and hypoxia have 
been shown to reduce hepcidin expression (Pak et al., 2006; Peyssonnaux et al., 2007), which 
allows an increase of systemic iron influx to sustain the erythropoietic iron needs. In addition, 
hepcidin also reacts to pathological stimuli (Fig 1.2). Noteworthy, hepcidin was initially 
discovered as a peptide associated to inflammation and its bactericidal properties earned it the 
original name of anti-microbial peptide (Krause et al., 2000; Park et al., 2001). Inflammatory cues 
and infection have been shown to induce hepcidin expression (Nicolas et al., 2002), thus resulting 
in restricted iron availability through a mechanism likely evolved as host-response to pathogen 
invasion. Overall, these different regulatory signals are detected and integrated by hepatocytes 
through a panel of different sensory molecules on their cell surfaces.  A network of intracellular 
signaling cascades, involving extracellular signal-regulated kinase (ERK)/ mitogen-activated 
protein kinase (MAPK), bone morphogenetic proteins (BMPs) as well as Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT), converge into the regulatory 
elements on hepcidin promoter (Fig. 1.2) (Hentze et al., 2010; Ganz and Nemeth, 2012). The 
resulting hepcidin transcriptional output is normally adequate to adjust systemic iron levels to the 
current body iron requirements.  
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Figure 1.2 Transcriptional regulation of hepcidin expression upon different stimuli. Hepcidin 
expression in hepatocytes is transcriptionally regulated by multiple signals. Intra- and extra-cellular iron 
concentration, as well as inflammation, induce hepcidin expression, while erythropoiesis represses hepcidin 
expression. On the left: putative erythroid regulators released by erythroid precursors and acting on BMP-
activated SMAD cascade, which induces hepcidin expression by binding to response elements (RE) on the 
hepcidin promoter. The BMP signaling is considered critical for hepcidin regulation in response to 
increased iron stores. Hemojuvelin (HJV) is a BMP coreceptor and can be cleaved by the matriptase 
TMPRSS6, with consequent inhibition of hepcidin expression. In the middle: upon increased transferrin-
iron binding to TfR1, HFE is displaced and binds to TfR2 (IRE-free TfR1 homolog, preferentially 
expressed in the liver), thereby activating hepcidin expression via ERK/MAPK and SMADs signaling. On 
the right: inflammatory cytokines, such as interleukin 6 (IL6), activate hepcidin transcription via the 
Jak/STAT pathway. (Hentze et al., 2010) RBCs: red blood cells. Picture modified from Hentze et al., 2010. 
 
 
Being central to the regulation of systemic iron homeostasis, it is not surprising that failure 
to modulate hepcidin expression results in life threatening diseases with systemic iron overload, 
such as hereditary hemochromatosis (HH) (Camaschella, 2005). The underlying cause of HH is 
an inappropriately low synthesis of hepcidin, which leads to FPN overexpression on the surface 
of enterocytes and macrophages. Consequently, dietary iron is absorbed and released into the 
blood in an uncontrolled manner, thus rising, over time, transferrin saturation. Accordingly, NTBI 
starts to build up in the plasma and also accumulates in parenchymal organs, such as liver, heart 
and pancreas. If not treated with iron-depletion therapies, like phlebotomy, HH can lead to fatal 
complications such as liver cirrhosis, heart failure and diabetes (Pietrangelo, 2010).  
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Family studies of HH patients have implicated four genes, besides HAMP (hepcidin) itself 
(Roetto et al., 2002), in the etiology of the disorder. These include genes encoding sensory 
molecules located on hepatocyte surface such as HFE (Simon et al., 1977; Feder et al., 1996), 
transferrin receptor-2 (TfR2) (Camaschella et al., 2000) and hemojuvelin (HJV) (Papanikolaou et 
al., 2003), which thus emerged as critical regulators of hepcidin expression (Fig. 1.2). In addition, 
hepcidin’s molecular target FPN, when mutated on aminoacid residues responsible for hepcidin 
interaction, determines a rare and dominant form of HH characterized by hepcidin resistance 
(Montosi et al., 2001; Njajou et al., 2001). Mouse models of the HH disease exist in which Hamp, 
Hfe, TfR2, Hjv and Fpn have been individually mutated (Donovan et al., 2005; Huang, 2005; 
Kawabata et al., 2005; Niederkofler, 2005; Lesbordes-Brion et al., 2006; Zohn et al., 2007; Vujić 
Spasić et al., 2008). Their study, complemented by biochemical in vitro approaches, has allowed 
the outlining of the molecular mechanisms regulating hepcidin activation as well as the dynamics 
of hepcidin-mediated regulation. 
 
 
1.3 Cellular iron metabolism 
 
A network of iron fluxes is not only present at the systemic level and also cellular iron 
homeostasis comprises analogous tasks of iron import, utilization, storage and export (Fig. 1.3). 
Depending on the cell-type, some of these tasks involve different molecular players, which 
reflects the tissue-specificities of systemic iron metabolism. 
 
 
1.3.1 Cellular iron uptake 
Iron circulates in the blood stream mainly bound to transferrin; thus, cellular iron uptake 
typically occurs via binding of diferric-transferrin to high-affinity TfR1 and subsequent clathrin-
dependent internalization of the whole complex (Fig. 1.3) (Chen and Paw, 2012). Following 
acidification of the endocytosed vesicles, ferric iron is released from transferrin (Dautry-Varsat et 
al., 1983) and reduced to its ferrous form by the STEAP family of metalloreductases (Ohgami et 
al., 2005, 2006). Ferrous iron is then transported into the cytoplasm through the DMT1 iron-
channel. Hence, DMT1 has a dual function: as key absorpting molecule transporting dietary iron 
across the apical membrane of duodenal enterocytes as well as, in all other cell-types, acting as 
endosomal protein involved in the iron transfer from the endosome to the cytosol. Inactivation of 
DMT1, both in mice and humans, leads to iron deficiency anemia due to impaired intestinal iron 
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absorption and usage by the erythron (Fleming et al., 1997; Gunshin et al., 2005; Mims et al., 
2005). Following iron release, the vescicles containing apo-transferrin and TfR1 are recycled 
back to the cellular surface where apo-transferrin is released into the circulation and TfR1 is 
ready for a new cycle (Fig. 1.3). Although ubiquitously expressed, the major role of TfR1 resides 
in maturing erythroblasts that highly express it on their surface to take up large amounts of iron 
required for hemoglobin synthesis. Targeted disruption of TfR1 in mice leads to embryonic 
lethality, mainly due to erythropoietic defects. This demonstrates that TfR1 is essential for 
erythropoiesis but can be dispensable for iron acquisition in non-erythroid cells (Levy et al., 
1999). As previously mentioned, iron can be also acquired in the form of heme and NTBI. 
Biochemical and genetic studies have proposed several molecular candidates for both heme and 
NTBI uptake (Hentze et al., 2010), which suggests redundancy in the underlying mechanisms 
rather than an exclusive pathway. 
 
 
Figure 1.3 Cellular iron metabolism. Depicted are the main pathways of iron uptake, utilization, storage 
and export in a generic cell. DCYTB: duodenal cytochrome B; Tf: transferrin; TfR1: transferrin receptor 
1; LIP: labile iron pool; CIA: cytosolic iron-sulfur cluster assembly machinery; ETC: electron transport 
chain; TCA cycle: tricarboxylic acid cycle; FECH: ferrochelatase; FXN: frataxin; GLRX5: glutaredoxin 5; 
ISCU: iron-sulfur cluster scaffold protein; PPIX: protoporphyrin IX; Mfrn: mitoferrin; FLVCR: Feline 
leukemia virus subgroup receptor -1 (heme exporter); SLC48A1: solute carrier family member 48A1 (the 
only bona fide heme importer identified so far) (Rajagopal et al., 2008). Picture modified from Hentze et 
al., 2010. 
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1.3.2 Cellular iron utilization 
Independent of the mechanism of cellular uptake, once in the cytosol iron is mainly routed 
to the major site of cellular iron usage, i.e. the mitochondria. Iron is transported into the 
mitochondria by members of the mitochondrial solute carrier family, i.e. mitoferrin -1 and -2 
(Shaw et al., 2006; Paradkar et al., 2009). Once inside the mitochondrial organelle, iron is used to 
produce heme and Fe-S clusters (Fig. 1.3). 
The biogenesis of heme comprises a series of steps, some of which occur in the cytoplasm. 
The rate limiting step of heme synthesis is catalyzed by the mitochondrial matrix enzyme 5-
aminolevulinic acid synthase (ALAS). Two isoforms of ALAS exist, produced either by the 
ubiquitously expressed (housekeeping) gene hALAS or by the erythoid-specific eALAS. 
Dysfunction of eALAS in humans results in impaired heme sysnthesis and leads to X-linked 
sideroblastic anemia, a disease characterized by ineffective erythropoiesis and mitochondrial iron 
deposition in maturing erythroblasts (Cotter et al., 1992). The last step of heme synthesis is the 
insertion of ferrous iron into the protoporphyrin ring by mitochondrial ferrochelatase (Dailey et 
al., 1994). Shortage of ferrochelatase activity in humans causes toxic accumulation of 
protoporphirin IX that results in erythropoietic protoporphyria (Lamoril et al., 1991). 
Besides heme, iron is used in the mitochondria to generate another important cofactor, the 
Fe-S cluster. The biogenesis of Fe-S cluster has been extensively studied in prokaryotic and yeast 
models (Vickery and Cupp-Vickery, 2007; Lill and Mühlenhoff, 2008), leading to the discovery 
of many crucial players of this biosynthetic machinery. The validity of the proposed molecular 
players has been subsequently confirmed and further emphasized in higher eukaryotes, including 
animal models and human patients with defective Fe-S cluster biogenesis (Rouault and Tong, 
2008; Sheftel et al., 2010). In essence, the process includes a series of early events that leads to 
the synthesis of Fe-S cluster intermediate on a scaffold protein called ISCU (Agar et al., 2000). 
During this early phase, the protein frataxin (FXN) has been proposed to take part as possible 
iron-donor (Bulteau et al., 2004). Once assembled on ISCU, the transient Fe-S cluster must be 
transferred and coordinated onto apoproteins through a process assisted by glutaredoxin-5 
(GLRX5) (Mühlenhoff et al., 2003). In contrast to mitochondrial Fe-S proteins, it is still unclear 
how Fe-S clusters are coordinately assembled on cytosolic and nuclear apo-protein. A cytosolic 
assembly machinery (called CIA) has been identified (Lill and Mühlenhoff, 2008), which seems 
to be connected to the mitochondrial apparatus at least via one component, the ABC transporter 
ABCB7. In fact, ABCB7 is located in the mitochondrial inner membrane and transports an 
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unknown intermediate “x”, containing the sulfur moiety necessary for the formation of cytosolic 
and nuclear Fe-S cluster proteins (Kispal et al., 1997). Defects in the Fe-S cluster biogenesis 
machinery not only impair the function of Fe-S cluster containing enzymes, but also lead to 
deregulation of cellular iron metabolism (Richardson et al., 2010). Remarkably, mutations of 
some specific components, such as FXN, ISCU, GLRX5 and ABCB7, have been associated with 
hematological and neurodegenerative disorders (see 1.5.4) (Campuzano et al., 1996; Camaschella 
et al., 2007; Mochel et al., 2008; Olsson et al., 2008; Bekri et al., 2009). 
 
 
1.3.3 Cellular iron storage 
Iron exceeding the cellular needs can be either exported or safely stored in a redox-inactive 
form inside ferritin shells (Fig. 1.3). Heteropolymers of 24 ferritin heavy (FTH) and light (FTL) 
subunits can accommodate up to 4500 iron atoms (Harrison and Arosio, 1996). The iron, which 
has been proposed to be chaperoned to ferritin by PCBP1 [poly(rC)-binding protein-1] (Shi et al., 
2008), is first oxidized by FTH, while FTL provides a nucleation center for its deposition. Despite 
being ubiquitously expressed, FTH and FTL levels vary among tissues, with FTH being 
predominant in the heart while FTL is expressed mostly in the liver (Arosio et al., 1976). A 
mitochondrial form of ferritin also exists, encoded by a distinct nuclear gene and with a very 
restricted tissue expression (Levi et al., 2001). Although its cellular role in normal conditions 
remains elusive, mitochondrial ferritin levels are found to be increased in sideroblastic anemia 
(Arosio and Levi, 2010). In addition, a glycosilated form of FTL is secreted into the serum 
(Meyron-Holtz et al., 2011); recent experiments in mice suggested that serum FTL derives 
primarily from macrophages, but its physiological function is still unclear (Cohen et al., 2010). 
Serum FTL is elevated in systemic iron loading and inflammation (Torti and Torti, 1994) and is 
commonly used as clinical marker of body iron stores. In the cell, iron stored in ferritin can be 
mobilized for metabolic purposes upon lysosomal or proteasomal ferritin degradation (Rudeck et 
al., 2000; Zhang et al., 2010). By sequestering redox-active iron, ferritin plays a fundamental role 
as cellular antioxidant. Its expression is regulated both transcriptionally (via antioxidant response 
elements, among others) and post-transcriptionally (Torti and Torti, 2002). Recently, an internal 
ribosome entry site (IRES) has been found within the untranslated region (UTR) of FTL mRNA, 
which suggests that FTL translation might be promoted under stress conditions (Daba et al., 
2012). The biological importance of ferritin is further emphasized by the embryonic lethality of 
genetic deletion of FTH in mice (Ferreira et al., 2000), while its conditional ablation in the 
hepatocytes results in iron-induced oxidative damage of the liver (Darshan et al., 2009). In 
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humans, mutations of FTL are associated with a neurodegenerative disorder, i.e. ferritinopathy, 
characterized by brain iron overload and ferritin inclusion bodies in the nucleus of cells mainly 
belonging to the central nervous system (Curtis et al., 2001). 
 
 
1.3.4 Cellular iron export 
Cellular iron export removes excess iron that is neither used nor stored by the cell. In 
specialized cells, such as duodenal enterocytes and macrophages, iron export is instrumental in 
maintaining adequate plasma iron levels. As previously mentioned (see 1.2.1), iron export occurs 
through the only known iron export channel in vertebrates, FPN (Fig. 1.3) (Abboud and Haile, 
2000; Donovan et al., 2000; McKie et al., 2000). Targeted disruption of FPN in mice is 
embryonic lethal (Donovan et al., 2005), which reflects its unique function as the sole iron 
exporter. Besides elemental iron, cells may also export iron bound to ferritin (through a yet 
elusive mechanism) as well as heme. FLVCR1 (Feline leukemia virus subgroup receptor -1) 
facilitates heme export in differentiating erythroblasts and in macrophages, thus maintaining 
proper iron levels for erythropoiesis as well as ensuring heme iron recycling, respectively (Keel et 
al., 2008). While mice with FLCVR1 ablation die embryonically and lack definitive 
erythropoiesis, FLCVR1 deletion after birth causes severe macrocytic anemia associated with an 
early erythropoietic blockade (Keel et al., 2008). 
 
 
At the crossroad between the intracellular fluxes of iron uptake, usage, storage and export 
lies the labile iron pool (LIP) (Fig. 1.3). The LIP is a redox-active form of iron serving immediate 
metabolic needs (Breuer et al., 2008) and is localized both in the cytoplasm and the mitochondria 
(Rauen et al., 2007). Coordination of cellular iron fluxes is necessary to ensure that cellular iron 
requirements are met, while avoiding the expansion of the redox active iron pool. The LIP, whose 
size mirrors the intracellular iron content, is the iron entity that can be sensed by the cellular iron 
homeostatic machinery (Wang and Pantopoulos, 2011). 
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1.4 Regulation of cellular iron metabolism 
 
The maintenance of cellular iron homeostasis is orchestrated by an iron-sensitive post-
transcriptional regulatory machinery modulating the expression of key proteins involved in 
cellular iron metabolism. The system is driven by iron regulatory proteins (IRPs) -1 and -2 
through their binding to cis-iron regulatory elements (IREs) located within the 5’- or 3’- UTR of 
the target mRNAs (Hentze et al., 2010; Anderson et al., 2012). A combination of biochemical, 
mutagenetic and structural approaches has allowed extensive in vitro exploration of the 
characteristics, function and regulation of this conserved cellular homeostatic machinery. 
 
 
1.4.1 The structure of the IREs and the IRPs 
IREs are evolutionarily conserved RNA hairpin structures of about 15-30 nucleotides 
contained in the UTR of various mRNAs. A typical IRE is defined by both sequence and structure 
(Bettany et al., 1992; Theil, 1994) and consists of a 6-nucleotide apical loop on a stem of 5 paired 
nucleotides, separated by an unpaired cytosine bulge from a lower stem of variable length (Fig. 
1.4) (Hentze et al., 1988; Addess et al., 1997). Study of the phylogenetic distribution of the IRE 
element of different genes revealed that the structure of the ferritin IRE might be the ancestral 
version that was then adopted by other genes through convergent evolution (Piccinelli and 
Samuelsson, 2007). 
 
 
Fig. 1.4 IRE secondary structure. A) The secondary structure of a schematic consensus IRE is shown. 
The 6 nucleotide upper loop usually contains a sequence CAGYGX, with Y being either a U or a C and X 
representing any residue except G. The upper stem contains 5 paired nucleotides consisting of variable 
residues (N). The stem below the unpaired cytosine can have variable length. B) The nuclear magnetic 
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resonance structure of the consensus IRE is depicted (Addess et al., 1997). The 6-nucleotide conserved 
sequence form an apical loop sitting on top of two A-conformation helical stems. The upper stem seems to 
work as a molecular ruler to orient the C bulge and the loop for optimal interaction with the IRPs. Figure 
adopted from Rouault, 2006. 
 
 
IRP1 and IRP2 are ubiquitously expressed proteins and members of the gene family of 
aconitases  (Gruer et al., 1997), which catalyze the conversion of citrate to iso-citrate in the 
tricarboxylic acid (TCA) cycle. It appears that the IRP1 gene diverged from mitochondrial 
aconitase (mACO) following an early duplication event and subsequent acquisition of the IRE-
binding function. In turn, IRP2 originated from a second duplication in higher eurkaryotes , but 
lost the aconitase activity some time during evolution (Gruer et al., 1997). The aconitase function 
of IRP1 is analogous to the enzymatic activity of mACO (Kennedy et al., 1992), but, in contrast 
to the mACO, IRP1 is prone to Fe-S cluster loss upon iron depletion (Rouault et al., 1992). The 
crystal structure of IRP1 in the cytosolic aconitase form (Fig. 1.5A) confirmed the high similarity 
with mACO (Dupuy et al., 2006), which was predicted on the basis of the sequence conservation 
(Rouault et al., 1991). Similar to mACO, IRP1 contains four globular domains, with a cleft 
formed at the interface between domains 1-3 and 4 (Dupuy et al., 2006). The Fe-S cluster is 
bound inside the cleft, which constitutes the aconitase catalytic site. Disassembly of the Fe-S 
cluster, upon iron depletion, leads IRP1 to switch to an open conformation and expose its IRE-
binding site (Fig. 1.5B) (Walden et al., 2006). The conversion of IRP1 between cytosolic 
aconitase and RNA-binding conformations is reversible, making IRP1 a bifunctional protein 
(Rouault et al., 1992). Mutagenesis experiments have revealed that three cysteins (C437, C503 
and C506) are responsible for Fe-S cluster coordination and whose substitution turns IRP1 into a 
constitutive IRE-binding protein (Philpott et al., 1993; Hirling et al., 1994). Experimental 
approaches including mutagenesis, crosslinking and chemical modification of IRP1 indicated that 
the aconitase active site and the RNA-binding site overlap (Hirling et al., 1994; Basilion et al., 
1994; Philpott et al., 1994), thus making the two IRP1 activities mutually exclusive. These earlier 
evidences have been then validated by comparison of the crystal structures of the cytosolic 
aconitase and the IRP1 bound to IRE (Fig. 1.5) (Walden et al., 2006). From analysis of the two 
crystal structures, it is evident that the switch of IRP1 between the two forms is associated with 
extensive conformational rearrangements. Although IRP2 has not been crystallized yet, the 
structural definition of the IRP1-IRE complex has enabled modeling of the structure of IRP2 
(Zumbrennen et al., 2009). Despite the great degree of identity (~64%) between the two IRPs, 
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IRP2 does not assemble a Fe-S cluster and does not retain aconitase active-site residues (Dupuy et 
al., 2006). Also, close to its N-terminus, IRP2 contains a cystein- and proline-rich stretch of 73 
amino acids, which is encoded by a separate exon and appears to be unstructured. Initially 
thought to be involved in iron-mediated degradation of IRP2 (Iwai et al., 1998), the role of this 
specific structural characteristic for IRP2 function is unknown. 
Both IRP1 and IRP2 bind IRE sequences with very high affinity (Butt et al., 1996). This 
was shown using electrophoretic mobility shift assays (EMSAs) with radiolabeled and in vitro 
transcribed IRE sequences as bait to “fish” active IRE-binding IRPs. There is a hierarchy in the 
binding affinities of different IRE sequences to the IRPs (Goforth et al., 2010), suggesting a 
differential regulation of distinct IRP-target genes according to various biological situations. 
 
 
Figure 1.5 Crystal structure of cytosolic aconitase and the IRP1-IRE complex. A) Represented is the 
crystal structure of IRP1 in its closed conformation bound to the Fe-S cluster. B) Upon Fe-S cluster 
disassembly, IRP1 assumes an open conformation and accommodate the IRE. To help the conformational 
change, a flexible hinge linker (in black) connects domains 1-3 to domain 4. Figures adopted from Dupuis 
et al., 2006 (cytosolic aconitase) and Walden et al, 2006 (IRP1-IRE complex). 
 
 
1.4.2 IRP/IRE post-transcriptional regulation of “iron-genes” 
IRPs and IREs work together to modulate the expression of key iron metabolism genes and 
coordinately regulate iron uptake, storage and export (Fig. 1.6). Typical targets of IRP post-
transcriptional regulation are mRNAs encoding proteins involved in iron uptake (TfR1 and 
DMT1), utilization (eALAS), storage (FTL and FTH) and export (FPN) (Hentze et al., 2004). The 
interaction of the IRPs with IRE hairpin structures is promoted under iron-scarce conditions and 
abolished during iron repletion by different mechanisms (see 1.5.2). Binding of the IRPs to 5’-
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IRE mRNAs (e.g. FTL and FPN) hinders the recruitment of the small ribosomal subunit, 
preventing translational initiation of the target mRNA (Muckenthaler et al., 1998). Conversely, 
IRP binding to 3’-IRE mRNAs (eg. TfR1) stabilizes the target mRNA against degradation 
(Hentze and Kuhnt, 1996). Therefore, the IRP-IRE interaction enhances TfR1-mediated iron 
uptake while diminishing storage into ferritin and export through FPN. Consequently, cellular 
iron availability increases, rescuing the cell from iron starvation. Conversely, in iron-replete 
conditions, iron uptake is decreased due to TfR1 mRNA degradation, while safe storage and 
export are promoted by actively translated ferritin and FPN, respectively. Therefore, loss of IRP-
IRE interaction under iron sufficiency prevents dangerous surfeit of redox active iron. 
 
 
Figure 1.6 The IRP/IRE system. In iron-deficient cells (right) IRPs are active and bind IRE-containing 
mRNAs within their 3’ or 5’ UTR, thus determining stabilization of the target (e.g. TfR1) or translational 
repression (e.g. ferritin -H and -L, ferroportin). Upon iron-repletion (left), the interaction between IRPs and 
the IRE-targets is prevented as IRP1 is mainly converted to cytosolic aconitase by Fe-S cluster assembly, 
while IRP2 is targeted for proteasomal degradation via the E3 ubiquitin-ligase complex (see 1.4.3). Picture 
modified from Hentze et al., 2010. 
 
 
1.4.3 Regulation of IRP activity 
For the IRP/IRE system to efficiently coordinate cellular iron fluxes, IRP activity must be 
coupled to the cellular iron status. The cellular iron pool regulates IRE-binding of the two IRPs 
through distinct mechanisms (Fig. 1.6).  
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The reversible Fe-S cluster switch is the main mechanism regulating IRP1 activity 
(Paraskeva and Hentze, 1996); under physiological iron (and oxygen) conditions, IRP1 
predominantly exists in the cytosolic aconitase form (Meyron-Holtz et al., 2004a, 2004b). The 
cytosilic aconitase pool can be up to 100-fold more abundant then the IRE-binding form of IRP1 
(Chen et al., 1997), thus representing a large latent pool of activatable IRP1.  This reserve of IRE-
binding activity could in principle allow a faster IRP-regulatory response upon substantial cellular 
demand. However, there is at most a 4-fold increase in IRP1 IRE-binding activity in response to 
iron deficiency (Chen et al., 1997). The biological significance of such an excess of cytosolic 
aconitase activity remains unanswered, especially in the light of the lack of abnormalities 
following IRP1 ablation in mice (see 1.5). 
By contrast to IRP1, IRP2 is regulated in an irreversible manner at the level of protein 
stability. This has recently been shown to involve FBXL5 (F-box and leucine-rich repeat protein 
5), which is part of an E3 ubiquitin-ligase complex and contains an iron-sensitive hemerythrin-
like domain (Salahudeen et al., 2009; Vashisht et al., 2009). In iron/oxygen deficient conditions, 
the diiron centre of the hemerythrin domain is destabilized, which results in FBXL5 degradation 
and IRP2 stabilization (Chollangi et al., 2012; Shu et al., 2012; Thompson and Bruick, 2012). 
Upon iron/oxygen repletion, accumulating FBXL5 interacts with IRP2 and targets it for 
proteasomal degradation (Salahudeen et al., 2009; Vashisht et al., 2009). While IRP1 is mainly 
regulated by the reversible Fe-S cluster switch, apo-IRP1 (the RNA-binding form of IRP1) is also 
targeted by FBXL5 (Salahudeen et al., 2009; Vashisht et al., 2009). This might represent a safety 
mechanism to avoid excessive activation of IRP1-IRE binding in conditions when the Fe-S 
cluster biogenesis is impaired. 
Besides inorganic iron and Fe-S cluster, a series of iron-dependent, like heme (Ishikawa et 
al., 2005),  and iron-independent mechanisms, like phosphorylation, oxygen and nitrogen reactive 
species (Drapier et al., 1993; Eisenstein et al., 1993; Pantopoulos et al., 1997), regulate the 
activity of the two IRPs (Anderson et al., 2012). The ability of IRPs to respond to multiple signals 
indicates their capacity to modulate their activity in response to a wide range of physiological 
conditions, thereby maintaining optimal cellular iron balance. 
 
 
1.4.4 Expanding the IRP regulon 
IRE motifs were initially identified in the 5’ and 3’ UTR of ferritin and TfR1 (the latter 
being the only mRNA found to possess multiple IREs), respectively, and in other genes 
connected to iron metabolism, including DMT1, eALAS and FPN (Hentze et al., 2004). Of note, 
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genes apparently less related to iron metabolism also contain IRE sequences, including the 
mitochondrial aconitase (mACO – TCA cycle) (Kim et al., 1996), Cdc14A (mitotic phosphatase – 
cell cycle) (Sanchez et al., 2006), MRCK (Cdc42-binding kinase  – cytoskeleton remodeling) 
(Cmejla et al., 2006), HIF2 (hypoxia-inducible factor 2 - hypoxia adaptation) (Sanchez et al., 
2007a), -amyloid precursor protein (APP – Alzheimer’s disease) (Rogers et al., 2002), -
synuclein (Parkinson’s disease) (Friedlich et al., 2007) and Drosophila succinate dehydrogenase 
(Kohler et al., 1995) (SDH – TCA cycle and mitochondrial electron transport chain). The 
definition of the structural requirements for IRPs recognition of IRE elements has been 
instrumental in the identification of genes containing IRE-like motifs. Most of these discoveries 
are based on directed approaches during the study of iron-regulated genes and specific 
bioinformatic searches (Dandekar et al., 1998; Campillos et al., 2010). More recently, a 
systematic transcriptome-wide approach has allowed the identification of 35 novel putative IRE-
containing mRNAs (Sanchez et al., 2011). The experimental strategy included immunoselection 
of IRP-IRE ribonucleoprotein complexes from mouse tissues, followed by microarray 
identification of the mRNA composition and bioinformatic identification of IRE-like motifs 
(Sanchez et al., 2011). While the role of many of these IREs still remains to be determined in 
vivo, the presence of IRE sequences in such a variety of genes is suggestive of a much broader 
competence of the IRP/IRE regulatory system beyond iron metabolism per se. 
 
 
1.5 The IRP/IRE system in physiology and disease 
 
The IRP/IRE regulatory system has been extensively studied in cultured cells, forming the 
basis for the molecular understanding of its central importance in cellular iron homeostasis (see 
1.4). In addition to maintaining cellular iron balance, the role of the IRP/IRE system has also 
important implications on systemic processes, including erythropoiesis, duodenal iron absorption 
and liver iron storage. Most of the knowledge that we currently have regarding the role of the 
IRP/IRE system in body physiology has been gained through the generation of animal models 
with IRP1 and IRP2 ablation. Mice lacking either of the two IRPs are viable and fertile, 
demonstrating that IRP1 and IRP2 can largely compensate for each other (LaVaute et al., 2001; 
Meyron-Holtz et al., 2004a; Galy et al., 2005b). Interestingly, IRP1-deficient mice display no 
overt phenotypic abnormalities under standard laboratory conditions, whereas mice with 
constitutive IRP2 deficiency exhibit altered body iron distribution and microcytic anemia 
(Cooperman et al., 2005; Galy et al., 2005b). These findings suggest a predominant role of IRP2 
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in the regulation of iron metabolism. However, ablation of both IRPs leads to embryonic lethality 
at blastocyst stage, showing that the IRP/IRE system is essential for viability (Smith et al., 2006; 
Galy et al., 2008). To study the effects of double IRP deficiency in vivo and overcome the 
embryonic lethality of double IRP ablation, mouse lines with tissue-specific deletion of the IRPs 
have been generated (Galy et al., 2008, 2010; Ferring-Appel et al., 2009). Together with the 
systemic IRP2 deficiency, models with conditional ablation of IRPs have provided fundamental 
insights into the role of the IRP/IRE system in key tissues involved in systemic iron metabolism, 
as discussed below. 
 
 
1.5.1 The IRP/IRE system in erythropoiesis 
Most of the iron in the body is employed in the erythropoiesis. Circulating erythrocytes 
carry hemoglobin-bound oxygen and deliver it to all cells in the body, thus securing proper 
oxygenation of the tissues. A feedback loop exists that modulates the erythropoietic activity 
according to the degree of tissue oxygenation. In the kidney hypoxia-inducible factor 2 (Hif2), 
which is a known IRP-target gene (Sanchez et al., 2007b), is the major oxygen sensor that 
transcriptionally regulates the expression of the hematopoietic hormone erythropoietin (EPO) 
(Scortegagna et al., 2003a, 2003b). In normoxia, Hif2 has a very short half-life because it is 
hydroxylated by the prolyl-hydroxylases (PHDs) and targeted for proteasomal degradation  
(Kallio et al., 1999). Under low oxygen and iron concentration (as iron is a PHD cofactor), PHD 
activity is reduced, thus resulting in HIF2stabilisation (Semenza, 2011). Accumulated HIF2 
translocates into the nucleus where it directly binds (as heterodimer with the constitutively 
expressed HIF1 subunit) to the hypoxia response elements (HRE) on the EPO promoter, thereby 
activating EPO expression (Warnecke et al., 2004). EPO secretion results in a direct stimulation 
of the proliferation and maturation, in the bone marrow, of early hematopoietic precursor cells 
expressing the EPO receptor on their surface (Fraser et al., 1988). As a consequence, an increased 
number of mature erythrocytes is released into the circulation with an ensuing net increase of the 
oxygen-carrying capacity of the blood. 
Systemic ablation of HIF2 in mice leads to anemia (Gruber et al., 2007), while conditional 
deletion in hepatocytes, as second minor source of EPO (Koury et al., 1991; Fandrey, 2004) 
specifically reduce hepatic EPO expression (Rankin et al., 2007). In addition to the PHD-
mediated post-translational regulation, HIF2 is also subjected to IRP-mediated translational 
regulation due to an IRE in the 5’UTR of its mRNA (Sanchez et al., 2007b). In kidney cells, 
under low iron conditions, IRP-driven translational repression of HIF2 may thus lead to 
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decreased EPO synthesis and diminished erythropoietic activity (Fig. 1.7). Hence, the IRP/IRE 
system has potential to control EPO expression via HIF2 and reduce the rate of red blood cell 
production in conditions of scarce iron availability. Because iron is necessary for the synthesis of 
heme and hemoglobin, this would avoid the generation of microcytic (smaller) and hypochromic 
(with low hemoglobin) erythrocytes. While the regulatory loop including IRP- HIF2-EPO and 
erythropoiesis has not been demonstrated in vivo, mice with systemic ablation of IRP2 develop 
microcytic anemia (Cooperman et al., 2005; Galy et al., 2005b). However, when the IRP2 
deficiency is limited to either hepatocytes, enterocytes or macrophages, mice do not display any 
hematological abnormalities (Ferring-Appel et al., 2009). Therefore, the macrocytic anemia of 
IRP2 KO mice is considered to be principally due to a local defect in maturing erytroblasts. 
 
Developing erythroid cells in the bone marrow have very special iron requirements as they 
need to continuously uptake large amounts of iron to ensure heme and hemoglobin synthesis and 
finalize their maturation. To achieve this task, erythroid precursors highly express TfR1 on their 
surface, allowing avid iron uptake. The importance of Tfr1-mediated iron uptake for 
erythropoiesis is highlighted by mouse models with deficiency of transferrin (the serum iron-
carrier) or TfR1 (necessary for transferrin-bound iron uptake). Hypotransferrinemic mice display 
severe anemia with microcytic hypochromic erythrocytes and tissue iron deposition (Trenor et al., 
2000), showing that while other cells in the body have alternative ways for NTBI uptake, 
erythroid precursors rely on transferrin-bound iron uptake. TfR1-deficiency in mice results in a 
more severe phenotype, which affects both erythropoiesis and neurological development (Levy et 
al., 1999). Connected to its function in the transferrin cycle, where DMT1 exports iron from the 
the endocytic vescicle to the cytoplasm, DMT1 mutant mice display impaired iron uptake into 
erythroblasts (Fleming et al., 1998). As both TfR1 and DMT1 are IRP target genes, their IRP-
mediated stabilization (via the 3’IRE in their mRNAs) in erythrocyte precursors could promote 
iron-uptake and facilitate their maturation process (Fig. 1.7). Consistently, the macrocytic anemia 
of IRP2 KO mice is associated with decreased TfR1 mRNA and iron levels in the bone marrow 
(Cooperman et al., 2005; Galy et al., 2005b), thus showing a failure to stabilize TfR1 against 
degradation and a consequent impaired iron uptake in IRP2 KO erythroblasts. The bone marrow 
of IRP2 KO mice also contained higher levels of ferritin, which is consistent with loss of IRP-
mediated translational repression (Cooperman et al., 2005; Galy et al., 2005b). Ferritin 
upregulation could contribute to the hematological defect of IRP2 KO mice by sequestering 
intracellular iron and preventing its use for hemoglobin production (Fig. 1.7). 
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In maturing erythroblasts, TfR1, ferritin and eALAS synthesis must be especially 
coordinated to guarantee efficient production of hemoglobin. A study on primary murin erythroid 
progenitors showed an apparent uncoupling of ferritin and eALAS synthesis compared to the 
IRP/IRE regulatory paradigm (Schranzhofer et al., 2006). Under conditions of IRP activation, 
TfR1 levels were enhanced and ferritin repressed, which is consistent with IRP-mediated 
stabilization of TfR1 and repression of ferritin via their 3’- and 5’- IREs, respectively. However, 
eALAS was efficiently translated despite a 5’IRE. To explain this unexpected finding, the authors 
proposed a mechanistic hypothesis accounting for the massive transcripition of eALAS in 
maturing erythroblast which may lead to an excess of IRE sites over available IRP molecules 
(Schranzhofer et al., 2006). In addition, the eALAS-IRE has a lower binding affinity to IRPs 
compared to the IRE sequences of ferritin and TfR1 (Cox et al., 1991). This may allow eALAS to 
escape IRP-mediated repression under the experimental conditions (Schranzhofer et al., 2006). 
The results of this ex vivo study are still a bit controversial when compared to the findings of 
others research. In support of the importance of IRP-mediated regulation of eALAS, primary 
erythroid precursors from IRP2 KO mice display a strong increase in eALAS expression and 
accumulation of protoporphirin IX (Cooperman et al., 2005). This suggests that IRP-mediated 
repression of eALAS may avoid the production and toxic accumulation of heme-intermediates 
under iron scarce conditions. Also, although IRP1 KO mice have normal blood values, the 
macrocytic anemia of IRP2 KO mice is more severe when one of the two IRP1 alleles is mutated 
in addition (Smith et al., 2004). This indicates also IRP1 has a role in erythropoiesis like IRP2. 
Moreover, the importance of IRP1 for hemoglobin synthesis is shown in a zebrafish model with a 
secondary abnormal increase of IRP1 activity (Wingert et al., 2005). IRP1 activation due to a 
primary defect in Fe-S cluster synthesis (caused by Glrx5 deletion) and, with genetic 
complementation assay, shown to directly reduce eALAS expression and cause anemia (Wingert 
et al., 2005). 
 
Regulation of iron export in erythroid precursors may also play a role in erythropoiesis 
along with iron uptake, sequestration and use for hemoglobin synthesis. In support of this 
argument, FPN has recently been shown to be expressed also in erythroblasts (Zhang et al., 2009). 
Bearing an IRE within its 5’UTR, FPN is normally subjected to IRP-mediated translational 
repression (Abboud and Haile, 2000; Donovan et al., 2000; McKie et al., 2000). Hence, FPN 
synthesis and function in erythroblasts would only be allowed upon intracellular iron 
accumulation and ensuing IRP inactivation. Therefore, FPN expression in erythroid precursors 
may represent a safety valve to avoid toxic iron accumulation in cases when the rate of iron 
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uptake exceeds iron usage in the mitochondria. Being also subjected to hepcidin-mediated 
translational regulation, FPN is degraded by hepcidin upon increased plasma iron levels (Zhang et 
al., 2011). Conversely, upon systemic iron depletion, FPN expression in erythroid precursors is 
reduced to possibly partially suppress erythropoiesis when non-erythropoietic tissues risk  to 
develop iron deficiency (Zhang et al., 2011). Intriguingly, alternative splicing generates a FPN 
transcript lacking the IRE (named FPN1B) preferentially in erythroid precursors (and, to a lower 
extent, in duodenal enterocytes) (Zhang et al., 2009). The predominant expression of FPN1B in 
early erythroid progenitors represents a way to by pass IRP-mediated repression during early 
stages when precursor cells commit to proliferation and erythroid differentiation. During terminal 
erythroid differentiation, FPN1A (containing the 5’IRE) predominates, which allows erythroid 
cells to limit iron export (by IRP-mediated FPN1A repression) and to efficiently manufacture 
heme without developing microcytic anemia (Zhang et al., 2009). These findings are in 
agreement with an earlier observation in the polycythemia (Pcm) mouse that bears a radiation-
induced deletion in the FPN promoter that eliminates the 5’IRE (Mok et al., 2004). Associated 
with a loss of IRP-mediated repression of FPN iron export, the Pcm mouse suffers from a 
transient hypochromic and microcytic anemia. The latter spontaneously corrects in young adult 
mice due to increased hepcidin expression. Hence, the loss of IRP-mediated translational control 
of FPN is compensated by increased hepcidin-mediated FPN degradation. The evidences from the 
Pcm mouse model show the importance of IRP-mediated regulation of FPN in erythroid cells, 
especially in early stages of life when hepcidin expression is not sufficient to effectively suppress 
FPN (Mok et al., 2004).  
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Figure 1.7 The IRP/IRE network in erythropoiesis. IRPs can influence erythropoiesis: by controlling, 
the synthesis of HIF2, the transcription factor that modulates the expression of the hematopoietic hormone 
erythropoietin (EPO) in the kidney; by regulating the expression of TfR1, DMT1, ferritin, FPN and eALAS 
in developing erythroid precursors; by influencing the iron recycling capacity of macrophages, mainly via 
FPN regulation. (Fe3+)2-Tf: diferric-transferrin; RBC: red blood cell. Figure modified from Muckenthaler et 
al., 2008. 
 
Adequate macrophage recycling function may also be regarded as a crucial determinant for 
erythropoietic activity. Erythropoiesis is largely sustained by the continuous supply of iron 
recycled from senescent or damaged erythrocytes by the macrophages of the reticulo-endothelial 
system (Fig. 1.1). Therefore, a defect in the iron recycling capacity of macrophages might 
jeopardize the maturation of red blood cells. Besides erythrophagocytosis, macrophages 
continuously absorb large amount of iron via multiple mechanisms, including scavenging of 
hemoglobin (Kristiansen et al., 2001) and heme derived from intravascular hemolysis (Hvidberg 
et al., 2005). For this reason, macrophages are considered as a transient iron storage compartment 
and, in agreement, ferritin is among the most abundant transcripts found in these cells (Hashimoto 
et al., 1999). The degree of iron sequestration within ferritin might in principle influence 
macrophage iron recycling and could in turn be affected by IRP translational regulation of 
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ferritin. However, FPN is considered as the critical determinant for macrophage function and 
mice with targeted deletion of FPN show marked iron retention in macrophages of the liver and 
spleen (Donovan et al., 2005). As a consequence, erythroid precursors are deprived of iron, 
resulting in the anemic phenotype of FPN-deficient mice (Donovan et al., 2005). Although FPN is 
subjected to IRP-mediated translational repression, spleen and bone marrow macrophages from 
IRP2 KO mice unexpectedly display reduced FPN and elevated ferritin expression, associated 
with reduced iron stores (Galy et al., 2005b). While the underlying mechanism remains unclear, 
this is unlikely to be due to a direct effect of IRP deficiency in macrophages, as suggested by the 
fact that macrophage-specific deletion of IRP2 does not recapitulate this phenotype (Ferring-
Appel et al., 2009). 
 
 
1.5.2 The IRP/IRE system in duodenal iron absorption 
As there is no controlled mechanism of body iron excretion, duodenal iron absorption is 
tightly controlled via a complex network of transcriptional, post-transcriptional and post-
translational mechanisms, with some of the key molecules involved being IRP-target genes (Fig. 
1.8). 
A representative example of such a complex regulatory network is DMT1, the channel 
mediating the transport of dietary iron across the apical membrane of duodenal enterocytes (see 
1.2.1). DMT1 is a special target of IRP regulation as it can be controlled by IRPs in different 
ways. First, DMT1 is encoded by a 3’IRE-mRNA, which mediates positive regulation by IRPs in 
a fashion similar to TfR1 (Galy et al., 2008). More indirectly, IRPs can also influence DMT1 
expression via HIF2 DMT1 belongs in fact to the targets of HIF2 transcriptional regulation, 
which emerged to have a critical role in maintaining systemic iron balance (Mastrogiannaki et al., 
2009). Specific deletion of HIF2 in the gut epithelium of mice leads to a decrease in serum and 
liver iron levels and a marked decrease in liver hepcidin expression, indicating an attempt to 
counteract the systemic iron deficiency (Mastrogiannaki et al., 2009). HIF2mRNA contains a 
5’IRE that subjects it to IRP-mediated repression (Sanchez et al., 2007b). Therefore, IRPs can 
indirectly negatively influence DMT1 expression by repressing HIF2. Interestingly, DMT1 can 
come in different flavors, as four isoforms of its mRNA can be generated by different 
mechanisms (Hubert and Hentze, 2002). Two 5’ variants are being generated by alternative 
transcriptional start site usage and are named DMT1-A and B. Two additional 3’ variants, with or 
without IRE, are instead produced by alternative splicing (Hubert and Hentze, 2002). In the 
duodenum, the IRE-containing isoforms of DMT1 prevail over the others (Galy et al., 2008). 
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Although control of dietary iron absorption is crucial for maintenance of systemic iron balance, 
DMT1 regulation appears to be directly dependent on the local iron status within enterocytes. 
This is evident in mice lacking hephaestin (sla mice) (Chen et al., 2003), which is the ferroxidase 
required for efficient FPN-mediated iron export across the basolateral membrane of enterocytes. 
In the absence of hephaestin, the duodenal enterocytes of sla mice fail to efficiently transport the 
iron absorbed from the diet to the circulation. As a consequence, sla mice display severe systemic 
iron deficiency due to iron accumulation within the enterocytes. In spite of that, DMT1 levels are 
not increased with the local iron loading in the duodenum (and the ensuing loss of IRP-mediated 
stabilization) (Chen et al., 2003). From the observations in the sla mouse model, it is clear that 
FPN is a crucial connection required to couple duodenal iron absorption to systemic iron demand 
and make duodenal enterocytes competent for systemic iron supply. In fact, it is not a coincidence 
that FPN is the molecular target of the systemic regulator of iron homeostasis hepcidin (Nemeth 
et al., 2004). In addition, FPN expression is also modulated by the IRP/IRE system (Abboud and 
Haile, 2000; Donovan et al., 2000; McKie et al., 2000). Yet, as aforementioned (see 1.5.1), a FPN 
variant lacking the IRE (FPN1B) is expressed, along with the IRE variant, in enterocytes and 
erythroid precursors (Zhang et al., 2009). In the duodenum, the presence of a FPN isoform with 
no 5’IRE might be a way to escape IRP-mediated repression in conditions of systemic iron 
scarcity. This would allow local iron deficiency in enterocytes to be ignored (by not repressing 
FPN in order to facilitate local iron increase) to favor iron flux into the bloodstream and satisfy 
the systemic iron demand. 
The role of the IRP/IRE system in duodenal function was investigated in mice with 
conditional ablation of IRP2 or both IRPs in enterocytes. Deletion of IRP2 in the intestine 
resulted in duodenal iron loading (as in the constitutive IRP2 KO model) associated with 
increased ferritin levels (Galy et al., 2005b; Ferring-Appel et al., 2009). The cell-autonomous 
nature of this phenotype was further confirmed by the fact that the duodenal iron loading was not 
recapitulated when IRP2 was specifically ablated in macrophages and hepatocytes (Ferring-Appel 
et al., 2009). Intestine-specific ablation of both IRPs resulted in a more severe phenotype, as mice 
displayed growth defects already at 7 days post partum and died shortly after weaning (likely 
because of dehydration) (Galy et al., 2008). This shows that IRPs are crucial for intestinal 
function and organismal survival. Histologically, duodenal samples displayed less structured 
crypts and villi, as well as increased apoptosis, while ultrastructural analysis revealed signs of 
mitochondriopathy (mitochondria appeared swollen and with unstructured cristae). At the 
molecular level, IRP-target genes displayed the expected pattern of a loss of IRP function, 
including induction of ferritin and FPN as well as reduction of TfR1 and DMT1 levels. Locally, 
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this results in a situation of cellular iron starvation because iron is sequestered into ferritin, while 
less dietary iron is absorbed and more iron is exported via FPN. At the systemic level, the 
increase in FPN-mediated iron export may compensate for the decreased dietary iron absorption, 
as mice do not show any signs of systemic iron deficiency. Findings from this study show that 
while hepcidin is considered the principal regulator of systemic iron homeostasis, IRP-mediated 
regulation of the same molecular target FPN is also important to secure systemic iron supply 
(Galy et al., 2008). 
 
 
Figure 1.8 The IRP/IRE network in duodenal enterocytes. The IRP/IRE system critically influences 
duodenal function by post-transcriptionally regulating key molecules involved in iron absorption (DMT1 
and HiF2), intracellular iron sequestration (ferritin) and usage (in the mitochondrion) and iron export into 
the circulation (FPN). Picture modified from Muckenthaler et al., 2008. 
 
 
1.5.3 The IRP/IRE system in liver function 
The liver is the body iron storage organ and is also the principal site of expression and 
secretion of the systemic regulator of iron homeostasis hepcidin, as well as the serum iron-carrier 
transferrin and the ferroxidase ceruloplasmin. Therefore, the liver represents a crucial node for 
systemic iron metabolism as well as general body metabolism. It is not surprising that 
dysregulation of local iron management in hepatocytic cells (Fig. 1.9) can have detrimental 
systemic consequences.  
Conditional ablation of the two IRPs in the hepatocytes is lethal to mice as they die within 
2 weeks after birth (Galy et al., 2010). From the liver biopsies and blood biochemical analyses, 
the animal death associated with profound liver damage, internal bleeding and hepatic steatosis 
(fatty liver).  On further examination, the hepatocytes displayed the typical molecular footprint of 
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loss of IRP function, including increased ferritin and ferroportin (due to loss of IRP-mediated 
repression), and reduced TfR1 and DMT1 (coherent with loss of IRP-mediated stabilization). Due 
to the ensuing increase in iron storage and export, alongside reduced iron import, the hepatocytes 
became iron-starved. Consequently, cellular iron starvation has detrimental effects on organelles 
such as the mitochondria. The mitochondrion requires iron as a main building block for the 
synthesis of heme and Fe-S clusters. The IRP double KO hepatocytes additionally presented with 
a reduction in the mitochondrial iron transporter mitoferrin 2 (although it is not an IRP-target) and 
thus contributed to further decrease in the iron content of the mitochondrial compartment. As 
expected, mitochondrial iron deficiency correlated with a decrease of heme- and Fe-S- proteins, 
including components of the mitochondrial electron transport chain and the TCA cycle, as well as 
the mitochondrial ferrochelatase and cytoplasmic Fe-S proteins, such as xanthine dehydrogenase. 
Likely, the deficit of mitochondrial energy metabolism caused the severe mitochondriopathy, 
which in turn represented the leading cause of the hepatic failure (Galy et al., 2010). Interestingly, 
mice with double IRP deficiency in the intestine also showed signs of mitochondriopathy, as 
mitochondria of the enterocytes contained numerous round electron-dense deposits and disfigured 
structure of the cristae (Galy et al., 2008). Hence, both in the intestine and the liver, double IRP 
ablation was associated with mitochondrial dysfunction and had severe consequences for the 
specific tissues, leading to death caused by malabsorption and liver failure (Galy et al., 2008, 
2010), respectively. 
The importance of the IRP/IRE system for liver function and viability is also highlighted by 
a more recent mouse model with targeted FBXL5 deletion (Moroishi et al., 2011). Being involved 
in iron-mediated degradation of IRP2 (and apo-IRP1) (Salahudeen et al., 2009; Vashisht et al., 
2009) (see 1.4.3), FBXL5 ablation determines a secondary increase of IRP2 expression. While 
systemic FBXL5 deficiency is lethal, its conditional deletion in hepatocytes has also detrimental 
consequences and leads to fatal liver failure (Moroishi et al., 2011). Interestingly, combined 
ablation of IRP2 rescues FBXL5 KO mice from death, showing that IRP2 overexpression plays a 
major role in the fatal consequences of FBXL5 deletion (Moroishi et al., 2011). However, it 
cannot be excluded that FBXL5 is also involved in the degradation of other proteins whose 
upregulation could contribute to the defects of the FBXL5 KO model. 
Overall, the conditional IRP ablation in the hepatocytes unraveled the importance of the 
IRP/IRE system in liver physiology. More in general, it demonstrated a crucial role of the 
IRP/IRE system for securing adequate iron supply to sustain mitochondrial function. 
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Figure 1.9 The IRP/IRE system sustains hepatic and mitochondrial function. The IRP/IRE 
system critically influences liver function by regulating cellular iron fluxes. The cellular iron regulatory 
machinery secures hepatocytic iron balance and, in particular, adequate iron supply to the mitochondrial 
compartment to sustain the synthesis of heme and Fe-S proteins necessary for energy metabolism. TCA: 
tricarboxylic acid cycle, ETC: electron transport chain. Modified from Galy et al., 2010. 
 
 
1.5.4 The IRP/IRE system in disease 
While animal models with targeted deletion of the IRPs have provided valuable insights 
into the role of the IRP/IRE system in body physiology (see 1.5.3), disturbed IRP/IRE regulation 
has also been reported in some human conditions, as described below. 
 
As many as 21 different mutations have been identified in the 5’UTR of the FTL gene, 
including single or double point substitutions as well as longer deletions (Cazzola et al., 1997; 
Cremonesi et al., 2003b). Some of them specifically affect the structure of the IRE sequence and 
have been associated with the autosomal dominant hyperferritinemia cataract syndrome 
(Beaumont et al., 1995; Girelli et al., 1995; Cazzola et al., 1997). This disease is characterized by 
early on-set bilateral cataract associated with abnormal FTL accumulation in the serum. 
Disruption of the interaction between the mutant FTL-IRE and IRP is consistent with a decreased 
repression of FTL and it has been confirmed in cultured lymphoblastoid cells from the affected 
patients (Cazzola et al., 1997). Yet, the reason why FTL specifically accumulates in the lens and 
it causes the cataract remains unclear. 
In contrast to FTL, just one single mutation of the FTH-IRE has been implicated in disease. 
Such a mutation has been identified in four members of a Japanese family affected by autosomal 
dominant iron overload (Kato et al., 2001). Surprisingly, this mutation in the FTH-IRE was found 
to increase the binding affinity to IRP and to be associated with FTH downregulation in the liver. 
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Also, serum ferritin was shown to be increased in the affected patients (Kato et al., 2001). While 
the reason underlying increased serum ferritin is not clear, it is consistent with a mouse model 
with reduced FTH expression (Ferreira et al., 2001). However, a larger study of subjects with 
abnormally high serum ferritin and iron levels could not identify point mutations in the FTH-IRE 
sequence (Cremonesi et al., 2003a). This suggests that mutations of the IRE sequence of the FTH 
gene are rather infrequent in human patients as compared to FTL-IRE and gives a hint to the 
importance of preserving the IRP-mediated regulation of FTH. 
 
Large studies including single nucleotide polymorphism identification and genome wide 
association studies have identified polymorphisms in the IRP2 promoter and coding sequence that 
could affect IRP2 expression. Interestingly, these polymorphisms associate with increased 
susceptibility to chronic obstructive pulmonary disease (COPD) and potentially explain the 
altered expression levels of IRP2 observed in the lung of COPD patients (DeMeo et al., 2009). 
Polymorphisms of the IRP2 gene are also associated with Alzheimer’s disease (AD) (Coon et al., 
2006) . Curiously, analysis of brain necropsies from AD patients showed altered distribution of 
IRP2, which co-localizes with the characteristic histopathological features of AD (Smith et al., 
1998). These included neurofibrillary tangles of hyperphosphorylated microtubule-associated 
protein Tau, as well as senile plaques composed of extracellular deposits of amyloids in the gray 
matter of the brain (Smith et al., 1998). Proteolysis of amyloid precursor protein (APP) generates 
-amyloid, the principal component of the senile plaques (Sinha et al., 1999). APP has been 
shown to work as a ferroxidase and mediate neuronal iron export in conjunction with FPN (Duce 
et al., 2010). Inhibition of APP ferroxidase activity results in neuronal iron loading, as observed 
in AD (Duce et al., 2010). Furthermore, Tau ablation in mice is associated with mislocalization of 
APP, as well as neuronal iron retention, which is consistent with disruption of FPN-mediated iron 
export (Lei et al., 2012). Intriguingly, APP has been recently recognized as an IRP-target gene 
(Rogers et al., 2002).  
 
Increasing the body of evidences linking dysregulation of the IRP/IRE system to 
neurodegenerative diseases, abnormally high IRP1 activity has been found in patients suffering 
from Parkinson’s disease (PD) (Faucheux et al., 2002). In PD, the degeneration of dopaminergic 
neurons of the substantia nigra is characterized by local iron accumulation. The iron loading was 
found to be associated with a lack of up-regulation of the iron storage protein ferritin, which may 
contribute to increased oxidative stress in this region. Consistent with abnormally low levels of 
ferritin, IRP1 activity was not decreased in spite of the iron loading (Faucheux et al., 2002). 
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While the primary cause of iron accumulation in dopaminergic neurons of PD patients is not 
clear, aberrant IRP1 activity might contribute to neuronal oxidative stress and death by decreasing 
safe storage of excess iron into ferritin. 
 
Along the line of neurodegenerative diseases, Friedreich’s ataxia (FA) has also been 
correlated with aberrant IRP activity. FA is a neurodegenerative condition caused by silencing of 
the FXN gene due to unstable expansion of a GAA repeat in its coding sequence (Campuzano et 
al., 1996). FXN has been proposed to function as iron chaperone for the synthesis of Fe-S clusters 
in the mitochondria (Bulteau et al., 2004) (see 1.3.2) and its deficiency impairs Fe-S cluster 
assembly (Mühlenhoff et al., 2002). Typically, defects that lead to disruption of Fe-S cluster 
biogenesis result in decreased activity of mitochondrial Fe-S proteins (due to reduced of Fe-S 
cluster availability) and mitochondrial iron accumulation (consequent to decreased iron 
utilization) (Sheftel et al., 2010). As a consequence, this leads to IRP1 activation (due to limited 
Fe-S cluster availability to form the cytosolic aconitase) and, in cases of cytosolic iron depletion, 
also to increased IRP2 stabilisation (Ye and Rouault, 2010). In FA, increased IRP1 activity along 
with mitochondrial iron loading are observed both in cardiac myocytes and neurons, as part of the 
tissues that are specifically affected by the disease (Pandolfo, 2003). A mouse model of FA that 
was generated by targeted deletion of FXN shows the same abnormalities observed in patients 
suffering from FA (Puccio et al., 2001).  
 
FA is not the only disorder associated with disrupted Fe-S cluster machinery and associated 
with aberrant IRP activation. Human patients carrying a mutation that results in a drastic 
reduction of the Fe-S cluster scaffold protein ISCU suffer from a form of hereditary myopathy 
with exercise intolerance (Mochel et al., 2008; Olsson et al., 2008). An intronic substitution leads 
to a splicing error that includes a premature stop-codon in the ISCU transcript. ISCU deficiency 
impairs Fe-S cluster synthesis and leads to abnormal IRPs activation in the skeletal muscle of  the 
affected patients (Crooks et al., 2012). 
 
A single nucleotide substitution interfering with correct splicing is also the leading cause of 
GLRX5 deficiency (Camaschella et al., 2007). Despite the dramatic reduction of GLRX5 in all 
tissues, only the erythron seems to be significantly affected. The only disease manifestation is an 
anemia characterized by erythroblasts with iron-overloaded mitochondria (also known as 
sideroblasts). The sideroblastic anemia linked to GLRX5 deficiency is also featured by IRP1 
activation, which was shown to be responsible for eALAS repression (via its 5’IRE) and 
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consequent impairment of hemoglobin synthesis (Camaschella et al., 2007). Study of the 
corresponding animal model of the disease, the mutant zebrafish shiraz, has revealed the 
centrality of abnormal IRP1 activation in the etiology of the disorder (Wingert et al., 2005). In 
fact, either the overexpression of a version of the eALAS mRNA lacking the 5’IRE or the use of 
an antisense oligo to knockdown IRP1 was sufficient to restore hemoglobin synthesis in the 
GLRX5 mutant fish (Wingert et al., 2005). 
 
 
To summarize, mouse models with loss of IRP function have extended our understanding 
on the importance of the IRP/IRE system in body physiology. Both systemic and conditional, as 
well as single and double, IRP deletions have provided information on the physiological role of 
the IRP/IRE system in vivo as well as the pathological consequences of its deregulation (see 
1.5.3). A handful of human conditions with alterations of the IRP/IRE system have been reported, 
either with mutations in the IRE sequence of IRP target genes or polymorphisms of the IRP2 
promoter. Intriguingly, abnormally high IRP activity, secondary to impairment of the Fe-S cluster 
biogenetic machinery, has also been observed in human patients. Of note, the aforedescribed 
diseases caused by primary defects in the Fe-S cluster biogenesis machinery display a strong 
tissue-specificity. Their manifestation appears to be limited either to the neurons (FXN 
deficiency), the muscles (ISCU deficiency) or the erythron (GLRX5 deficiency). Conceivably, 
this may account for tissue-specific roles of the respective defective genes (FXN, ISCU and 
GLRX5) and/or for the special requirement for efficient production of heme- and Fe-S- proteins 
in the relevant tissues. Alternatively, or in addition, the tissue-specific manifestations of these 
disorders could be due to the unique effects of aberrant IRP activation in a given tissue, as it has 
been clearly demonstrated in the case of GLRX5 deficiency. A model with primary 
overexpression of IRP activity could help dissect these different hypotheses and show the direct 
consequences of aberrant IRP activity on body physiology. Attempts to generate such an in vivo 
experimental model system have been made, although the apparent toxicity of IRP 
overexpression has posed a great challenge (DeRusso et al., 1995; Lind et al., 2006; Surdej et al., 
2008). A mammalian model of gain of IRP function has not yet been described. 
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1.6 AIM OF THE THESIS 
 
Deregulation of iron metabolism is a key feature and frequent cause of some of the most 
common human diseases worldwide. Hepcidin is the systemic regulator of iron homeostasis and 
mutations affecting the genes involved in its expression, i.e. HAMP, HFE, HJV, TfR2 (Feder et 
al., 1996; Camaschella et al., 2000; Roetto et al., 2002; Papanikolaou et al., 2003), as well as its 
direct molecular target ferroportin (FPN) (Montosi et al., 2001; Njajou et al., 2001), are well 
known causes of hereditary iron overload disease. Iron regulation at the cellular level is secured 
by the IRP/IRE system. The importance of the IRP/IRE system for life was revealed by the 
embryonic lethality of mice with constitutive combined ablation of both IRPs (Smith et al., 2006; 
Galy et al., 2008). While the regulation of systemic iron balance is certainly essential, an 
integrated view of the implications of deregulated cellular iron homeostasis for body physiology 
is still missing. Mouse models with loss of IRP function have provided insights to the detrimental 
consequences of altered cellular iron deregulation (Cooperman et al., 2005; Galy et al., 2005b, 
2008, 2010). In humans, various reports exist connecting defects of the IRP/IRE system to 
diseases (Beaumont et al., 1995; Girelli et al., 1995; Kato et al., 2001; Coon et al., 2006; DeMeo 
et al., 2009). In particular, abnormally high IRP activity has been observed in disorders including 
sideroblastic anemia linked to Glrx5 deficiency (Camaschella et al., 2007), Friedreich’s ataxia 
(Lobmayr et al., 2005) and Parkinson’s disease (Faucheux et al., 2002). However, until now a 
suitable animal model system to specifically investigate the pathological consequences of IRP1 
hyperactivity was not available. 
To gain a deeper understanding of the significance of appropriate IRP activity in vivo, our 
laboratory generated a new mouse model with gain of IRP1 function. The aim of this PhD project 
was to: 
1. analyze the impact of abnormally high IRP1 activity on iron homeostasis in vivo; 
2. explore the consequences of IRP dysregulation on general body physiology under standard 
laboratory conditions; 
3. characterize the adaptive response of mice with gain of IRP1 function to acute and chronic 
iron challenges.  
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2. MATERIALS AND METHODS 
 
 
2.1 MATERIALS 
 
 
2.1.1 Chemicals and reagents 
All chemicals used in this study were purchased from Gibco BRL, Merck or Sigma-Aldrich 
with the following exceptions: 
 
Chemical       Company    
100bp DNA ladder            New England Biolabs  
1kb DNA ladder                                                                              New England Biolabs  
40% Acrylamide/Bis Solution 19:1                 BioRad 
30% Acrylamide/Bis Solution 37.5:1                                            BioRad  
α[32P]UTP, 800 Ci/mmol        Hartmann Analytic 
Amino acid mixture, complete            Promega 
ATP, CTP, GTP, UTP      Roche  
Agar               Serva  
Agarose              Invitrogen  
Apoprotin              Roche 
Complete EDTA-free Protease Inhibitor Cocktail          Roche 
Dextran       Chemos GmBH 
Deoxynucleotides (dNTPs)             PeqLab 
Ethidium bromide              MP Biomedicals  
E-64               Roche 
EDTA               Roche 
Fetal Bovine Serum (low endotoxin)                                               Invitrogen 
G418        Invitrogen 
Hemin        Normosang 
Iron atomic spectroscopy standard solution   Fluka 
Leupeptin              Roche 
Milk powder               Frema Reform 
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N,N,N’;N’-tetramethylethylenediamine (TEMED)                        Fluka 
Pefabloc              Roche 
Penicillin-streptomycin      Invitrogen 
Pepstatin              Roche 
Phenol/chloroform/isoamylalcohol, 25:24:1                            AppliChem 
Random hexamer primers             Invitrogen 
RPMI 1640 plus Glutamax      Invitrogen 
Tungsten Carbide Bead, 3mm     QIAGEN 
TRIzol®               Invitrogen 
 
 
2.1.2 Antibodies and enzymes 
 
Table 2.1 Enzymes used for western blot. All secondary antibodies were coupled to horseradish 
peroxidase. 
Primary Source Dilution Secondary Company Dilution 
IRP1 “home-made”* 1:1000 -rabbit GE 
Healthcare 
1:10000 
FLAG-tag BioLegend 1:2000 -rat GE 
Healthcare 
1:10000 
FPN Alpha Diagnostic 1:1000 -rabbit GE 
Healthcare 
1:10000 
-TfR1 Zymed 1:1000 -mouse GE 
Healthcare 
1:10000 
-FTL Santa Cruz 1:500 -goat Invitrogen 1:5000 
--actin Sigma 1:10000 -mouse GE 
Healthcare 
1:10000 
* immunoprecipitated rabbit antibody raised against full length mouse IRP1 
 
Table 2.2 Enzymes used for flow cytometry.  
Antigen Conjugated fluorophore Company Dilution 
Ter119 PeCy5 eBiosciences 1:200 
CD44 FITC eBiosciences 1:400 
CD71 PE eBiosciences 1:800 
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Other enzymes used in this study were: 
Enzyme       Company    
FastStart PCR master       Roche 
Platinum taq DNA polymerase     Invitrogen 
Proteinase K       Sigma 
Restriction enzymes              New England Biolabs  
RNaseA       Sigma 
RNAsin® RNase inhibitor             Promega 
RQ1 DNase               Promega 
Spermidin       Sigma 
Superscript II reverse transcriptase    Invitrogen  
SYBR Green PCR master mix            Applied Biosystems 
T7-RNA polymerase              Promega 
  
 
2.1.3 Buffers and solutions 
All solutions were prepared with double deionized water (ddH2O). 
 
          Buffer             Composition    
Depurination solution (for Southern Blot)  0.25M HCl   
 
Denaturizing solution (for Southern Blot)  0.5M NaOH 
1.5M NaCl 
 
DNA loading buffer (6x)     0.25% (w/v) Bromphenol blue 
        0.25% (w/v) Xylene cyanol FF 
        40% (w/v) Sucrose 
 
HotSHOT Alkaline Lysis Reagent   25 mM NaOH 
0.2 mM EDTA 
pH 12 
 
HotSHOT neutralizing reagent     40 mM Tris-HCl pH 5 
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Lysis buffer (for DNA extraction)   50mM Tris pH8 
100mM EDTA 
100mM NaCl 
1% SDS) 
 
Monroe buffer      10 mM Hepes 
       3mM MgCl2 
       40 mM KCl 
       5% Glycerol 
       0.2% Nonidet P-40 
 
Neutralizing solution (for Southern Blot)  1M Tris pH 7.6 
1.5M NaCl 
                                                                  
RIPA buffer      10mM TrisHCl pH8 
150mM NaCl 
1mM EDTA 
1% NP-40 
0.1% SDS 
 
RNA elution buffer     0.1% SDS 
0.3 M ammonium acetate 
0.02 M Tris PH 7.5 
0.01 M EDTA 
 
RNA loading buffer (2x)    95% Formamide 
                                                                                       0.025% SDS 
                                                                                       18 mM EDTA 
                                                                                            0.0012% Bromophenol blue 
 
SDS Protein loading buffer (4x)    350mM Tris pH 6.8 
30% Glycerin 
1% SDS 
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0.5 M DTT 
0.0012% Bromophenol blue 
 
TBARS reaction buffer     0.005 μM butylated hydroxytoluene 
0.4% SDS 
7.5% acetic acid pH 3.5 
0.3% thiobarbituric acid 
 
TBE buffer (10x)                           0.89 M Tris, pH 8.0 
       0.9 M boric acid 
                 10 mM EDTA 
 
TBST       25 mM Tris 
150 mM NaCl 
2 mM KCl pH 7.4 
0.1% Tween 20 
 
Transfer buffer (10x)                                                         250 mM Tris 
                                                                                           2M Glycin 
 
RIPA buffer       10mM TrisHCl pH8 
150mM NaCl 
1mM EDTA 
1% NP-40 
0.1% SDS 
 
 
2.1.4 Laboratory materials and kits 
The following section lists laboratory materials used in this study as well as their suppliers. 
 
Material        Company   
0.2 ml reaction tubes (Thermo TubeTM)    PeqLab  
1.5 ml reaction tubes       Eppendorf  
80 μm cell strainer      BD Biosciences 
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Biomax films       Kodak 
Bottle top filters, 0.22 μm pore size     Millipore  
Cell culture plates       Nunc  
CHROMA SPIN 30 and 100 columns     Clontech  
DC Protein Assay      Biorad 
General glass ware       Schott  
General plastic ware       Nunc  
Glass potters Duall 20      Kontes Glass, Co 
Gloves (Latex or Nitrile)     Kimberley-Clark 
Iron (SFBC) Bathophenanthroline    BIOLABO 
Parafilm        Pechiney Plastic Packaging 
Plastic cuvettes         Nunc 
PVDF membrane                                                         Millipore 
QIAquick Gel Extraction Kit      QIAGEN  
Syringes          Becton Dickinson 
Supersignal West Femto Chemiluminescent Substrate    ThermoScientific 
U.I.B.C. Unsaturated Binding Capacity    BIOLABO 
Western Lightning-PLUS ECL kit                    ThermoScientific 
 
 
2.1.5 Instruments 
The following section lists laboratory instruments used in this study as well as their 
suppliers. 
 
Instrument       Company   
ABC Animal Blood Analyzer     Scil Vet 
ABI PRISM 7500 instrument      Applied Biosystems 
Cooled tabletop microcentrifuge     Eppendorf 
Electrophoresis power supply                                       Pharmacia 
FLA2000 phosphorimager     Fuji film 
MOFLO high-speed cell sorter     Beckman-Coulter 
Nanodrop 1000       Peqlab 
RC-5B/C Centrifuge and appropriate rotors    Sorvall  
Scintillation counter                    PerkinElmer 
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Spectrophotometer (Ultrospec 2100 pro)    Amersham Biosciences  
T-100 Thermal Cycler      Biorad 
TissueLyser II       QIAGEN 
Western Blot wet transfer cell                                        Biorad 
 
 
2.1.6 PCR primers 
 
Table 2.3 Primer sequences. All primers were purchased from Eurofins MWG. They were 
obtained in desalted, lyophilized form and were diluted in H2O to a 100 pmol/l working 
solution. 
Gene/Locus Sequence (5’-3’) Code Use 
Rosa26  AGTCGCTCTGAGTTGTTATCA G P1 
Splicing Acceptor GCGAAGAGTTTGTCCTCAACC P2 
Rosa26 CCCAGATGACTACCTATCCTC P3 
PCR - genotyping 
    
Rosa26  TCCTCAGAGAGCCTCGGCTAGG P4 
Splicing Acceptor GTTTGTCCTCAACCGCGAGC P5 
RT-PCR 
    
Rosa26 TGGAGCCGTTCTGTGAGACAG P6 
Irp1 CTCAGCAAGGTGTGCAAATGGG P7 
RT-PCR 
    
Rosa26 AAGGATACTGGGGCATACGCCACAGG PB1-F 
Rosa26 CGTTGGGCCTAACTCGAGTCTCGCTGC PB1-R 
PCR (probe pb1) 
    
Neo 
(-geo stop 
cassette) 
TCAGAAGAACTCGTCAAGAAGGCG PB2-F 
Neo 
(-geo stop 
cassette) 
GCTTACATAAACAGTAATACAAGGGG PB2-R 
PCR (probe pb2) 
    
Cre CGCAGAACCTGAAGATGTTCG  PCR - genotyping 
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Cre GTCGAAATCAGTGCGTTCGAAC  
    
Hepcidin AACAGATACCACACTGGGAA  
Hepcidin ATACCAATGCAGAAGAGAAGG  
qPCR 
    
Fpn GGGTGGATAAGAATGCCAGACTT  
Fpn GTCAGGAGCTCATTCTTGTGTAGGA  
qPCR 
    
TfR1 CCCATGACGTTGAATTGAACCT  
TfR1 GTAGTCTCCACGAGCGGAATA  
qPCR 
    
Ftl CGTGGATCTGTGTCTTGCTTC  
Ftl GCGAAGAGACGGTGCAGACT  
qPCR 
    
Tubulin GGGAAATCGTGCACATCCA  
Tubulin ATGCCATGTTCATCGCTTATCA  
qPCR 
    
Actin GCTTCTTTGCAGCTCCTTCGT  
Actin ACCAGCGCAGCGATATCG  qPCR 
 
 
Mouse transgenesis 
The plasmids pBigT and pROSA26PA were obtained from S. Srinivas (Srinivas et al., 
2001). The PGK-Neo cassette from pBigT was modified to an IRESbgeo (Galy et al., 2004). The 
KpnI linearization site of pROSA26PA was replaced by a SfiI/FseI/PmeI multi-cloning site. Irp1 
cDNA was cloned from mouse Sv129 ES cells. By step PCR, three cysteine residues required for 
Fe-S cluster assembly, C437, C503, C506, were mutated to serine and a fourth one, C118, to 
alanine, resulting in stabilization of the apoprotein in the presence of heme (A. Vasanthakumar 
and R. Eisenstein, unpublished findings). The resulting mutant Irp1 cDNA was fused to a 
DYKDDDDK (FLAG) tag (designated Irp1*) and inserted into pBigTIRESbgeo to produce the 
pBigTIRESbgeoIRP1* plasmid. PacI-AscI digested pBigTIRESIRP1* was inserted into the 
modified pROSA26PA plasmid. 
E14 ES cells were electroporated with the XhoI-linearized targeting contruct and cultivated 
in the presence of G418 (Invitrogen). Resistant ES cell clones were analysed using RT-PCR and 
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Southern blotting. Targeted ES cell clones were injected into C57BL6/J embryos to obtain 
chimeras that were backcrossed to C57BL6/J to check for germ-line transmission of the knock-in 
Rosa26 locus. Animals carrying the targeted allele have been crossed with a Hprt-Cre deletor 
strain (Tang et al., 2002). Mice bearing the recombined Rosa26 locus were backcrossed to 
C57BL6/J for 5 generations and heterozygotes were then intercrossed to obtain wild-type, 
heterozygous and homozygous littermates.  
 
 
 
2.2 METHODS 
 
 
2.2.1 Standard conditions and treatments of laboratory animals  
 
Mouse husbandry and sample collection 
Animals were kept on constant light/dark cycle and food was supplied ad libitum. Mice 
were normally sacrificed at 8-10 weeks of age by CO2 inhalation. Heparinized blood was 
collected by cardiac puncture and pieces of tissues were flash-frozen. For molecular analyses of 
duodenal samples, mice were euthanized by cervical dislocation to avoid sample degradation. 
Animal handling was in accordance with EMBL guidelines. 
 
Pharmacological iron overload 
30 weeks old males received one single intravenous dose of 1 mg of iron-dextran (Sigma-
Aldrich) versus dextran alone (Chemos GmBH). Both chemicals were diluted in NaCl 150 mM 
and filtered through 0.22 µm filters before use. Animals were euthanized 24 hours after injection. 
 
Chronic iron overload 
HFE KO mice (Herrmann et al., 2004) were kindly provided by Muckenthaler laboratory. 
Mice bearing the recombined Rosa26 locus (IRP1*) in homozygosis were crossed with 
homozygous HFE KO mice, as a model of chronic iron overload. Double heterozygous mice were 
then intercrossed and, among the littermates, four experimental groups were selected, including 
double homozygous (IRP1*/HFE KO), double wildtype as well as single homozygous mice. 
Animals were analysed at the age of 20 weeks. 
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Determination of 59Fe distribution in mouse tissues  
To determine body iron distribution, mice were administered intravenously with 59Fe in 
isotonic HEPES-buffered saline (Fe(NO3)3-complexed with nitrotriacetic acid (NTA) (1:2); 
labeled with ~2Ci 59Fe/animal; 0.2mol Fe/kg body weight). 59Fe activity in tissues was 
measured 2 weeks after injection using a well-type -counter (1282 Compugamma CS, LKB, 
Wallac, Finland). Results were normalized by subtraction of the amount of 59Fe calculated to be 
in the residual blood of each organ (Schümann et al., 2007). 
 
 
2.2.2 Standard mouse phenotyping 
The standard phenotypic analysis was performed at the Mouse Clinic Institute (ICS - 
Strasbourg) in accordance with the European Council Directive of 24 November 1986. Here is 
described only a short selection of the standard tests performed at the ICS and whose 
corresponding results are shown in the main body of this thesis (see 3.3). A more comprehensive 
list of the assays carried out is included in the Appendix. 
 
Rotarod test 
The rotarod test measures the ability of the animal to maintain balance on a rotating rod 
with a diameter of 4.5 cm (Bioseb, Chaville, France). Mice were submitted to 3 repeated trials, 
separated by 15 min intervals, during which the rotation speed accelerated from 4 to 40 rpm in 5 
min. The latency before falling was recorded and used as index of motor coordination/motor 
endurance performance. 
 
Exercise test 
Exercise performance was assessed using a treadmill system, which comprises a belt 
enclosed in a plexiglass chamber and a stimulus device consisting of a metal shock grid attached 
to a rear of the belt. The speed and the slope of the belt are electronically adjusted. Mice were 
first subjected to an incremental protocol, whereby they began with a 20 min acclimatization 
period at 25 cm/s and a slope of 5 degrees. The following day, a defined protocol was applied 
with increase in speed and slope until exhaustion of the animal. The duration of the running and 
the total distance covered were measured to evaluate the performance of the mice. 
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Grip test 
This test measures the muscle strength using an isometric dynamometer connected to a 
grid (Bioseb, Chaville, France). Once the animal was holding the grid with its forepaws, it was 
slowly moved backwards until it released it. The dynamometer recorded the maximal strength 
developed. 
 
Electromyography 
Electromyographic recording allows neurophysiological measurement of sensory-motor 
function. Recordings were performed under Imalgen-Rompun anesthesia using a Key Point 
electromyograph (EMG) apparatus (Medtronic, France). The body temperature was maintained at 
37 °C with an homeostatic blanket (Harvard, Paris, France). 
To measure the sensitive nerve conduction velocity (SNCV), recording electrodes were 
inserted at the base of the tail, while stimulating electrodes were placed 20 mm away from the 
recording needles, towards the extremity of the tail. A ground needle electrode was inserted 
between the stimulating and recording electrodes. The caudal nerve was stimulated with a series 
of 20 pulses during 0.2 ms each at a supramaximal intensity. The average response of these 20 
stimulations was included for statistical analysis. 
To assess the stimulation-evoked activity, the compound muscle action potential (CMAP) 
was measured in gastrocnemius or plantar muscles after the sciatic nerve stimulation. For this 
purpose, stimulating electrodes were placed at the level of the sciatic nerve and recording 
electrodes in the gastrocnemius muscle. A ground needle was inserted in the contralateral paw. 
Sciatic nerve was stimulated with a single 0.2 ms pulse at a supramaximal intensity. The 
amplitude (mV) and the distal latency of the responses (ms) were measured. 
 
 
2.2.3 Hematology and tissue biochemistry 
 
Blood cell profiles and serum biochemistry 
Hematological parameters were determined from freshly collected and heparinized blood 
samples using a Scil Vet ABC Animal Blood Analyzer. Serum was obtained by centrifugation of 
the blood samples at 4500 rpm for 10 minutes at 4°C and collection of the supernatant. Serum 
iron and transferrin saturation were measured using BIOLABO reagent kits, i.e. Iron (SFBC) 
Bathophenanthroline and U.I.B.C. Unsaturated Binding Capacity (BIOLABO) according to the 
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manufacturer’s instructions. Serum ferritin was measured by the Claude Bernard Institute 
Chemistry Laboratory (Paris, France) using an Olympus 400 analyser. 
 
Determination of total non-heme iron content in mouse tissues 
Non-heme iron content was measured in whole tissue lysates using the bathophenanthroline 
chromogen method. Tissues were dried at 45ºC for 3 days, weighted and digested for 48 hours at 
65ºC in 10% TCA/10% HCl (1 ml per 100 mg of dried liver material; 3 ml per 100 mg of splenic 
and duodenal material) to allow deproteinisation and mineralization of non-heme iron. 200 l of 
diluted extracts (1:20 for spleen, 1:10 for liver and duodenum) were added to 1 ml of chromogen 
solution (bathophenanthroline-disulfonic acid 0.01% / thioglycolic acid 0.1% / 7M Na-acetate). 
The thioglycolic acid allows ferric iron to be reduced to its ferrous form that can then react with 
disulphonated bathophenanthroline and form a coloured complex. After 10 min of incubation, 
absorbance at 535 nm (Abs535) was read using a Ultrospec 2100 pro (Amersham Biosciences). 
The amount of non-heme iron was quantified using a standard curve made with iron atomic 
spectroscopy standard solution (Fluka). 
 
Determination of lipid peroxides in mouse tissues 
Thiobarbituric acid reactive substances (TBARS) were measured according to Okawa et al, 
1979 (Ohkawa et al., 1979). Tissue homogenates were prepared in 20mM sodium-phosphate 
buffer (pH 7.4) and 0.1% SDS. While an aliquot was used for the determination of protein 
concentration, a 200-μl aliquot of tissue homogenate was added to 0.005 μM butylated 
hydroxytoluene, 0.4% SDS, 7.5% acetic acid at pH 3.5, and 0.3% thiobarbituric acid in a final 
volume of 4 ml. Samples were incubated at 95°C for 60 min and then cooled at room 
temperature. Lipids were extracted using n-butanol:pyridin (15:1, v/v), centrifuged at 4,000×g for 
10 min and the Abs532 of the upper layer was estimated using a Ultrospec 2100 pro (Amersham 
Biosciences). The amount of TBARS was quantified using a standard curve of malonaldehyde 
bis- (dimethyl acetal) (Sigma-Aldrich). 
 
 
2.2.4 Cell biology 
 
Primary cultures of bone marrow-derived macrophages (BMDM)  
BMDM were obtained from femurs. Bones were disinfected in ethanol (EtOH) 70% and 
their heads removed with a scalpel. The marrow was flushed out using a syringe and ice-cold 
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Hank's Balanced Salt Solution (HBSS) 14185 (Gibco) and the cell suspension was filtered 
through a 80 μm cell strainer (Falcon, BD Biosciences). Cells were seeded at a density of 
approximately 5x104 cells/cm2 in RPMI 1640 plus Glutamax (Invitrogen) supplemented with 
10% (v/v) heat-inactivated low endotoxin fetal bovine serum (FBS) (Invitrogen), 1% Penicillin + 
Streptomycin (Invitrogen) and 100 ng/ml macrophage colony-stimulating factor 1 (Sigma-
Aldrich). Cells were grown at 37°C in a 5% CO2 atmosphere. After 4 days, non-adherent cells 
were removed by washing with HBSS and the medium daily replaced until cells reached a 70-
80% confluence (typically 6 to 7 days after seeding), when they were treated. Treatment consisted 
in a 10 hours exposure to hemin 100M (Normosang), as an iron source, to the chelator 
deferoxamine (DFO) 100 M or to an equivalent amount of DMSO as a control. After incubation 
with the stimulus, cells were quickly harvested in ice-cold phosphate-buffered saline (PBS), 
centrifuged for 5 min at 5000 rpm and at 4°C. The supernatant was then removed and the dry cell 
pellet snap-frozen for subsequent molecular analysis. 
 
Flow cytometry analysis of bone marrow-derived cells 
Bone marrow derived cells were obtained from femurs. Bones were quickly crushed in a 
mortar with ice cold RPMI 1640 plus Glutamax supplemented with 2% FBS and the cell 
suspension was then filtered through a 40 μm cell strainer. 2x106 cells were co-stained with 
PeCy5-labeled Ter119 (1:200), FITC-conjugated CD44 (1:400) and PE-conjugated CD71 (1:800) 
antibodies (eBiosciences) in 200 l of 50% 2.4G2 (BD Biosciences) / 50% (PBS 2% FBS) at 4°C 
for 20 minutes and in the dark. Flow cytometry was performed with a MOFLO high-speed cell 
sorter (Beckman-Coulter). Flow-Jo software (Tree Star, Ashland, OR) was used for analysis. 
 
 
2.2.5 Molecular biology 
 
DNA extraction 
When high quality genomic DNA was needed for Southern Blot analysis, the following 
procedure was applied. A piece of tissue was incubated in 500µl lysis buffer (50mM Tris pH8; 
100mM EDTA; 100mM NaCl; 1% SDS) supplemented with 200µg proteinase K (Sigma), at 
55°C shaking overnight. The DNA was then purified by phenol/chloroform/isoamylacohol 
(25:24:1) extraction, performed twice, followed by chloroform and isopropanol precipitation. The 
precipitated DNA was washed once with EtOH 70%, air dried and re-dissolved in water. The 
concentration of the DNA samples was determined by reading of the Abs 260 using a Nanodrop 
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1000 (Peqlab). When genomic DNA was required for genotyping, a fast “HotSHOT” (Hot 
Sodium Hydroxide and Tris) method of DNA extraction was performed as described (Truett et 
al., 2000). Briefly, a small piece of tissue (typically the tip of the tail) was boiled at 95°C and for 
40 min in 100 l of alkaline lysis reagent (25 mM NaOH, 0.2 mM EDTA – pH 12). The sample 
was then briefly cooled on ice and 100 l of neutralizing reagent (40 mM Tris-HCl in water – pH 
5) were added. DNA samples were stored at -20°C. 
 
RNA extraction 
Total RNA was extracted with Trizol reagent (Invitrogen) according to the manufacturer’s 
instructions. Briefly, a small piece of tissue was added to an eppendorf tube containing one 
Tungsten Carbide Bead of 3mm (QIAGEN) and 1 ml of cold TRIzol reagent. For RNA extraction 
from BMDM pellets, the amount of TRIzol reagent (as well as of the subsequent reagents) was 
halved. The sample was homogenised for 2 min at maximum speed using a TissueLyser II 
(QIAGEN). To completely dissociate nucleoprotein complexes, the homogenates were incubated 
at room temperature for 5 min. 200 l of chloroform was added, and the tubes were vigorously 
shaken and incubated at room temperature for a further 3 min. The samples were centrifuged at 
12,000 x g for 15 min at 4°C. RNA was obtained by removal of the aqueous phase, and 
precipitated by addition of 500 l of isopropanol at room temperature. After 10 min, precipitated 
RNA was collected by centrifugation at 12,000 x g for 15 min at 4°C. The supernatant was 
removed and the RNA precipitate was washed with 75% ethanol, air dried and re-dissolved in 
water at 60°C. The RNA concentration was determined by measuring the Abs 260 using a 
Nanodrop 1000 (Peqlab) and the samples stored at -80°C. 
 
Protein extraction 
Total protein extracts from pieces of tissue (or BMDM pellet) were obtained by 
homogenization of the sample in ice-cold RIPA buffer (10mM TrisHCl pH8, 150mM NaCl, 1mM 
EDTA, 1% NP-40, 0,1% SDS) supplemented with a cocktail of protease inhibitors (Pefabloc 4 
ml/ml, Apoprotin 0.1 mg/ml, Leupeptin 0.02 mg/ml, E-64 0.04 mg/ml, Pepstatin 0.004 ml/ml, 
EDTA 2 mg/ml) (Roche) using  glass potters Duall 20 (Kontes). To obtain cytosolic protein 
extracts, Monroe buffer (10 mM Hepes pH 7.6, 3 mM MgCl2, 40 mM KCl, 5% glycerol, 0.2% 
nonided P-40) supplemented with an EDTA-free proteinase inhibitor cocktail (Roche) was used 
instead. Homogenates were incubated on ice for 30 min, clarified by centrifugation at 10,000 rpm 
for 15 min in a cooled tabletop microcentrifuge (Eppendorf) and supernatants collected. Protein 
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concentration was measured using a Lowry-based DC Protein Assay (Biorad). Protein samples 
were snap-frozen and stored at -80°C. 
 
cDNA synthesis 
Total RNA was treated with RQ1 DNase (Promega) and 1 g was reverse-transcribed with 
random primers and Superscript II (Invitrogen) following the manufacturer’s instructions. When 
the cDNA was generated for subsequent qPCR analysis, 2 independent reverse-transcription 
reactions were performed on each sample, to control the degree of technical variability. In 
addition, mock reactions (without the reverse-transcriptase) of a selection of the samples were 
also included, to control the RNA dependence of the synthesized cDNA. Newly generated cDNA 
was then stored at -20°C. 
 
Polymerase Chain Reaction (PCR) 
Duplex PCR was routinely performed for genotyping of the mice. For discrimination of the 
wildtype and targeted/recombined Rosa26 alleles primers P1, P2 and P3 were used. The Cre 
transgene was detected using primers Cre_fwd and Cre_rev. Cre-mediated removal of the stop 
cassette was assessed by RT-PCR using primer pairs P4/P5 and P6/P7. FastStart PCR master 
(Roche) was used for all PCR reactions, which included 2 l of genomic DNA, primers at a 
concentration of 1.75 M in a total reaction volume of 20 l. PCR conditions were as following: 
95°C for 5 minutes, (95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds) for 35 
cycles, 72°C for 5 minutes. The same PCR conditions, but scaled up to a reaction volume of 50 to 
100 l, were used to generate, with the appropriate primer pairs, DNA fragments to be 
subsequently used as standard for absolute quantification of the qPCR data. By contrast, 
genotyping of the HFE allele required different PCR conditions, including the use of a platinum 
taq DNA polymerase (Invitrogen) and of a different amplification cycle. The latter consisted of:  
95°C for 5 minutes, (95°C for 30 seconds, 63°C for 30 seconds, 72°C for 1 minute) for 30 cycles, 
72°C for 5 minutes. All primers used for PCR are listed in table 2.3. 
 
Quantitative real-time PCR (qPCR) 
As template for the qPCR reaction, duplicate cDNA, produced by 2 independent reverse-
transcription reactions, were used for each sample. When the reverse-transcription was performed 
using 1 g of RNA as starting material, the generated cDNA was diluted 1:100 before use for 
qPCR. The reaction mix contained 10 µl of SYBR Green PCR Master Mix (Applied Biosystems), 
0.3 µM of the forward and reverse primers and 5 µl of cDNA in a total volume of 20 µl. The 
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qPCR reaction was run on ABI Prism 7500 sequence-detection system and software (Applied 
Biosystems) according to the following thermocycle protocol: 50°C 2 min, 95°C 10 min, (95°C 
15 s, 60°C 1 min) × 40 cycles. An ABI Prism 7500 sequence-detection software was used for 
analysis of the qPCR data. A method of absolute quantification was adopted and required the use 
of appropriate standard curve produced with PCR-generated fragment of the gene of interest. For 
each target gene, the level of expression was calculated as average of the duplicates and then 
calibrated to -tubulin mRNA levels. Similar results were obtained when using -actin as 
reference gene (not shown). All primers are listed in table 2.3.  
 
Agarose gel electrophoresis. 
Typically, a 2% agarose gel was used for electrophoretic separation of PCR-generated 
fragments, e.g. for genotyping analysis. A 0.8% agarose gel was instead used for analysis of 
intact genomic DNA, i.e. for Southern Blot. The desired amount of agarose was boiled in 1x TBE  
buffer (45 mM Tris-borate, 1 mM EDTA – pH 8) until it was completely dissolved. After it 
cooled down, ethidium bromide (EtBr) solution (0.5 μg/ml final concentration) was added to the 
liquid agar, which was then poured in a flat-bed tray with combs. When the agarose solidified, the 
DNA in the loading buffer was loaded into the wells and separated electrophoretically. Ethidium 
bromide intercalates with the DNA’s GC base pairs resulting in DNA-EtBr-complex that could be 
detected on a UV-light tray at 265 nm or using a gel documentation system. For preparative gels, 
a weaker UV-light source was used (365 nm) to avoid irradiation damage of DNA.  
 
Purification of DNA fragments 
PCR-generated DNA fragments of a gene of interest were purified from agarose gels, to be 
subsequently quantitated and used as standard for absolute quantification of qPCR data. DNA 
fragments were purified using a Gel Extraction Kit (Qiagen) according to the manufacturer’s 
instructions. Briefly, slices containing the fragment of interest were excised from the gel and 
dissolved at 50°C in an appropriate amount of buffer QG and applied to the silica-based 
purification column. The DNA selectively adsorbs to the silica membrane in the presence of high-
salt, while contaminants pass through the column during a centrifugation step. After washing the 
column with EtOH-containing buffer PE, the pure DNA was eluted with 30-50 μl water. 
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Restriction digest of DNA 
Restriction digests were performed either for Southern Blot analysis of genomic DNA or 
for linearization of a plasmidic template to be used for in vitro transcription of RNA probes for 
EMSA. For Southern Blot, about 4 g of genomic DNA were digested in a 20 l reaction, 
overnight at 37°C. 30000 units of either EcoRV or Mfe1 restriction enzymes (NEB) were used, 
together with the buffer suggested by the supplier and supplemented with Spermidine 0.4 M and 
2 g of RNaseA (Sigma). To generate the template for in vitro transcription, a I12CAT plasmid, 
containing the FTH1-IRE sequence was linearized with XbaI restriction enzyme (NEB) following 
the manufacture’s recommendations, overnight at 37°C. The linearized plasmid was then purified 
by phenol/chloroform extraction and the concentration determined by measuring the Abs260 with 
the Nanodrop. 
 
Southern Blot 
Proper targeting of the Rosa26 locus was verified by Southern blotting. Digested genomic 
DNA was run on 0,8% agarose-TBE gel, with no EtBr. When the size marker was sufficiently 
separated, the gel was depurinated with in 0,25 M HCl  for 20min, rinsed with water for 20 min, 
denaturized with 0,5M NaOH/1,5M NaCl twice for 20 min, neutralized with 1M Tris pH 7,6; 
1,5M NaCl twice for 20 min, washed with water twice for 10min and equilibrated  in 10x SSC 
(NaCl 1,5 M, Na-citrate 150 mM - pH 7) for 10min. The genomic DNA in the gel was then 
blotted overnight onto a Hybond N+ nylon membrane and subsequently crosslinked to it with a 
Stratalinker (autocrosslink program: 254 nm and 1200 Joules). For hybridization, PCR probes, 
obtained with primers PB1-F/PB1-R and PB2-F/ PB2-R (table 2.3), were radio-labeled using 
P32-dCTP labeling beads (Amersham), according to the manufacturer’s instruction, for 30 min 
at 37°C. Radiolabeled probes were then purified over Chromaspin P100 column (Clontech). 
Hybridization was performed following the protocol from Church and Gilbert (Church and 
Gilbert, 1984). The hybridized probe was detected by exposure of the treated membrane to x-ray 
Biomax film (Kodak). 
 
In vitro transcription 
In vitro transcription was performed to synthesize RNA probes for EMSA. For synthesis of “hot” 
P32-labeled IRE-probes, 1g of XbaI-linearized I12CAT plasmid, containing the FTH1-IRE 
sequence downstream to T7 promoter, was used as template for the in vitro transcription reaction. 
4 l of -P32-UTP (800 Ci/mmol) (Hartman) were used as only source of UTPs and the 
transcription was carried out with T7 polymerase (Promega) following the manufacture’s 
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instructions. After the synthesis of radiolabeled transcripts, the RNA was loaded onto 
Chromaspin P30 columns (Clontech) to remove the excess of unincorporated radio-nucleotides. 1 
volume of formamide blue loading dye was then added to the RNA sample, which was boiled at 
95°C for 3 min and quickly chilled on ice. Samples were electrophoretically separated on 
denaturing 7.5% acrylamide gel (20:1 acrylamide:bis/ urea 7M) in order to purify the correct band 
from potential side-products of the reaction. After electrophoretic run, the gel was exposed to x-
ray Biomax film (Kodak). The correct RNA band was cut out and eluted from the gel in 800 l of 
RNA elution buffer (0.1% SDS/ 0.3 M ammonia acetate/ 0.02 M Tris PH 7.5/ 0.01 M EDTA, in 
H20), overnight at 37°C. The eluted RNA probe was then purified by phenol/chloroform/isoamyl 
alcohol extraction. The concentration in cpm/l of the final resuspension was determined with a 
scintillation counter (Perkin Elmer). Aliquots were stored at -20°C and used within 2 weeks. 
“Cold” trace-labeled IRE-probes were in vitro transcribed using the Megascript T7 kit (Ambion) 
following the manufacture’s protocol. The newly synthetized probes were purified by 
phenol/chloroform/isoamyl alcohol extraction and additionally loaded onto Chromaspin P30 
columns (Clontech) to remove the unincorporated radio-nucleotides. After quantification of the 
cpm/l of the final resuspension, aliquots were stored at -80°C. 
 
Electrophoretic Mobility Shift Assay (EMSA) 
EMSAs were performed using 8 g of cytoplasmic extracts and in vitro-transcribed 32P-
labeled human ferritin-H1 IRE probe (40.000 cpm per reaction). Probes were pre-boiled at 95°C 
for 2 min and chilled on ice. The binding reaction was performed as following: cytoplasmic 
protein extracts were incubated with probes and 4 units of RNasin (Promega) for 15 min at room 
temperature and for additional 10 min upon addition of heparin (50 g). For supershift 
experiments, antibodies (0.5 and 1.5 g) against either IRP1 and FLAG or the appropriate rabbit 
and rat IgG controls were added to the reaction during the 10 min incubation with heparin. 
Competitive EMSAs were performed using an increasing molar excess (i.e 0.25x, 1x, 4x, 16x, 
64x) of unlabeled wildtype FTH1-IRE probe or a mutant version bearing a C deletion in the IRE 
loop, which impairs the IRP-IRE interaction (Gray et al., 1996). The competitor was normally 
pre-mixed with the “hot” probe before addition to the reaction. At the end of the 25 min of 
binding-reaction, loading buffer (50% glycerol/H20) was added and the reaction immediately 
loaded on 5% native acrylamide (60:1 acrylamide:bis) gel. Electrophoretic separation of the 
RNA-protein complexes was carried out at 5V/cm2 for about 5 hours. Gel was then dried and 
exposed to Biomax film (Kodak). The bands corresponding to IRP-IRE complexes were 
quantified using a FLA2000 phosphorimager (Fuji film, Tokyo, Japan). 
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Western Blot 
Equal amounts of total protein extracts were prepared and loading buffer (350mM Tris, pH 
6.8, 30% Glycerin, 1% SDS, 0.5 M DTT, 0.0012% Bromophenol blue) was added to them. 
Proteins were denaturated at 95°C for 5 min (except when FPN needed to be detected) and 
separated by 8% or 12% SDS-PAGE. Proteins were subsequently transferred onto a PVDF 
membrane pre-activated by a short incubation in methanol. A BioRad wet-blot chamber was used 
and blotting occurred in 1x Transfer buffer (25 mM Tris, 0.2M Glycin) at 400mA for two hours, 
or at 200 mA overnight. The membrane was subsequently blocked with 5% dry fat-free milk in 
TBST (25 mM Tris, 150 mM NaCl, 2 mM KCl, pH 7.4, 0,1% Tween 20) for 1 hour at room 
temperature. Incubation with primary antibody in 1x TBST/5% milk was performed for 2 hours at 
room temperature. Primary antibodies used and the relative dilutions were: -IRP1 (1:1000), -
FLAG-tag (1:2000) (BioLegend), -FPN (Alpha Diagnostic) (1:1000), -TfR1 (Zymed) 
(1:1000), -FTL (1:500) (Santa Cruz) (1:500), --actin (Sigma) (1:10000). After washes with 
1x TBST, the membrane was incubated for 1 hour at room temperature with appropriate 
secondary antibody  coupled to horseradish peroxidase (1:10000) in 1x TBST/5% milk. After 
washing, the secondary antibody was detected using ECL-Plus (Thermoscientific) and by 
exposure to Biomax film (Kodak). A Femto-ECL (ThermoScientific) was employed when the -
flag primary antibody was used. Relative protein expression was assessed by densitometric 
analysis of immunoblot staining intensity using the ImageJ software (National Institutes of 
Health, Bethesda, Maryland, US). 
 
 
2.2.6 Statistical Analyses 
 
Data are shown as mean values ± SEM. Statistical analysis was performed using two-tailed 
Student's t test. For the phenotypical analysis, data were analysed using one-way or two-way 
analysis of variance (ANOVA) with one between-subjects factor (genotype) and one within-
subjects factor (time). Qualitative parameters were analysed using χ2 test. P values < 0.05 were 
considered statistically significant. 
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3. RESULTS 
 
 
Due to the great similarities between mouse and human iron metabolism, murine models 
have proven to be very useful in providing important insights into the regulation of human iron 
homeostasis as well as disorders of iron metabolism. In particular, such models provide an 
integrated picture of the dynamics and complexities of iron metabolism in the whole animal, 
which is not possible in the simpler cell culture systems. Following the advent of the Cre/Lox 
technology, the number of available mouse lines with floxed iron-related genes, together with the 
broad availability of tissue-specific and ligand-induced Cre-deletor strains, has allowed elegant 
studies on the in vivo consequences of cell- and temporal-selective deletion of these genes 
(Fleming et al., 2011).  
In particular, to explore the in vivo functions of the IRP/IRE regulatory system, mouse lines 
with constitutive and tissue-specific IRP ablation have been analyzed during the last decade 
(LaVaute et al., 2001; Galy et al., 2004, 2005a; Meyron-Holtz et al., 2004a). Using a 
complementary approach, but still exploiting the advantages of the Cre/Lox technology, a new 
mouse line with conditional gain of IRP1 function has been recently generated in our laboratory. 
When I joined the project, chimeras had just been derived from blastocystes injected with 
transgenic ES clones. My initial task was to validate the proper insertion of the targeting cassette 
into the genomic locus. Next, in order to systemically activate the gain-of-function IRP1 
transgene, the targeted mice were crossed with a pan-Cre-deletor strain. The molecular 
characteristics of the resulting mouse line expressing a constitutive gain of IRP function are 
described, including the extent of gain of IRP function achieved in different tissues. The line has 
been investigated to reveal the impact of abnormally high IRP1 activity on iron homeostasis and 
general body physiology, under standard laboratory conditions as well as in response to 
experimental challenges. 
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3.1 Generation of a mouse model with gain of IRP1 function 
 
3.1.1 Targeted expression of a conditional gain of IRP1 function allele from the 
mouse Rosa26 locus 
Normally, IRP1 is present mostly in its cytosolic aconitase form, but is able to switch to 
IRE-binding upon Fe-S cluster disassembly (Rouault, 2006). To generate a gain of IRP1 function 
expression construct, three cysteine residues required for Fe-S cluster assembly (C437, C503, 
C506) (Clarke et al., 2006) and one contributing to heme-targeted degradation (C118) (A. 
Vasanthakumar and R. Eisenstein, unpublished results) were substituted by serine or alanine 
residues, respectively. The resulting mutant IRP1, referred to as IRP1*, is stabilized and escapes 
Fe-S cluster-mediated regulation (Clarke et al., 2006), being constitutively active in its IRE-
binding form (Fig. 3.1). IRP1* was also C-terminally FLAG-tagged, in order to be able to 
distinguish it from the endogenous IRP1. 
 
Figure 3.1. The gain-of-function IRP1* protein is a constitutive IRE-binder. 
Schematic representation of the aminoacidic substitutions to prevent the Fe-S switch and heme-targeted 
degradation of IRP1*. The C-terminally-fused flag-tag is also displayed. Shown are the crystal structures of 
both cytosolic aconitase (Dupuy et al., 2006) and IRP1-IRE (Walden et al., 2006).  
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To avoid the potential toxicity of high level IRP1 expression, we generated a conditional 
mutant using Cre/Lox technology. To express the transgene at a moderate level, we targeted the 
permissive and ubiquitously expressed Rosa26 locus (Zambrowicz et al., 1997) with a 
promoterless construct. In addition, the IRP1* cDNA was placed downstream of a floxed -geo 
stop cassette to prevent IRP1* transcription from the endogenous promoter. The targeted allele is 
normally silent (hence mice carrying it are phenotypically identical to wildtype) until activated by 
Cre-mediated removal of the stop cassette, which enables IRP1* expression in a conditional 
manner (Fig. 3.2). 
Proper targeting of the Rosa26 locus and subsequent successful Cre-mediated activation of the 
knock-in allele were first tested on targeted ES clones transfected with a plasmid encoding the 
Cre transgene (experiments performed by post-doc Lydie Viatte prior to my arrival and not 
shown in this thesis).  
 
Figure 3.2. Targeting of the Rosa26 locus with a Cre/Lox inducible IRP1* expression construct. 
Schematic representation of the wildtype, IRP1*-targeted and -activated Rosa26 locus and of the targeting 
construct. The targeting construct contains arms homologous to the Rosa26 locus to allow targeted 
insertion by homologous recombination. The cDNA encoding IRP1* is engineered downstream to a floxed 
-geo stop cassette to allow conditional expression of IRP1* by Cre-mediated recombination. 
 
Correct insertion of the targeting cassette was also confirmed by Southern-blot on chimeras 
derived from embryos injected with targeted ES clones (Fig. 3.3); routine genotyping was 
performed by PCR analysis (Fig. 3.4).  
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Figure 3.3. Southern-blot showing bona fide targeting of the Rosa26 locus. 
(A) Restriction enzymes used for digestion of genomic DNA and 32P-labeled DNA probes are specified 
below the panels; genotypes are indicated above each lane. (B) Scheme showing the localization of the 
restriction sites for EcoRV (EV) and Mfe1 (M) on the wildtype and targeted Rosa26 locus. The external 
probe, pb1, (recognizing the 1st exon of the Rosa26 locus) and the internal one, pb2, (recognizing the stop 
cassette) are also shown. 
 
 
Figure 3.4. Detection of the targeted Rosa26 locus by multiplex-PCR. 
(A) Representative PCR analysis of genomic DNA. Genotypes are indicated above each lane. (B) Scheme 
indicating the localization of the primer pairs used on the wildtype and targeted Rosa26 locus. 
 
To achieve systemic expression of IRP1*, we crossed mice bearing the IRP1*-targeted 
Rosa26 allele with a Cre deletor strain expressing the Cre transgene under the control of the 
ubiquitously active murine Hprt promoter (Tang et al., 2002). The latter allows removal of the 
stop cassette early at the zygote stage and consequent IRP1* expression in the whole body. Figure 
3.5 depicts the RT-PCR analysis to confirm Cre-mediated excision of the stop cassette. 
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Figure 3.5. RT-PCR analysis confirms Cre-mediated recombination of the targeted Rosa26 locus. 
(A) Representative RT-PCR performed on cDNA derived from duodenal samples. Genotypes are indicated 
above each lane. Primer pair P4/P5 is specific for the targeted locus, but does not discriminate the 
recombination event (top panel). P6/P7 is specifically designed to detect the activated allele (bottom panel). 
(B) Scheme showing the primer pairs used to distinguish the targeted and recombined Rosa26 locus. 
 
Mice homozygous for the systemically activated IRP1*-Rosa26 locus have been obtained 
in Mendelian ratio (Table 3.11); they are viable, fertile and reach adulthood without overt 
abnormalities. 
 
  
Table 3.1 IRP1* mice are obtained in Mendelian ratios. 
Ratios (%) of each genotype are calculated over a total number of 252 animals. % do not significantly 
differ from what is expected according to mendelian distribution, i.e. 12.5 % of each homozygous and 25% 
of heterozygous, for each gender. 
 
 Immunoblot with an anti-FLAG antibody shows IRP1* expression in different organs, 
including spleen, duodenum, kidney and liver. Consistently, IRP1* expression is higher in 
homozygotes compared to heterozygous mice (Fig. 3.6). The use of an anti-IRP1 antibody, 
reactive with IRP1* as well as endogenous IRP1, indicates that IRP1* protein is not highly 
overexpressed compared to the endogenous protein (Fig. 3.6). 
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Figure 3.6. IRP1* protein expression is detected by Western-blot in tissues from IRP1* mice. 
Representative Western-blot showing IRP1* or IRP1+IRP1* (IRP1/IRP1*) expression in spleen, 
duodenum, kidney and liver extracts. An anti-FLAG-tag antibody is used to detect IRP1*, an antibody 
raised against IRP1 recognizes both IRP1 and IRP1*. In liver, duodenum and kidney samples, a cross-
reacting band is marked with an asterisk. -actin is used as protein loading control. 
 
Overall, systemic expression of IRP1* from the Rosa26 locus is well tolerated in the 
mouse, which allows for the first time to study the consequences of in vivo gain of IRP1 function 
in a mammalian organism. 
 
 
3.1.2 Mice expressing IRP1* display increased IRE-binding activity 
First, the functionality of IRP1* as a specific IRE-binding protein was tested. To this end, 
we performed electrophoretic mobility shift assays (EMSAs) using cytoplasmic protein extracts 
from selected tissues. Typically, when samples from wildtype animals are incubated with a 32P-
labeled FTH1-IRE probe, two RNA-protein complexes, representing IRP1- and IRP2-IRE 
respectively, are electrophoretically separated from the free IRE probe (Fig. 3.7). When samples 
from IRP1* mice were analysed, a third RNA-protein complex appeared with intermediate 
mobility between the two endogenous complexes. The intermediate band was specifically 
supershifted by an anti-FLAG antibody and also, together with IRP1-IRE, by an anti-IRP1 
antibody recognizing both IRP1 and IRP1* (Fig. 3.7). Addition of control immunoglobulins does 
not produce similar effects. This experiment shows that IRP1* is able to bind IRE sequences. 
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Figure 3.7. IRP1* shows IRE-binding activity. 
EMSA analysis to assess the IRE-binding activity of IRP1*. Cytoplasmic extracts from ileum are incubated 
with a 32P-labeled FTH1 IRE probe. An anti-FLAG antibody is used to identify the IRP1*-IRE complex by 
supershift. An antibody recognizing both IRP1 and IRP1* is used to supershift both IRP1- and IRP1*-IRE 
complexes. Normal rat and rabbit IgGs, respectively, are used as a negative controls. 
 
Competitive EMSA experiments also demonstrated the specificity of the IRP1*-IRE 
interaction (Fig. 3.8). IRP1* binding to the radiolabeled IRE probe was progressively competed 
by increasing molar excess of unlabeled wildtype IRE sequence but not by a mutant version 
bearing a C deletion in the IRE loop which impairs the IRP-IRE interaction (Gray et al., 1996). 
 
 
Figure 3.8. The IRE-binding activity of IRP1* is specific. 
Competitive EMSA using cytoplasmic extracts from ileum. Molar excess of an unlabeled wildtype or 
mutant FTH1 IRE competitor RNAs over the radiolabeled FTH1 IRE probe is used. 
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To quantify the degree of gain of IRP1 activity, we systematically analysed extracts from 
different organs, namely brain, spleen, kidney, liver, heart, lung and duodenum, by EMSA. Figure 
3.9 depicts a representative result from brain, spleen and kidney samples, showing the increase in 
IRE-binding activity in organs expressing IRP1*. 
 
 
Figure 3.9. Expression of IRP1* yields a detectable gain of IRP activity in mouse tissues. 
Representative EMSA showing the degree of gain of IRP1 activity in cytoplasmic extracts from brain, 
spleen and kidney. Wildtype and IRP1* homozygous animals are analysed; genotypes are indicated above 
each lane. 
 
Quantification of the assays performed on a larger number of animals (Fig. 3.10) revealed 
that, while IRP2 binding activity remains largely unchanged, the sum of IRP1 and IRP1* activity 
is significantly higher in IRP1* samples compared to wildtype. This increase in IRE-binding 
activity displays tissue-dependent differences, ranging from a mild gain (10-30%) in kidney and 
liver, to a 2- to 3-fold increase in the brain, spleen, heart, lung and duodenum.  
These data document that IRP1* exerts specific IRE-binding activity and that its presence 
results in a significant gain of total IRP1 activity in all organs analysed. 
 
Overall, the engineering of a constitutively active IRP1 protein, as well as its targeting and 
expression from the Rosa26 locus via Cre/Lox technology, proved to be a successful strategy. 
Indeed, it allowed the generation of a viable mouse model with detectable gain of IRP function 
that can be explored to gain valuable insights into the relevance of adequate IRP regulation in 
vivo. 
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Figure 3.10. Quantification of IRP activity in IRP1* mouse tissues reveals tissue-specific differences 
in the degree of gain of IRP function. 
The histogram represents the relative quantification of a series of EMSAs performed on a larger number of 
animals using cytoplasmic extracts from brain, spleen, kidney, liver, heart, lung and duodenum. Sample 
size is indicated (n). * is p<0.05, *** is p<0.001. 
 
 
 
3.2 Impact of gain of IRP1 function on iron metabolism 
 
To study the importance of adequate IRP activity in vivo, we first looked at a series of 
parameters directly related to iron metabolism. At the molecular level, we analysed the effect of 
abnormally high IRP1 activity on the pattern of expression of direct IRP target genes. At the 
systemic level, we explored the consequences of gain of IRP function on body iron distribution as 
well as on blood values and erythropoiesis. 
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3.2.1 Increased IRE-binding activity alters the expression of IRP targets in vivo 
Increased IRE-binding activity is predicted to translationally repress 5’IRE-targets, such as 
FPN and FTL, and to stabilize mRNAs bearing an IRE in their 3’UTR, such as TfR1. To assess 
the in vivo effects of gain of IRP1 function on the post-transcriptional regulation of IRP target 
genes, we determined RNA and protein levels of FPN, TfR1 and FTL in key tissues of iron 
metabolism, including liver, spleen and duodenum (Fig. 3.11).  
In the liver, FPN protein levels are mostly unchanged, while FPN mRNA levels tend to be 
diminished. In splenic samples, we observe a tendency towards decreased FPN protein levels 
without corresponding changes in mRNA levels. Duodenal FPN mRNA also appears unchanged, 
while the corresponding protein expression is slightly increased. TfR1 protein and mRNA levels 
tend to be upregulated in the spleen. In the duodenum, TfR1 protein levels are also elevated, 
while its mRNA is mostly unchanged. In the liver, TfR1 mRNA and protein levels are largely 
normal. Surprisingly, the expected decrease of FTL expression could not be observed in any of 
the three tissues. In the spleen, both FTL protein and mRNA are unchanged. FTL protein appears 
upregulated in the liver, while its mRNA is decreased. In the duodenum, we detected a marked 
and statistically significant increase of FTL protein without change of the corresponding mRNA. 
(Fig. 3.11) 
Despite the apparent tissue-specific and inter-individual variability observed, the gain of 
IRP1 function has a detectable impact on the expression of IRP target genes, resulting in a 
predicted tendency towards FPN repression and TfR1 upregulation. However, an unexpected 
sustained FTL protein expression was observed in IRP1* mice. This last point will be further 
discussed in the next chapter, section 4.2.1. 
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Figure 3.11. Impact of gain of IRP1 function on the expression of IRP target genes. 
(A) Representative Western-blots of ferroportin (FPN), transferrin receptor 1 (TfR1) and ferritin L (FTL) 
using protein extracts from liver, spleen and duodenum. -actin is used as protein loading control. 
Homozygous males are analysed; genotypes are indicated above each lane. (B) The histograms represent 
relative quantification of protein and RNA levels (obtained by qPCR) of each IRP target in the three 
organs. Protein levels are normalized to -actin, RNA levels to -tubulin mRNA. Wildtype and IRP1* 
homozygous animals are analysed; sample size is indicated (n). ** is p<0.01. 
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3.2.2 Gain of IRP1 function promotes iron loading in liver, spleen and duodenum 
IRE-binding activity is normally increased in conditions of cellular iron depletion. An 
artificially generated state of IRP activation, such as IRP1* expression, would thus be expected to 
trigger an increase in cellular iron content. To assess whether gain of IRP1 function affects iron 
levels in mouse tissues, we performed spectrophotometric measurements of the total non-heme 
iron content of liver, spleen and duodenum. This analysis revealed increased iron levels in all 
three organs, between 1.7-fold in the liver, 1.5-fold in the duodenum and 1.3-fold in the spleen, 
respectively (Fig. 3.12A).  
To determine whether gain of IRP1 function affects body iron distribution more broadly, in 
collaboration with Prof. Klaus Schümann (Technische Universität München, Germany), we 
injected 59Fe intravenously and monitored its deposition in several tissues two weeks after 
administration (Fig. 3.12B),. In agreement with the spectrophotometric measurements described 
above, this experiment shows preferential accumulation of 59Fe in the liver and spleen of mice 
expressing IRP1* (Fig. 3.12C). There was no detectable accumulation of 59Fe in the duodenum, 
which could reflect the consequences of sloughing of duodenal enterocytes during the two weeks 
following the 59Fe injection. 
To test whether the increased non-heme iron content observed in the duodenum might 
result from higher dietary iron intake, rather than increased serum iron uptake, we measured the 
levels of the apical iron importer DMT1. Currently, four DMT1 transcript variants have been 
described, which are generated by the use of alternative exons, 1A or 1B, and alternative 3’ 
splicing giving rise to IRE- or non-IRE-containing transcripts (Gunshin et al., 2001; Hubert and 
Hentze, 2002). Knowing that DMT1A is the predominant 5’ isoform expressed in the duodenum 
(Hubert and Hentze, 2002), we used primer pairs specific for either of the two 3’ variants and 
measured the mRNA levels of the IRE- and non-IRE-containing isoforms. Similar to TfR1, the 
3’IRE isoform of DMT1 was predicted to be increased by gain of IRP function. We found that the 
levels of DMT1-no-IRE were unchanged, while DMT1-IRE was unexpectedly diminished in 
IRP1* mice (Fig. 3.13). This correlated with a slight decrease of DcytB, the reductase coupled to 
DMT1 to allow cellular ferric intake. These results indicate that the elevated duodenal non-heme 
iron in IRP1* mice is not associated with increased levels of DMT1 and thus unlikely due to 
increased dietary iron uptake. 
Overall, these data show that gain of IRP1 function alters body iron distribution with 
preferential iron loading in liver, spleen and duodenum, associated with changed expression of at 
least some of the IRE-containing target mRNAs. 
3. RESULTS
   
 65
 
 
Figure 3.12. Gain of IRP1 function causes iron loading in liver, spleen and duodenum. 
(A) Spectrophotometric determination of non-heme iron content in total extracts from liver, spleen and 
duodenum. (B) Schematic representation of the experimental setup to determine the kinetics of body iron 
distribution. (C) Histogram showing the 59Fe content determined in different tissues. Homozygous males 
are analysed; sample size is indicated (n). * is p<0.05, *** is p<0.001. 
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Figure 3.13. DMT1 levels are not increased in the duodenum of IRP1* mice. 
Relative quantification of DMT1-IRE, DMT1-noIRE and DcytB mRNAs (by qPCR) from the duodenum of 
IRP1* mice. mRNA levels are calibrated to -tubulin. 6 homozygous animals per genotype are analysed. 
 
 3.2.3 Abnormally high IRP1 activity causes macrocytic anemia 
In the body iron is mainly used for the hemoglobinization of red blood cells. To evaluate 
whether gain of IRP1 function affects hematological parameters, we analysed blood cell profiles 
as well as plasma iron values. IRP1* mice are erythropenic (decreased red blood cell count - 
RBC) and have a lower hemoglobin content, lower hematocrit and increased mean cell volume 
(MCV) with some differences between genders (IRP1* females display a bigger increase in MCV 
and mean cell hematocrit (MCH) compared to males of the same genotype) (Table 3.2). 
 
 
Table 3.2. IRP1* mice display moderate macrocytic erythropenia. 
Table of blood cell profiles. Results are shown as mean + SEM. 10 homozygous animals per gender and per 
group are analysed. RBC, red blood cell; MCV, mean corpuscular volume; MCH, mean corpuscular 
hemoglobin. * is p<0.05, ** is p<0.01 and *** is p<0.001. 
 
Serum iron and ferritin levels are unchanged, although transferrin saturation is decreased in 
males as a result of increased total iron binding capacity (TIBC) (Table 3.3). 
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Table 3.3. Serum iron parameters in IRP1* mice. 
Blood biochemistry values. TIBC (total iron-binding capacity) = serum Fe + UIBC (unbound iron binding 
capacity); Tf: transferrin; Tf saturation = serum Fe/TIBC x 100. Results are shown as mean + SEM. ** is 
p<0.01. 
 
To assess potential responses of the systemic regulator of iron homeostasis, we measured 
hepcidin mRNA levels in the liver and found it to be largely unchanged (Fig. 3.14). This result 
shows that systemic gain of IRP1 function and the ensuing changes in body iron distribution and 
hematological parameters do not trigger changes in hepcidin expression. 
Altogether, increased IRP1 activity causes a mild macrocytic anemia, without altered 
systemic iron availability. 
 
 
Figure 3.14. IRP1* expression does not alter hepcidin mRNA levels. 
Relative quantification of hepcidin (Hamp) mRNA from the liver of IRP1* mice, obtained by qPCR. 
Hepcidin mRNA levels are calibrated to -tubulin. 6 homozygous animals per genotype are analysed. 
 
 
3.2.4 IRP1 hyper-activity impairs erythroid maturation 
To assess whether the macrocytic anemia affecting IRP1* mice results from impaired 
erythropoiesis, we analysed the maturation state of bone marrow-derived erythroid progenitors by 
flow cytometry. Co-staining for Ter119 (erythroid lineage marker) and CD71 (corresponding to 
TfR1) allows separation of erythroblasts into immature (Ter119+, CD71 high) and more mature 
(Ter119+, CD71 low) erythroid cells (Fig. 3.15A). Quantification of erythroid cells isolated from 
a larger number of animals revealed a ~1.3 fold increase in the frequency of immature progenitors 
3. RESULTS
   
 68 
accompanied by a ~30% decrease of the more mature erythroid cells in IRP1* mice (Fig. 3.15B). 
As a matter of fact, this analysis holds a contextual bias as it relies on TfR1 levels to define the 
maturation stage of erythroid cells. TfR1 is an IRP target and has been shown to be upregulated in 
other tissues from IRP1* mice and the same could apply to erythroblasts. The cumulative cell 
frequency distribution of Ter119+ cells according to TfR1 intensity (Fig. 3.15C, left panel) shows 
that the majority of IRP1* erythroblasts (lying in the 3rd quartile, including the 50-75% of the 
total cells) are indeed characterized by profoundly higher TfR1 intensities compared to 
erythroblasts from wildtype mice. This prompted us to use an alternative marker of erythroid 
differentiation that would not be affected by IRP activity, such as CD44 (adhesion receptor). 
Distribution of Ter119+ cells according to CD44 intensity (Fig. 3.16C, right panel) shows similar 
CD44 levels in erythroblasts from both wildtype and mutant mice. 
 
 
 
Figure 3.15. IRP1* expression impairs normal erythropoiesis.  
(A) Representative FACS profiles of bone marrow-derived erythroid progenitor cells co-stained with 
Ter119 and CD71. For each genotype, indicated on top of each panel, the panels show the classical 
Ter119/CD71 profiles allowing for separation of immature (Ter119+, CD71 high) and more mature 
(Ter119+, CD71 low) cells. (B) Relative quantification of the frequencies of the two populations (defined 
by Tfr1 levels) of Ter119+ cells. 6 homozygous females per each genotype are analysed. (C) Cumulative 
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cell frequency distribution of Ter119+ cells according to TfR1 (left panel) and CD44 levels (right panel). 
*** is p<0.001. 
 
Co-staining for Ter119 and CD44 has recently shown (Chen et al., 2009) to allow a finer 
separation of erythroblasts into five different subpopulations according to FSC (forward scatter) 
and CD44 levels (Fig. 3.16A-B). We found a significant increase (1.4- to 1.6- fold) in the relative 
abundance of the three earliest precursors, i.e. proerythroblasts, basophilic and 
polychromatophilic erythroblasts (Fig. 3.16C). Also, we detected a significant decrease of the 
mature erythrocytes (~30%) (Fig. 3.16C), which is consistent with the decrease in RBC observed 
in peripheral blood. 
 
Figure 3.16. IRP1* expression impairs erythroblastic maturation.  
(A) Schematic representation of erythroid cells differentiation. Ter119 is expressed in all cells from the 
erythroid lineage, while CD44 shows a defined and discrete pattern of expression, with higher levels in 
immature erythroblasts and sequentially lower levels following the maturation steps. Figure modified from 
Porayette P., Phd thesis 2008. (B) Representative FACS profiles of bone marrow-derived erythroid 
progenitor cells co-stained with Ter-119 and CD44. For each genotype, indicated above each panel, the 
panels represent CD44 vs FSC (forward scatter) distribution of cells in the erythroid gate established in the 
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Ter119/CD71 profile. I, II, III, IV and V represent distinct and progressively more mature erythroid 
populations (Chen et al., 2009). (C) Relative quantification of the frequencies of each erythroid population. 
6 homozygous females per each genotype are analysed. * is p<0.05, ** is p<0.01 and *** is p<0.001. 
 
Co-staining for TfR1 also revealed increased levels of the iron importer in all five 
subpopulations of bone marrow-derived erythroid precursors (Fig. 3.17A). We observed a 
significant increase of TfR1 intensity, corresponding to increases of ~1.7-fold in subpopulation I, 
~2-fold in II, ~2.8-fold in III, ~3.2-fold in IV and ~1.3-fold in V (the latter not being apparent in 
the graph due to TfR1 approaching background levels in mature erythrocytes from both wildtype 
and IRP1* mice) (Fig. 3.17B). These data suggest that excessive iron import via TfR1 may 
interfere with normal erythropoiesis.  
 
 
Figure 3.17. TfR1 levels are increased in erythroblast progenitors of IRP1* mice. 
(A) Histograms showing the peaks of cell frequency distribution as a function of TfR1 intensity in the 
distinct five subpopulations of erythroid progenitors. (B) Relative quantification of TfR1 intensity in each 
erythroid subpopulation. 6 homozygous females per each genotype are analysed. ** is p<0.01, *** is 
p<0.001. 
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These observations indicate that IRP1 activity critically influences erythroid maturation. 
The mechanisms underlying this phenotype are not entirely resolved yet (discussed in 4.2.2). 
 
Overall, we showed that gain of IRP1 function has a detectable impact on IRP target genes, 
resulting in an altered pattern of expression in different organs. Moreover, analysis of IRP1* mice 
revealed an important role of physiological IRP regulation for maintenance of appropriate body 
iron distribution as well as for securing normal erythropoiesis. 
 
 
3.3 Standard phenotyping of mice with gain of IRP1 function 
 
Our study was focused so far on the examination of parameters directly related to iron 
metabolism. However, the current emergence of the IRP regulon beyond the circle of well-known 
iron handling molecules (see 1.4.4), together with the involvement of iron in many different 
biological pathways, encouraged us to broaden our focus of research. To explore additional 
aspects of mouse physiology that could be affected by the gain of IRP1 function, IRP1* mice 
have been subjected to a broad standard phenotyping protocol. This has been done in 
collaboration with the mouse clinic Institut (ICS, Strasbourg, France). The standard phenotyping 
program included a large panel of tests ranging between hematology and clinical chemistry, 
metabolism, cardiology, neurobiology and behaviour. The homogenization of the procedures to 
the EMPReSS (European Mouse Phenotyping Resource of Standardised Screens) standards also 
offers the possibility to directly compare the phenotype of IRP1* mice with other mouse models 
that have been subjected to the same protocols. The following section covers experiments where 
IRP1* mice have shown differences compared with wildtype mice. Data not shown in this chapter 
are documented in the Appendix. 
 
3.3.1 Gain of IRP1 activity does not affect the general health status of IRP1* mice 
Animals were not found to have gross abnormalities by inspection. While confirming the 
hematological data obtained in our laboratory describing a moderate macroytic erythropenia (see 
Appendix), analysis of body weight and temperature, fat/lean ratio, blood biochemistry, energy 
metabolism, and glucose homeostasis did not identify any significant anomalies (see Appendix). 
This indicates that the gain of IRP1 activity does not affect the general health status of 
IRP1* mice under standard laboratory condition.  
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3.3.2 IRP1* mice display altered motor coordination and reduced endurance 
Gross neurobehavioral examination revealed that the physical appearance, including body 
posture, tremor and locomotion, together with neurological reflexes and sensory abilities (vision, 
audition, touch and vestibular function) were normal in IRP1* mice (see Appendix). Interestingly, 
while not showing abnormalities in spontaneous locomotory activity or anxiety behavior, as 
assessed by the open field test (see Appendix), IRP1* mice displayed decreased performance in 
the rotarod test. In this test, the time (latency) before the mouse falls off a rod rotating under 
continuous acceleration is considered as measure to maintain balance; performance over repeated 
trials is quantitated as a measure of motor learning. The histogram (Fig. 3.18) shows that mice 
with gain of IRP1 function fall off the accelerated rotating drum earlier than wildtype littermates. 
The difference is further enhanced over repeated trials as a result of the improved performance of 
wildtype mice. This test indicates that IRP1* mice have altered motor coordination and slightly 
reduced motor learning capacity. 
 
 
Figure 3.18. IRP1* mice display altered motor coordination. 
The time (latency) before mice fall off the accelerated (4-40rpm) reel is measured over 3 trials separated by 
15 minutes interval. 12 homozygous males per each genotype are analysed. *** is p<0.001. 
 
Moreover, when forced to run on a treadmill, mice with gain of IRP1 function displayed 
lower latency to exhaustion and travelled for shorter distances (Fig. 3.19). This shows that IRP1* 
mice also have reduced motor endurance. These motor alterations cannot be explained by a 
general decrease in muscle strength, as assessed by the grip strength test when calibrated over 
weight (Fig. 3.20).  
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Figure 3.19. IRP1* expression decreases motor endurance. 
The duration (latency) of the running and the distance covered by mice forced to run on an electronically 
controlled treadmill are measured. 12 homozygous males per each genotype are analysed. 
 
 
 
Figure 3.20. IRP1* mice display normal muscle strength calibrated over weight. 
Grip strength developed by mice pulled away from a grid connected to a dynamometer is measured. 12 
homozygous males per each genotype are analysed. * is p<0.05. 
 
Overall, these data demonstrate that basic sensory functions, spontaneous locomotory 
activity and behaviour appeared to be normal in IRP1* mice However, IRP1* expression has a 
negative impact on motor coordination and endurance, which is not correlated to decreased 
muscle strength. 
 
 
3.3.3 Abnormally high IRP1 activity impairs neuromuscular transmission 
To investigate whether the altered motor functions of IRP1* mice correlated to defects in 
nerve conduction or neuromuscular transmission, mice were subjected to electromyographic 
examination. Nerve conduction was assessed by measuring the speed of an electrical impulse 
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travelling along the caudal nerve, which is one of the most accessible nerves in the mouse 
(together with the sciatic nerve) for investigation. While nerve conduction was not affected, 
IRP1* mice displayed a delayed motor response of the gastrocnemius muscle after sciatic nerve 
stimulation (Fig. 3.21). This suggests that the altered motor functions in mice with gain of IRP1 
function may be associated with a neuromuscular defect. 
 
 
Figure 3.21. IRP1* expression impairs neuromuscular transmission. 
The left panel shows the sensitive nerve conduction velocity (SNVC) after the caudal nerve stimulation. 
The right panels display the compound muscle action potential (CMAP) of gastrocnemius muscle after 
sciatic nerve stimulation. The time (latency) before contraction and the intensity (amplitude) of the muscle 
response are measured. 12 homozygous males per each genotype are analysed. * is p<0.05. 
 
To explore this aspect further, muscle biopsies were subjected to histological and 
ultrastructural analyses. Sections of both fast-twitch (i.e. gastrocnemius and tibialis) and slow-
twitch (i.e. soleus) leg muscles, stained with hematoxilin-eosin, did not show any signs of altered 
fiber structure or organization (see Appendix). This ruled out the possibility that the observed 
defects could be linked to a gross structural problem of the muscular fibers.  
These data show that IRP1* expression has an impact on neuromuscular function, with 
effects on motor coordination and endurance. Since the impaired neuromuscular transmission of 
IRP1* mice could potentially derive from alterations of the neuromuscular junction and/or of 
mitochondria (discussed in 4.3), muscle samples have been submitted for investigation by 
electron microscopy. 
 
Phenotypic analysis of IRP1* mice under standard laboratory conditions did not reveal a 
significant impact of inappropriate IRP1 regulation on general health. In fact, IRP1* mice do not 
display any gross abnormalities when subjected to a large battery of analyses of their health status 
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(see Appendix). However, appropriate IRP1 expression appears to be important to secure proper 
body iron distribution and normal erythropoiesis. Also, adequate IRP activity seems to be a 
requirement for normal neuromuscular transmission, although further investigation is needed to 
understand the underlying mechanism (discussed in 4.2.2). 
 
 
3.4 Impact of IRP1* expression on the response to iron loading 
 
In addition to the analysis of the effect of abnormally high IRP activity on body physiology 
under standard laboratory conditions, we also intended to assess whether IRP1* expression 
affects the response to iron loading, a condition when IRPs are normally switched off. In a 
wildtype cell, iron loading typically leads to IRP inhibition, which helps preventing potential 
cellular iron toxicity by reducing further iron entry and increasing iron export and storage (see 
1.4.1). In a cell expressing IRP1*, while endogenous IRPs will be switched off, IRP1* will still 
be active, thus preventing the physiological response to iron loading, potentially leading to 
oxidative stress. 
In a first ex vivo experiment, we looked for a proof of principle that gain of IRP1 activity impairs 
cellular iron sensitivity. Subsequently, we examined how mice with abnormally high IRP1 
activity handle either acute or chronic iron overload. 
 
3.4.1 IRP1* expression alters the response of bone marrow-derived macrophages to 
fluctuations of iron levels ex vivo  
To assess whether IRP1* expression affects the cellular response to iron loading, we 
performed a pilot experiment on an ex vivo system. We chose to analyse bone marrow-derived 
macrophages (BMDM), because they are relatively easy to obtain from the mouse, they express 
the IRP target genes and their response to iron exposure has been well characterized in our 
laboratory. BMDM were isolated from femurs of wildtype and IRP1* mice and exposed to an 
external iron source (to deactivate endogenous IRPs) or an iron chelator (to activate endogenous 
IRPs). The pattern of expression of some IRP target genes was then analysed, both at the protein 
and mRNA level (Fig. 3.23).  
Iron chelation caused an increase in TfR1 mRNA level, consistent with IRP-mediated 
stabilization. Besides that, treatment with the iron chelator desferrioxamine (DFO) was not 
detectable on the pattern of expression of the other IRP targets. In contrast, BMDM from 
wildtype mice showed the expected response to hemin treatment. That included an increase in 
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FPN and FTL protein levels, consistent with a reduced IRP-mediated translational repression. In 
addition, the mRNA of both targets was also increased, in agreement with hemin-mediated 
transcriptional activation, as already described (Coccia et al., 1992; Delaby et al., 2008). On the 
other hand, TfR1 mRNA and protein levels were decreased, consistent with loss of IRP-mediated 
mRNA stabilization. Compared to wildtype, BMDM from IRP1* mice showed an altered 
expression pattern of IRP target genes already under control condition. FPN protein levels were 
increased along with elevated TfR1 protein levels, with no change of the corresponding mRNAs. 
This is in agreement with what is expected from a state of higher IRP activity. In addition, upon 
hemin treatment, IRP1* BMDM showed an impaired response to iron loading.  Both FPN and 
FTL were not upregulated to the same extent as in wildtype BMDM, at the protein and mRNA 
levels. Also, TfR1 protein was not downregulated as strongly as in wildtype, while the 
corresponding mRNA was similarly decreased. This altered expression pattern of FPN, FTL and 
TfR1 could be explained by persistence of post-transcriptional regulation by IRP1*, which, in 
contrast to endogenous IRPs, is still active even in iron-replete conditions. 
 
 
Figure 3.23. IRP1* expression alters the pattern of expression of IRP target genes in BMDM exposed 
to changes in iron levels ex vivo. 
(A) Representative Western-blots of FPN, TfR1 and FTL, using protein extracts from BMDM isolated from 
wildtype or IRP1* homozygous mice. -actin is used as protein loading control. Genotypes and 
corresponding conditions are indicated above each lane. Ctr: untreated BMDM; DFO and hemin: BMDM 
exposed ex vivo to DFO or hemin (100 M for 10 hours). (B) Relative quantification of mRNA of each 
IRP target (normalized to -tubulin) by qPCR. Genotypes and corresponding conditions are displayed 
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above the histograms. Sample size (n) is indicated. Biological replicates displayed similar response in an 
indipendent experiment (not shown). 
 
To assess the actual degree of IRE binding activity under iron-replete conditions, we 
performed EMSA analysis (Fig. 3.24). As expected, due to IRP1* expression, the total IRE 
binding activity in IRP1* BMDM is higher than in wildtype cells, already under control 
conditions (and, to a greater extent upon iron chelation). This is accompanied by partial 
downregulation of IRP2. The latter could be due to elevated intracellular iron levels following 
IRP1*-driven increase of TfR1-mediated iron intake and/or decrease of FPN-mediated iron 
export. As expected, IRP1*-IRE binding activity persists upon hemin treatment, although 
diminished to some extent. 
 
 
Figure 3.24. Total IRP activity remains high in IRP1* BMDM upon ex vivo iron loading. 
Representative EMSA experiment on cytoplasmic extracts from BMDM isolated from wildtype or IRP1* 
homozygous mice. Genotypes and corresponding conditions are indicated above each lane. Ctr: untreated 
BMDM; DFO and hemin: BMDM exposed ex vivo to DFO or hemin (100 M for 10 hours). 
 
To address whether the Rosa26 locus is sensitive to iron levels, we measured IRP1* mRNA 
levels and found them to be largely unchanged compared to controls (Fig. 3.25). This indicates 
that the promoter activity of the Rosa26 locus is unlikely to be affected by iron. 
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Figure 3.25. IRP1* mRNA levels from the Rosa26 promoter are not affected by changes in iron 
levels. 
Relative quantification of IRP1* mRNA (normalized to -tubulin), by qPCR, in BMDM isolated from 3 
IRP1* homozygous mice. Ctr: untreated BMDM; DFO and hemin: BMDM exposed ex vivo to DFO or 
hemin (100 M for 10 hours). 
 
When measuring IRP1* protein levels, we found a significant reduction of IRP1* 
expression upon hemin treatment (Fig. 3.26). This could be explained by hemin-induced IRP1* 
protein degradation and would suggest that mutation of C118 diminishes but not completely 
abolishes heme-mediated degradation. 
 
 
Figure 3.26. IRP1* protein levels are diminished upon hemin treatment ex vivo. 
Representative Western-blots of IRP1* and IRP1, using protein extracts from BMDM isolated from 
wildtype or IRP1* homozygous mice. -actin is used as protein loading control. An anti-FLAG-tag 
antibody is used to detect IRP1*. The anti-IRP1 antibody recognizes both IRP1 and IRP1*. Genotypes and 
corresponding conditions are indicated above each lane. Ctr: untreated BMDM; DFO and hemin: BMDM 
exposed ex vivo to DFO or hemin (100 M for 10 hours). 
 
These data on primary BMDM demonstrate that expression of IRP1* alters the set point of 
IRP/IRE-mediated responses to iron loading. Having shown that in a simplified ex vivo setting, 
we next wanted to assess the organismal response to iron loading using two approaches, i.e. acute 
and chronic iron overload in vivo. 
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3.4.2 IRP1* does not detectably aggravate liver iron accumulation and ensuing 
oxidative injury in acutely iron overloaded mice 
The adaptive response to pharmacological administration of colloidal iron has been well 
studied both in animals and humans. A well established in vivo model of experimental acute iron 
overload is generated by iron-dextran injection. Once in circulation, iron-dextran is readily 
cleared by the reticuloendothelial system (Muir and Golberg, 1961). There, the iron-dextran 
complex dissociates and iron is released into the circulation bound to plasma transferrin. Excess 
iron is then absorbed primarily by the liver where it accumulates (Theurl et al., 2005). Being a 
well-known catalyst for the formation of highly toxic radicals, tissue iron overload can lead to 
damage and organ dysfunction (Halliwell and Gutteridge, 1992). 
Based on a pilot dose-/time-response experiment on wildtype mice, we decided to 
administer a dose of Fe-dextran equal to 1 mg, which triggered substantial iron loading without 
major adverse effects (not shown). We also decided to sacrifice mice one day after injection, 
corresponding to the peak in hepatic iron accumulation (not shown). Wildtype and IRP1* mice 
were intravenously injected with Fe-detran, or detran alone (vehicle), and analysed for hepatic 
iron accumulation and potential signs of oxidative injury. Compared to vehicle-injected wiltype 
mice, we found that pharmacological iron treatment determined, both in wildtype and IRP1* 
mice, a ~5 fold increase of hepatic iron (Fig. 3.27A). Hepatic iron loading was accompanied by a 
~1.6 fold and ~1.8 fold increase in lipid peroxides (measured as sign of oxidative injury) in 
wildtype and IRP1* mice, respectively (Fig. 3.27B). 
 
 
Figure 3.27. IRP1* expression does not aggravate liver iron accumulation and lipid peroxides levels 
in response to acute iron loading. 
(A) Non-heme iron content in total extracts from liver of mice intravenously injected with 1 mg of Fe-
dextran or dextran alone. 6 homozygous males per group are analysed. (B) Corresponding malondialdehyde 
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(MDA) levels measured in total liver extracts (with the TBARS assay) as index of lipid peroxidation. ** is 
p<0.01. 
 
These data indicate that the response to acute iron loading, under the above mentioned 
experimental conditions, is not detectably altered in the liver of IRP1* mice. However, it is 
possible that other organs may be more sensitive than the liver to acute iron overload. 
 
3.4.3 Consequences of IRP1* expression in chronic iron overloaded mice 
HFE is part of sensory complex present on the surface of hepatocytes and that stimulates 
the expression of the hepatic hormone hepcidin to avoid/combat inappropriate increase of plasma 
iron levels. HFE deficiency diminishes hepcidin expression and ensuing systemic iron overload 
(see 1.2.2). To study the effect of IRP1* expression on the adaptive response to chronic iron 
overload, we crossed IRP1* mice with HFE KO mice, a mouse model of primary iron overload. 
Mice carrying both IRP1* and the HFE null allele in homozygosity (referred to as 
IRP1*/HFE) have been generated. Animals are viable, fertile and reach adulthood with no overt 
abnormalities. IRP1*/HFE KO mice were compared to control groups, namely wildtype mice and 
single mutants (IRP1* and HFE KO). Since the yield of double mutant males was initially poorer 
compared to the other experimental groups of the same gender, this thesis focuses on the analysis 
of female mice. 
HFE ablation normally results in high serum iron, ferritin and transferrin saturation, 
together with hepatic iron loading. Indeed, when compared to wildtype animals, HFE KO mice 
showed a ~ 1.2 and ~ 1.4 fold increase in serum iron and ferritin respectively (Table 3.4). This 
was accompanied by a ~1.4 fold increase in transferrin saturation (Table 3.4) as well as a ~ 4.2 
fold elevated liver iron content (Fig. 3.28). Despite the systemic iron loading, hepcidin levels 
were unchanged and therefore inappropriately low (Fig. 3.29). Having confirmed the hallmarks of 
HFE ablation in our experimental setting, we next measured the same parameters in IRP1*/HFE 
KO mice to confirm the chronic iron overload. Compared to IRP1* mice, IRP1*/HFE KO 
animals showed a ~1.4 fold increase in serum iron, a ~ 2.2 fold higher transferrin saturation as 
well as a ~ 1.6 fold increase in serum ferritin (Table 3.4). In addition, IRP1*/HFE KO mice 
displayed a ~ 2.7 fold elevated hepatic iron (Fig. 3.28). This shows that IRP1*/HFE KO mice are 
significantly iron overloaded compared to IRP1*. In spite of that, hepcidin expression was found 
not to be detectably increased (Fig. 3.29). Next, we examined whether gain of IRP1 function 
potentially aggravated the iron loading driven by HFE ablation. We found that the increase in 
serum iron, transferrin saturation, ferritin (Table 3.4) as well as liver iron (Fig. 3.28), when 
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compared to wildtype animals, was similar in IRP1*/HFE KO and HFE KO mice. Also, despite 
the general iron loading, hepcidin was unchanged in both IRP1*/HFE KO and HFE KO animals 
(Fig. 3.29). 
Overall, these data suggest that higher IRP1 activity does not have a strong impact on the 
chronic iron loading driven by HFE ablation. However, the consequences of gain of IRP1 
function on the response to chronic iron challenge remain to be examined in detail, including 
measure of oxidative injury in different tissues as well as serum markers of organ dysfunction. 
 
 
 
Table 3.4. Serum iron, ferritin and transferrin saturation are elevated in primary iron loaded mice 
with gain of IRP1 function. 
Blood biochemistry values. TIBC (total iron-binding capacity) = serum Fe + UIBC (unbound iron binding 
capacity); Tf: transferrin; Tf saturation = serum Fe/TIBC x 100. Results are shown as mean + SEM. * is 
p<0.05, ** is p<0.01, compared to IRP1* mice. 
 
 
Figure 3.28. Primary iron loaded mice with high IRP1 activity show strong hepatic iron 
accumulation, similarly to HFE KO animals. 
Non-heme iron content in total extracts from liver. Homozygous females are analysed. Sample size is 
indicated (n). *** is p<0.001. 
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Figure 3.29. Hepcidin levels are unchanged in primary iron loaded mice with hyper-active IRP1. 
Relative quantification of hepcidin (Hamp) mRNA from the liver, obtained by qPCR. Hepcidin mRNA 
levels are calibrated to -tubulin. 6 homozygous females per genotype are analysed. Genotypes are 
indicated below the histogram. 
 
Taken together, IRP1* expression alters the sensitivity to iron and the response to iron 
loading ex vivo. However, acute or chronic iron overload in vivo does not yield clear alterations 
in IRP1* compared to wildtype mice. This will be discussed in the next chapter (section 4.4). 
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4. DISCUSSION 
 
 
Since its initial discovery 25 years ago, enormous progress has been made towards the 
understanding of the IRP/IRE system as an elegant posttranscriptional regulatory machinery that 
maintains intracellular iron homeostasis. Extensive studies in cultured cells have formed the basis 
for the molecular understanding of how the IRP/IRE system acts on its molecular targets and how 
the IRPs themselves are in turn regulated by iron-dependent and -independent mechanisms 
(Anderson et al., 2012). The generation of murine models with loss of IRP function has provided 
insights into the importance of the IRP/IRE system for viability (Smith et al., 2006; Galy et al., 
2008, 2010) and for the functionality of central organs of iron metabolism (LaVaute et al., 2001; 
Cooperman et al., 2005; Galy et al., 2005b, 2008, 2010; Ferring-Appel et al., 2009). Recently, 
transcriptome-wide studies have revealed novel IREs in mRNAs encoding proteins involved in 
diverse cellular pathways (Sanchez et al., 2011), thus expanding the IRP/IRE network (or 
regulon) beyond iron homeostasis. Furthermore, diverse human diseases have been linked to 
alterations of the IRP/IRE system, including mutations of the ferritin-IRE (Beaumont et al., 1995; 
Girelli et al., 1995; Kato et al., 2001), polymorphisms of the IRP2 promoter (Coon et al., 2006; 
DeMeo et al., 2009), or abnormally high IRP activity (Faucheux et al., 2002; Lobmayr et al., 
2005; Camaschella et al., 2007; Crooks et al., 2012).  
To complement published studies of IRP KO models and to expand our understanding on 
the involvement of dysregulated IRP activity in disease progression, we generated a mouse model 
of gain of IRP1 function.  
 
 
 
4.1 First mammalian model with primary gain of IRP1 function 
 
At physiological tissue oxygen and iron concentrations, IRP1 is present mostly in its 
cytosolic aconitase form, but is able to switch to IRE-binding upon Fe-S cluster disassembly 
(Meyron-Holtz et al., 2004a, 2004b). To generate a constitutively active form of IRP1, we 
replaced the three cysteines that are required for Fe-S cluster coordination by serines, blocking 
the iron-dependent molecular switch to its cytosolic-aconitase form and locking it into its IRE-
binding conformation (Fig. 3.1). IRP1 overexpression has previously been reported to be toxic in 
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cells (DeRusso et al., 1995). In flies, ubiquitous and muscle-specific overexpression of IRP1A, 
the only IRP homolog possessing IRE-binding activity of the two cytosolic aconitases, has been 
shown to cause pre-adult lethality (Lind et al., 2006; Surdej et al., 2008). To minimize the risk of 
potential lethality associated with expression of a constitutively active IRP1 (IRP1*), we 
generated a conditional allele by Cre/Lox technology. For moderate rather than excessive levels 
of IRP1* expression, we targeted the ubiquitously active Rosa26 locus (Zambrowicz et al., 1997) 
with a promoterless construct, which allows IRP1* transcription at the endogenous Rosa26 
promoter rates. The engineering of a silent targeted cassette, together with the permissivity of the 
Rosa26 locus (Zambrowicz et al., 1997), made possible the generation of animals bearing an 
inactive IRP1* transgene. The latter can be subsequently activated, either in a constitutive- or a 
tissue- specific manner, by breeding with relevant Cre-deletor strains (Fig. 3.2). In this thesis, the 
effects of the ubiquitous gain of IRP1 function have been explored in a mouse line where the 
IRP1* transgene has been activated in the whole body. Future work could focus on the 
consequences of activation of IRP1* in specific tissues, which would allow a finer dissection of 
local anomalies caused by gain of IRP1 function. This would also enable the discrimination 
between systemic and cell-autonomous effects among the alterations observed in mice expressing 
IRP1* systemically. Among others, the use of an erythroid-specific Cre-line would be of 
particular interest to further characterize the macrocytic anemia of IRP1* mice. If the blood 
defect was phenocopied upon erythroid-restricted IRP1* expression, this would prove an 
erythroid-autonomous nature of the macrocytic anemia in IRP1* mice. Conceivably, the organism 
may also, over time, adapt to a certain degree of gain of IRP function by adopting appropriate 
counterbalancing mechanisms. Hence, an inducible activation of IRP1* expression at a specific 
stage of mouse development might allow acute effects of gain of IRP1 function to emerge. 
 In general, the conditional targeting strategy applied proved to be successful in obtaining, 
for the first time, live animals expressing a gain of IRP1 function protein (IRP1*). Moreover, it 
holds promise for further studies on the effect of abnormally high IRP1 activity in specific tissues 
or at specific stages of the mouse life. 
Increased IRP1 activity is achieved in all tissues analysed (Fig. 3.10), with a tissue-specific 
increment of total IRE-binding activity that is partially derived from the strength of the Rosa26 
promoter and the basal activity of endogenous IRP1 in each tissue. The kidney and, to a lower 
extent, the liver are among the organs where IRP1 is normally expressed at the highest levels 
(Meyron-Holtz et al., 2004a). This most probably explains why the contribution of IRP1* in those 
2 organs is relatively smaller when compared to the gain of IRP1 function achieved in the other 
tissues with lower basal IRP1 activity, such as brain, spleen, heart, lung and duodenum. 
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IRP1* mice are viable and fertile, suggesting that IRP1* expression is well tolerated and 
does not dramatically interfere with overall mouse physiology. Yet, we cannot conclude that 
appropriate IRP1 regulation is not important for health. Conceivably, the rather moderate level of 
gain of IRP1 function that we used to avoid potential lethality of IRP1 overexpression may be 
below a hypothetical pathological threshold. Upregulating IRP1* expression in the mouse may 
result in increasingly prominent pathological effects, potentially affecting multiple biological 
processes and organs and eventually leading to animal death. 
 
 
 
4.2 Appropriate IRP1 regulation is necessary for body iron homeostasis 
 
4.2.1 IRP1* expression affects the expression of IRP targets and alters body iron 
distribution 
IRP1* alters the expression of IRP target genes (Fig. 3.11), although we noticed inter-
individual and tissue-dependent variability. Tissue-specific responses to high IRP1 activity as 
well as the different degree of gain of IRP1 function in different organs may account for the inter-
tissue variability of the expression of IRP targets.  
Expression of IRP1* causes iron accumulation in liver, spleen and duodenum (Fig. 3.12A). 
While the molecular mechanisms underlying iron deposition in IRP1* mice remain to be 
understood in detail, forced cellular iron accumulation entirely meets the predicted phenotype. 
Indeed, IRE-binding activity is normally increased to combat cellular iron depletion, thus 
artificial IRP activation is expected to elevate intracellular iron levels. Contrary to the IRP2 KO 
mouse phenotype where the spleen is iron-depleted, the splenic iron content of IRP1* mice is 
elevated, which correlates with a decreased expression of the iron exporter FPN. The latter is 
likely explained by stronger translational repression of the FPN mRNA, which is in agreement 
with high IRP activity and unchanged hepcidin expression. When IRP2 is ablated, liver and 
duodenum are iron-loaded and this is associated with higher ferritin levels (Galy et al., 2005b, 
2008). In mice with gain of IRP1 function, hepatic and duodenal iron accumulation is also 
associated with FTL upregulation. Sustained FTL expression in a context of high IRP1 activity is 
somewhat counterintuitive considering the IRP/IRE regulatory paradigm, which would instead 
predict repression of 5’IRE targets, such as FTL. While future work will have to dissect the 
molecular mechanisms underlying this unexpected response, lack of FTL repression concomitant 
with elevated IRP1 activity has already been reported in other experimental settings (Cairo et al., 
1997, 1998; Wang and Pantopoulos, 2002; Chen et al., 2007). IRPs translationally repress 5’IRE 
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targets by inhibiting the cap-dependent recruitment of the small ribosomal subunit (Muckenthaler 
et al., 1998). Sustained FTL expression in the liver and duodenum from IRP1* mice could 
possibly be explained by an alternative mechanism of cap-independent translation via the internal 
ribosomal entry site (IRES) recently found in the 5’UTR of FTL mRNA (Daba et al., 2012). 
Otherwise, ferritin turnover has previously been shown to be directly affected by iron levels, as 
ferritin protein levels linearly increase with iron influx, as a consequence of its reduced 
degradation (Truty et al., 2001). Conversely, ferritin is destabilized and degraded upon cellular 
iron depletion (De Domenico et al., 2006; Kidane et al., 2006). Hence, increased FTL protein 
levels in IRP1* mice could also be a consequence of reduced FTL degradation due to iron excess, 
both in the liver and duodenum.  
The exact molecular mechanisms underlying iron accumulation in the duodenum of IRP1* 
mice remain to be elucidated. Yet, several hypotheses can be entertained. For instance, duodenal 
iron loading could result from elevated TfR1-mediated serum transferrin-bound iron transport 
across the baso-lateral surface of enterocytes. This would be in agreement with increased levels of 
TfR1 found in the duodenum of IRP1* mice. However, intravenously administered 59Fe did not 
preferentially accumulate in the duodenum (Fig. 3.12C), which might show that duodenal iron 
loading is not associated with increased baso-lateral serum iron uptake. Perhaps more likely, the 
lack of radioactive iron accumulation in the duodenum might be a consequence of sloughing of 
duodenal mucosa during the two weeks following the 59Fe injection. In IRP2 KO mice, duodenal 
iron accumulation also seemed to be independent from TfR1 mediated serum iron uptake. Iron 
deposits were indeed restricted to the duodenal villi rather then the crypts (Galy et al., 2005b), 
where TfR1 is preferentially expressed (Roy and Enns, 2000). Alternatively, duodenal iron 
accumulation in IRP1* mice might also originate from elevated dietary iron absorption. This 
could in principle be explained by increased DMT1-mediated apical iron transport, which was an 
expected consequence of IRP1*-mediated stabilization of the DMT1 3’IRE-containing isoform. 
However, duodenal DMT1 was found not to be upregulated in IRP1* mice (Fig. 3.13). This might 
be explained by a superimposition of HIF2 mediated regulation. HIF2 is at the same time a 
transcriptional activator of DMT1 (Mastrogiannaki et al., 2009) and a target of IRP translational 
regulation (Sanchez et al., 2007b) (see 1.5.2). Conceivably, IRP1*-mediated repression of 
HIF2via its 5’IRE may account for a decrease of HIF2-mediated activation of DMT1, which 
might in turn predominate over the DMT1 mRNA stabilization by IRP1*. Ribosome profiling on 
sucrose density gradient analysis would be a good way to assess if HIF2mRNA is repressed in 
duodenal extracts from IRP1* mice. The latter would predict that HIF2mRNA is predominantly 
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localized in the subpolysome fraction of translational inactive mRNAs as opposed to the heavier 
ribosome-associated mRNAs. 
 
 
4.2.2 High IRP1 activity impairs normal erythropoiesis 
Mice with gain of IRP1 function display macrocytic anemia (Table 3.2) associated with 
impaired erythroid maturation (Fig. 3.16). Thus, an abnormally high IRP1 activity compromises 
normal erythropoiesis, which can in turn explain the macrocytosis by a release of abnormally 
differentiated erythrocytes into the circulation. The detailed mechanism underlying the 
hematological phenotype observed in IRP1* mice remains to be elucidated but it could be due to 
systemic and/or cell-autonomous defects, as following described. 
Example of a systemic defect that could potentially be involved in the etiology of 
macrocytosis is dietary malabsorbtion of either folate or vitamine B12. These are two important 
cofactors required for the maturation of red blood cells and their deficiency is commonly 
associated with macrocytic anemia (Koury and Ponka, 2004). To examine whether IRP1* mice 
appropriately acquire these two vitamins from the diet, folate and vitamin B12 serum levels could 
be measured. Alternatively, macrocytic anemia can also be associated with kidney failure (Suega 
et al., 2005), which results in the decreased production of erythropoietin (EPO) and the ensuing 
reduced stimulation of erythropoiesis. EPO expression in the kidney is under the positive 
transcriptional control of HIF2 (Scortegagna et al., 2003a, 2003b), being part of a loop that 
activates erythropoiesis in response to low tissue-oxygenation. HIF2 is in turn a target of IRP-
mediated translational regulation and its repression via 5’IRE is conceivable in a setting of high 
IRP1 activity (see 1.5.1). If IRP1* expression results in HIF2 downregulation, this may in turn 
impair HIF2-mediated induction of EPO expression in the kidney, resulting in reduced 
erythropoietic stimulus. EPO levels in the serum would need to be tested to further explore this 
hypothesis. 
However, an alternative hypothesis is that the macrocytic anemia of IRP1* mice is a cell-
autonomous defect. Indeed, the anemia seems to be independent of changes in systemic iron 
availability, as, under standard laboratory conditions, IRP1* mice show unchanged serum iron 
and ferritin level (Table 3.3) as well as normal hepcidin expression (Fig. 3.14). Generation of 
mice with erythroid-specific IRP1* expression would be a good way to test this hypothesis, as 
IRP1* expression limited to red blood cells might phenocopy the macrocytosis of IRP1* pan-
expressing mice. Otherwise, bone marrow transplantion could be used to demonstrate the cell-
autonomous nature of the blood defect. In that case, wildtype mice transplanted with IRP1* bone 
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marrow would be expected to recapitulate the macrocytic anemia. Alternatively, the anemia of 
IRP1* mice should be reverted following wildtype bone marrow transplantation. 
Assuming that the macrocytic anemia of IRP1* mice is a cell-autonomous defect, different 
hypotheses could explain the underlying molecular mechanism. In IRP2 KO mice, the microcytic 
anemia is associated with lower TfR1 levels (Galy et al., 2005b) and iron depletion in bone 
marrow iron (Cooperman et al., 2005). Conversely, we have shown that TfR1 expression on the 
cell membrane of erythroid progenitors from IRP1* mice is increased (Fig. 3.17). This finding 
points towards the possibility that the erythropoietic defect in the IRP1* mouse model is a 
consequence of increased iron uptake by erythroid precursors and ensuing iron toxicity. The 
opposite pattern of TfR1 expression could also account for the microcytosis of IRP2 KO mice and 
the macrocytic red blood cells in IRP1* mice. While alternative or additional explanations are 
possible, iron toxicity represents one of the potential causes of the defective erythropoiesis in 
IRP1* mice. FPN has recently been hypothesized to export iron also from erythroid cells (Zhang 
et al., 2011) and our data suggest that FPN tends to be diminished in IRP1* expressing tissues. If 
reduced FPN expression also applies to erythroid precursors, diminished iron export could 
contribute to intracellular iron toxicity. Erythroid 5-aminolevulinate synthase (eALAS), the 
enzyme catalyzing the rate-limiting step in heme biosynthesis, could also be implicated in the 
anemia of IRP1* mice (see 1.5.1). eALAS mRNA is translationally regulated by the IRP/IRE 
system and has previously been shown to be upregulated in erythroid precursors from IRP2 KO 
mice (Cooperman et al., 2005). If eALAS was translationally repressed via its 5’IRE in 
erythroblasts from IRP1* mice, an ensuing block of heme synthesis could contribute to toxic iron 
accumulation. This would also be consistent with the zebrafish shiraz model, where IRP1 over-
activation (secondary to GLRX5 deficiency) is demonstrated to cause anemia due to eALAS 
repression (Wingert et al., 2005). Furthermore, the 5’IRE target mitochondrial aconitase 
(mACO), an enzyme involved in the TCA cycle, could possibly also be downregulated by a gain 
of IRP1 activity. Interestingly, when mACO is pharmacologically inhibited by fluoroacetate, 
mice develop a hematological phenotype reminiscent of that of IRP1* mice (Talbot et al., 2011). 
Although the heme exporter FLCVR does not appear to be an IRP target, the hematological 
phenotype of IRP1* mice somewhat recalls the FLCVR KO model. There, heme toxicity has 
been hypothesized to cause the early erythropoietic blockade and ensuing macrocytosis (Keel et 
al., 2008). In principle, all these factors, involving different IRP targets, could act either in 
isolation or in combination to cause the macrocytic anemia of IRP1* mice. Prussian blue staining 
of bone marrow-derived cells could reveal the presence of iron accumulation, while isolated 
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erythroblasts could also be assessed for the level of the expression of each of the aforementioned 
IRP targets as well as for the presence of oxidative stress. 
 
 
 
4.3 The IRP1* model reveals a potential involvement of the IRP/IRE system in 
neuromuscular function 
 
Mice with gain of IRP1 function show altered motor coordination (Fig. 3.18) and 
endurance (Fig. 3.19), together with a defect in neuromuscular transmission (Fig. 3.21). Together, 
this potentially reveals a novel and intriguing role of the IRP/IRE system in neuromuscular 
function. While an understanding of the underlying mechanisms determining this phenotype 
require further in depth investigation, the neuromuscular defect of IRP1* mice could reflect a 
problem with structure/organization of the muscular fibers, mitochondria/energy metabolism or 
alterations at the neuromuscular junction. 
Regarding the possibility of a morphological defect, histological analysis of muscle fibers 
of IRP1* mice did not reveal any sign of structural alterations (see Appendix). This indicates that 
the neuromuscular defect of IRP1* mice cannot, at least, be attributed to gross dysmorphology of 
the muscles. 
IRPs strongly respond to iron fluctuation in skeletal muscle following dietary iron 
manipulation (Liew and Shaw, 2005), thus showing that the IRP/IRE system plays a role in this 
tissue. Additionally, IRP activation correlates with human myopathies due to defects in iron-
sulfur cluster assembly/disassembly and ensuing problems with energy metabolism or oxidative 
stress (Crooks et al., 2012) (see 1.5.4). In flies, muscle-specific overexpression of the homolog 
IRP1A is lethal (Lind et al., 2006). When human IRP1 was heterologously overexpressed in flies, 
it was coupled to 5’IRE-mediated translational repression of succinate dehydrogenase B (SDHb), 
which is part of the mitochondrial respiratory chain (Surdej et al., 2008). Given the importance of 
SDHb for mitochondrial energy metabolism, the authors speculated that IRP1A-mediated 
repression of SDHb in muscles was the main cause of flies’ lethality (Surdej et al., 2008). In 
humans, deficiency of SDH, together with decreased mACO, has been linked to lifelong exercise 
intolerance marked by premature muscle fatigue (Haller et al., 1991), which was later recognized 
as a myopathy due to iron-sulfur cluster assembly protein (ISCU) deficiency (Mochel et al., 2008; 
Olsson et al., 2008). This disorder shows that there is a correlation between severely impaired 
muscle oxidative phosphorylation and an abnormal response to physical exercise. However, 
nothing resembling an IRE sequence has been identified in the 5’UTR of mouse or human SDH 
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mRNAs, thus preventing any direct connection between IRP1* and SDH to explain the 
neuromuscular phenotype of IRP1* mice. Nevertheless, a direct connection with mACO could 
instead be drawn. In iron-deficient muscles, increased IRPs activity correlates with decreased 
levels of mACO function (Liew and Shaw, 2005), thus fitting with the paradigm of IRP-mediated 
translational repression of mACO via its 5’IRE (Gray et al., 1996). Furthermore, aberrant IRP 
activation has been recently shown in muscles from patients affected by myopathy with ISCU 
deficiency (Crooks et al., 2012). This pathology of exercise intolerance is also characterized by 
deficiency of mACO, as well as of several other Fe–S cluster containing proteins in the 
respiratory chain (Haller et al., 1991; Hall et al., 1993). IRP1*-mediated translational repression 
of mACO is conceivable in skeletal muscles from IRP1* mice and might directly interfere with 
muscular energy metabolism. 
 
The defect in neuromuscular transmission in IRP1* mice may also be explained by 
potential alterations at the neuromuscular junction, which is reminiscent of a mouse model with 
complete loss of superoxide dismutase (SOD1) (Missirlis et al., 2003; Clarke et al., 2006). SOD1 
catalyzes the conversion of O2- to H2O2 and O2, thus preventing oxygen toxicity. Mutations of 
SOD1 in mice cause marked denervation of the muscles, with distinct alterations of synaptic 
vesicles and mitochondria within the neuromuscular junctions (Cappello et al., 2012). SOD1 
mutant mice are largely used as models to study the inherited amyotrophic lateral sclerosis (ALS). 
In humans, ALS is a fatal adult-onset neurodegenerative disease characterized by loss of motor 
neurons and progressive muscle atrophy and paralysis (Dupuis and Loeffler, 2009). Of note, 
SOD1 deficiency in mice promotes cytosolic oxidative stress, damaging Fe-S clusters, including 
the one of cytosolic aconitase.  Hence, the consequent increase in IRP1 activity might potentially 
play a role in some of the neuromuscular defects observed in SOD1 mutant mice. 
Both ALS and ISCU deficiency, among other disorders of Fe-S cluster biogenesis, have shown a 
connection between dysfunction of the mitochondrial Fe-S cluster assembly machinery and 
abnormal IRP activation (see 1.5.4). In addition, mouse models with IRP deficiency have 
revealed a crucial role of the IRP/IRE system in securing mitochondrial function (see 1.5.3). In 
that context, it would be interesting to further investigate the IRP1* mouse model for the 
expression and activity of heme- and Fe-S cluster- enzymes involved in the TCA cycle and the 
mitochondrial respiratory chain. This could help to better define the apparent relationship 
between the mitochondrion and the IRP/IRE system and whether an adequate level of IRP 
activity is also important to secure mitochondrial function. Further exploration of the IRP1* 
mouse model, including electron microscopic analysis of muscles, has been initiated to assess 
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whether any alterations of the neuromuscular junctions and/or of mitochondria morphology could 
be revealed. 
 
 
 
4.4 Impact of IRP1*expression on acute or chronic iron loading 
 
During iron overload, downregulation of IRPs is a physiological response that cells activate 
to combat iron toxicity. We have shown that expression of IRP1* impairs the adaptive response 
to iron loading ex vivo. In iron overloaded cells from IRP1* mice, sustained IRP activity 
correlated with an altered expression pattern of IRP target genes (Fig. 3.23). The impact of IRP1* 
on the adaptation to iron loading ex vivo, prompted us to examine the response of IRP1* mice to 
in vivo challenges, such as acute and chronic iron loading. 
Pharmacological iron overload triggered a similar hepatic iron accumulation in wildtype 
and IRP1* mice (Fig. 3.27A). Lack of a cumulative effect of IRP1* on the degree of hepatic iron 
loading was expected due to the intrinsic characteristics of the experimental setting. The iron 
injected intravenously is indeed quickly absorbed by the liver, where it rapidly reaches a virtual 
plateau. However, due to increased IRP1 activity, we investigated the possibility that IRP1* mice 
would show an impaired capability to manage iron loading, potentially resulting in a higher 
oxidative insult. Our data show that while elevated levels of oxidative stress could be detected in 
the liver of iron-challenged wildtype and IRP1* mice, there was no detectable differential 
increase in the oxidative injury due to IRP1* expression (Fig. 3.27B). 
There are multiple factors that could explain the apparent lack of differential response to 
iron loading of IRP1* mice. First, the dose of iron injected could be a critical parameter if we 
assume that a possible effect of IRP1* could only be detectable over a certain range. For instance, 
the amount of iron injected could have been excessive and lead to saturation of the system, hence 
masking any possible contribution of IRP1*. Conversely, the dose used could have been too low 
to trigger a differential response in IRP1* mice. A possible way to discern between these two 
options would be analysing the response of IRP1* mice to a range of different doses of iron. 
Furthermore, the increase in complexity that is added when moving from the ex vivo to the in 
vivo setting is not neglectable. In vivo, the significant gain in systemic networks and buffer 
mechanisms, which are lost in the ex vivo culture, may be responsible for counterbalancing any 
potential effect triggered by IRP1*. For instance, the increase in FTL observed in the liver of 
IRP1* mice kept under standard laboratory conditions was not reproduced on ex vivo cultures of 
BMDM isolated from IRP1* mice. In vivo, a potential mechanism of cap-independent translation 
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of FTL, via its recently discovered IRES (Daba et al., 2012), could compensate for an increased 
tendency of FTL translational repression driven by IRP1*. This would eventually result in a net 
increase of safe iron storage into ferritin shells, thus protecting the hepatocytes from iron-
mediated oxidative stress. The levels of FTL could be measured to verify a possible differential 
increase of FTL in the liver of iron-loaded IRP1*. Besides, the liver, as an iron-storage organ, is 
specialized to handle a sudden burst of iron, which might mask any possible IRP1* contribution. 
Moreover, together with the kidney, the liver of IRP1* mice is the organ that displays the mildest 
gain of IRP function under steady state condition. In addition, IRP1* contains a mutation of a 
cystein shown to be important for iron-mediated degradation of IRP1 (R.S. Eisenstein, 
unpublished findings). However, ex vivo iron loaded BMDM from IRP1* mice revealed that 
IRP1* expression was partially impaired upon hemin-treatment (Fig. 3.24), indicating that the 
mutant IRP1* protein may not be fully resistant to iron-mediated degradation. Therefore, we 
cannot exclude a potential further decrease in the degree of hepatic gain of IRP function 
following IRP1* partial degradation upon acute iron loading. Potentially, analysis of other organs 
that are more sensitive to iron overload, as well as displaying a higher gain of IRP1 function, 
could still reveal a role for proper IRP1 regulation in response to iron loading in vivo.  
As in the acute iron challenge, the exploration of the response of IRP1* mice to chronic 
iron loading will benefit from further investigation. Secondary iron overload was generated in 
IRP1* mice by concurrent HFE ablation. HFE is part of a sensory complex responsible for 
activation of hepcidin negative response to systemic iron loading (Vujić Spasić et al., 2008). 
IRP1* mice have shown, under standard conditions, elevated TfR1 expression in the liver (as 
result of increased IRP-mediated TfR1 mRNA stabilization). Despite the basal tendency of 
hepatic TfR1 levels to be elevated, the liver of chronically-iron overloaded IRP1* (or IRP1*/HFE 
KO) mice does not accumulate more iron than single HFE KO mice (Fig. 3.28). The lack of 
aggravated hepatic iron loading in IRP1*/HFE KO mice might relate to the nature of iron that is 
normally accumulated in the hepatocytes from HFE KO mice. In fact, iron overload in HFE KO 
mice leads to an over-saturation of serum transferrin, with a consequent accumulation of non-
trasferrin-bound-iron (NTBI). NTBI is then taken up by the liver via, yet to be determined, TfR1-
independent mechanisms (Chua et al., 2004). Despite an apparently non-aggravated iron overload 
as compared to the single HFE KO mouse, further analyses need to be carried out to address 
whether IRP1*/HFE KO mice are more sensitive to the pathological consequences of chronic iron 
loading. This will include assessment of oxidative stress markers in different organs, such as liver 
and heart, which are the organs that most typically suffer failure due to chronic iron loading 
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(Camaschella, 2005). Related to that, serum markers of organ dysfunction could also be 
measured. 
Importantly, the HFE KO is a mouse model of hereditary hemochromatosis (HH), which is 
a frequent human disorder of systemic iron overload in the Caucasian population (see 1.2.2). The 
most common HFE-related HH occurs in approximately 1 in 400 individuals and has an estimated 
carrier frequency of 1 in 10 individuals of Northern European descent (Feder et al., 1996). The 
HFE mutant allele has typically low penetrance, which implies that other genetic and/or 
environmental factors can influence the development of the disease (Deugnier and Mosser, 2008). 
Given the prevalence of the disease, an increasing field of research is directed to finding possible 
“modifier genes” that, if co-occurring in combination with the HH mutations, could trigger the 
manifestation of the disease. In this context, we analyzed whether gain of IRP1 function could be 
able to modify the HFE phenotype. The results showed that compound mutant IRP1*/HFE KO 
mice have a similar increase in serum iron and ferritin levels (Table 3.4), transferrin saturation, as 
well as hepatic iron loading (Fig. 3.28) (which are the distinctive characteristics of the single HFE 
KO model).  
Overall, our current data show that IRP1*/HFE KO mice largely phenocopy the hallmarks 
of HFE-driven systemic iron overload, thus suggesting that gain of IRP1 function does not 
influence the typical alterations caused by HFE ablation per se.  
 
 
 
4.5 Concluding remarks 
 
The IRP/IRE system has fascinated researchers in the iron metabolism field since its 
discovery over 20 years ago for its sophisticated mode of securing proper cellular iron balance by 
post-translational regulation of iron metabolism genes. During the last decade, the IRP/IRE 
system has increasingly emerged as complex homeostatic machinery whose action extends to 
pathways beyond iron metabolism and the cellular boundaries. The generation of genetically 
modified mice carrying single or double deletions of the IRP genes has been pivotal for the 
understanding of the critical influence of the IRP/IRE system in the function of  key organs of 
iron metabolism (LaVaute et al., 2001; Galy et al., 2004, 2005a, 2008, 2010; Meyron-Holtz et al., 
2004a; Smith et al., 2006; Ferring-Appel et al., 2009). However, fundamental questions about the 
relevance of adequate IRP1 regulation and activity have remained unanswered mainly because of 
the lack of a suitable model system. The work described in this thesis presents the IRP1* mouse, 
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which embodies the first model of primary and inducible gain of IRP1 function in a mammalian 
organism. Complementing the findings obtained from the mouse lines with loss of IRP function, 
the IRP1* model provides the perfect ground for better understanding the significance of 
adequate IRP regulation in vivo. The results have shown that appropriate IRP1 activity is 
important for the maintenance of physiological body iron distribution and for normal 
erythropoiesis. Intriguingly, deeper phenotypic exploration of IRP1* mice uncovered a novel role 
of the IRP/IRE system in neuromuscular function. This is particularly captivating as IRP1 
overactivation, concurrent with mitochondrial dysfunction, is a common denominator of a 
number of human neurodegenerative disorders. Deeper exploration of the IRP1* model may thus 
have profound implications on our understanding of the molecular etiology of human diseases 
such as sideroblastic anemia linked to GLRX5 deficiency (Camaschella et al., 2007) or 
Friedreich’s ataxia (Lobmayr et al., 2005). 
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6. APPENDIX 
 
 
 
This chapter includes experiments that were performed at the Mouse Clinic Institut (ICS, 
Strasbourg) and are not shown in the main body of this thesis. The description of the experimental 
procedures as well as of the data has been adopted from a written report provided by the ICS. 
 
 
6.1 STUDY DESIGN 
 
A first cohort of mice was used for metabolic and cardiac exploration, as well as for blood 
analysis. This pipeline was constituted of 36 mice, 18 wild type control mice (WT) (9 males and 9 
females) and 18 IRP1* mice (9 males and 9 females) fed with a standard chow diet. Body weight 
and food intake were recorded once a week from the age of 10 to 18 weeks. At the age of 10 
weeks, body composition (lean, fat and free body fluid content) was evaluated on conscious mice 
by quantitative nuclear magnetic resonance (qNMR). At the age of 11 weeks mice were housed 
individually in TSE cages for evaluation of energy expenditure by indirect calorimetry. At the end 
of the experiment, 48 hours feces were collected for evaluation of the food efficiency by a 
calorimetric bomb. Cardiac electrical activity was assessed by electrocardiography (ECG) at the 
age of 12 weeks. 3 weeks later, an oral glucose tolerance test (OGTT) was performed after 16 
hours fasting. At the age of 17 weeks, insulin sensitivity was evaluated by an intraperitoneal 
insulin sensitivity test (IPIST) after 2 hours fasting. At the end of the study (at 19 weeks of age) 
blood was collected on 4h fasted mice by retro orbital puncture under isoflurane anaesthesia. 
Mice were sacrificed for visual inspection and measurement of body weight and body length. 
 
For the neurobehavioral assessments, a second cohort of 12 WT and 12 IRP1* male mice 
was used. Following their arrival to the testing area, animals were group housed in MICE cages 
and maintained in a room with controlled temperature (21-22°C) under a 12-12 light-dark cycle 
(light on at 07 a.m.), with food and water available ad libitum. All experiments were carried out 
in accordance with the European Communities Council Directive of 24 November 1986. 
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6.2 MATERIALS AND METHODS 
 
6.2.1. Body weight, food intake and body composition 
Body weight and food intake were recorded once a week from the age of 10 to 18 weeks. 
qNMR analysis was performed at 10 weeks of age to give precise analysis of the body 
composition for fat content, lean tissues and free body fluid. The was conducted using a the 
Minispec+ analyzer (Bruker) by Nuclear Magnetic Resonance (NMR) and during light period on 
conscious fed mice. 
 
6.2.2 Energy expenditure 
Energy expenditure was evaluated at 11 weeks of age through indirect calorimetry. Oxygen 
consumption was assessed with an open flow respirometric system (TSE system, Labmaster, 
Germany). The system contains CO2 and O2 sensors to measure the difference in CO2 and O2 
concentrations in air volumes flowing through control or animal cages. The amount of oxygen 
consumed over a given period of time was calculated, knowing the volume of the air flow. Data 
from gas exchange were expressed as Kcal/h/kg^0.75. CO2 production was also monitored and 
both the respiratory exchange ratio (RER; which define fuel preference between glucose and lipid 
metabolism) and heat production (Kcal/h/kg^0.75) calculated. An activity and food intake 
monitoring system was integrated to measure activity and feeding/drinking behaviors, which are 
involved in the energy expenditure. Following a 24h-acclimatization period, the experiment was 
performed over 24 hours, overlapping both with light period of day 1 and day 2 (from 3:00pm 
Day 1 to 3:00pm Day 2), under a 12h light: 12h dark photoperiod, at ambient temperature (21°C 
± 2). 
 
6.2.3 Calorimeter bomb 
 The feces were collected during 48 hours at the age of 11 weeks in the TSE cages. The 
energy content of the stools was evaluated in a bomb calorimeter (C503 control, IKA). The 
sample was burned in an oxygen-rich atmosphere inside a sealed chamber surrounded by a jacket 
containing a known volume of water. The rise in temperature of the water was recorded and used 
to calculate the amount of heat produced. The assay was performed on stools to evaluate the 
energy digested by mice and then, indirectly, the intestinal function. The energy digested was 
calculated by the difference between the total calories ingested and excreted in feces and 
expressed as “food efficiency”. 
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6.2.4 Oral glucose tolerance test with insulin measurement  
An oral glucose tolerance test was performed at 15 weeks of age to evaluate the regulation 
of the glycemia. Acute hyperglycemia was induced by administration of a standardized glucose 
bolus (2g/kg). The glucose was administrated by oral gavage and blood glucose measured at 
different time points, over 180 minutes after the administration, using blood glucose monitor and 
glucose test strips (Roche Diagnostics, Accu-Chek). Tail bleeding was performed to collect blood 
measurement of the plasmatic insulin level at T0, T15 and T30 minutes after glucose 
administration. The test was conducted during the light period, after overnight fasting (16h fasted 
mice). 
 
6.2.5 Intra peritoneal insulin sensitivity test 
An intra peritoneal insulin sensitivity test was performed at 17 weeks of age to measure the 
regulation of the glycemia after administration of a standardized insulin load (0.5 UI/kg). The 
insulin was administrated by intraperitoneal injection and blood glucose measured at different 
time points over 90 minutes after the administration, using blood glucose monitor and glucose test 
strips (Roche Diagnostics, Accu-Chek). The test was conducted during the light period, after 2h 
fasting. 
 
6.2.6 Blood analysis 
Blood was collected by retro orbital puncture under isoflurane anesthesia after 4 hours 
fasting, at the age of 19 weeks. Blood chemistry was performed on an OLYMPUS AU-400 
automated laboratory work station (Olympus France SA, Rungis, France) using commercial 
reagents (Olympus Diagnostica GmbH, Lismeehan, Ireland). A complete blood count was 
performed on an Advia 120 Vet. (Siemens). All the data are expressed as mean +/- SEM. All 
comparison between IRP1* and WT mice were performed using Anova test followed by a 
Student t test. A statistically significant difference was considered for p<0.05. 
 
6.2.7 Gross neurological examination 
The general health and basic sensory motor functions were evaluated using a modified 
SHIRPA protocol (EMPReSS, eumorphia.org). This analysis provides an overview of physical 
appearance, body weight, body temperature, neurological reflexes and sensory abilities. 
Spontaneous activity was measured using 24 individual boxes equipped with infra-red captors 
allowing automatic measurement of ambulatory locomotor activity and rears (Imetronic, Pessac, 
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France). Mice were tested for 2 hours and the evolution of global locomotion and rears was 
followed per 10-min bins over the testing period. 
 
6.2.8 Open field test 
The openfield test allows evaluation of anxiety and exploratory drive. Mice were tested in 
automated open fields (Panlab, Barcelona, Spain), each virtually divided into central and 
peripheral regions. The open fields were placed in a room homogeneously illuminated at 150 
Lux. Each mouse was placed in the periphery of the open field and allowed to explore freely the 
apparatus for 30 min, with the experimenter out of the animal’s sight. The distance traveled, the 
number of rears, and time spent in the central and peripheral regions were recorded over the test 
session. The latency and number of crosses into as well as the percent time spent in center area 
were used as indices of emotionality/anxiety. 
 
6.2.9 Histology 
For histopathological analysis, heart, anterior tibialis and gastrocnemius + soleus muscles 
were collected on 6 mice per group. All tissues were paraffin embedded and hematoxilin-heosin- 
(HE) stained. 
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6.3 RESULTS 
 
6.3.1 Body weights and food intake 
Body weights tended to be lower in IRP1* mice than in the controls; however the 
difference was not significant between IRP1* and WT mice (in both genders) (Fig. 6.1a, top). The 
food intake tended to be slightly lower in IRP1* mice than in the controls; however the difference 
was not significant between the 2 groups (Fig. 1a, bottom). 
 While body weights were comparable, IRP1* mice showed a slight increase in the 
percentage of fat; however their fat mass in gram was comparable to the controls. Lean and free 
body fluid content were not significantly changed in male IRP1* mice. Female IRP1* mice did 
not showed any significant change in their body composition (lean, fat and free body fluid 
content). (Fig. 6.1b) 
 
 6.3.2 Energy expenditure, activity, food and water intake  
Oxygen consumption, RER and heat production were not significantly changed in female 
IRP1* mice. Male IRP1* mice showed a slight increase in oxygen consumption and in heat 
production only during the light period, which could be considered as a physiological change 
(Fig. 6.a). Ambulatory activity was comparable between IRP1* and WT mice (Fig. 6.2b). Food 
and water consumption were also similar (Fig. 6.2c).  
 
6.3.3 Calorimetric bomb 
The feces energy content, the total energy excreted and ingested by day and the food 
efficiency were similar between IRP1* and WT mice (Fig. 6.3). 
 
6.3.4 Oral glucose tolerance test 
 After 16 hours fasting, body weights were similar between IRP1* and WT mice. All the 
parameters of the OGTT were comparable between IRP1* and WT mice. Time 0 glucose and the 
area under the glucose curve (AUC) were not significantly changed in IRP1* mice (Fig. 6.4a). 
Insulin levels at time 0, 15 and 30 minutes were also similar between IRP1* and WT mice (Fig. 
6.4b).  
 
6.3.5 Insulin sensitivity test 
 At the age of the test, body weights were similar between IRP1* and WT mice. T0 glucose 
levels and the slope of glucose decrease during the IPIST were similar between male IRP1* and 
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WT mice (Fig. 6.5, left). T0 glucose levels were similar between female IRP1* and WT mice; 
however the slope of glucose decrease after insulin injection was slightly higher in female IRP1* 
mice than in the controls (Fig. 6.5, right). 
 
6.3.6 Blood analysis 
Erythrocytes number was significantly lower in male and female IRP1* mice than in the 
controls. In addition hemoglobin, and hematocrit levels were decreased in IRP1* mice, while the 
MCV was higher in IRP1* mice than in the controls (Fig. 6.6a). 
Regarding blood chemistry parameters and enzymatic activities: glucose, total, HDL and 
LDL cholesterol, triglycerides, free fatty acids (FFA), and glycerol levels were comparable 
between IRP1* and WT mice (Fig. 6.6b).  
 
6.3.7 General health and specific motor abilities 
IRP1* males had good general health, showing normal body weight, normal body 
temperature and locomotor activity (Fig. 6.7). Gross neurological evaluation of mice did not 
reveal any obvious sign of altered sensory or vestibular functions in IRP1* mice (not shown).  
 
6.3.8 The openfield test 
In the openfield test, overall locomotor activity and rears were comparable between WT 
and IRP1* males (t22≤0.72, NS) (Fig. 6.8, top). Exploration of the central part of the openfield 
arena (% time in the centre and the number of entries) was also comparable between genotypes 
(t22≤0.99, NS), suggesting that IRP1* did not affect anxiety in this test (Fig. 6.8, bottom). 
 
6.3.9 Histology 
No significant microscopic lesions were detected in any of the organs proposed for 
analysis. As to skeletal muscles (Fig 6.9), the diameter of the fibers was equivalent in IRP1* mice 
compared to controls; nuclei were peripheric, and striation was present. No significant interstitial 
inflammation was detected.  
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6.4 CONCLUSION 
 
Mice with gain of IRP1 function did not display major changes in body weight, body 
composition, energy expenditure and food efficiency. Their glucose metabolism did not appear 
significantly modified and no changes were observed in their circulating lipid levels. IRP1* mice 
displayed a macrocytic anemia. General health, spontaneous locomotor activity and anxiety 
related behavior were not affected in IRP1* mice under the experimental conditions. No major 
lesions were detected in any tissues submitted for analysis. 
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6.5 FIGURES 
 
Figure 6.1a 
 
 
Figure 6.1b 
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Figure 6.2a 
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Figure 6.2b 
 
 
Figure 6.2c 
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Figure 6.3 
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Figure 6.4a 
 
Figure 6.4b 
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Figure 6.5 
 
 
Figure 6.6a 
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Figure 6.6b 
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Figure 6.7 
 
 
Figure 6.8a 
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Figure 6.8b 
 
 
Figure 6.9 
 
6. APPENDIX
   
 143
   
 144
   
 145
7. PRESENTATIONS AND PUBLICATIONS 
 
 
 
7.1 PRESENTATIONS 
 
 
D. Casarrubea, L. Viatte, R. Eisenstein, B. Galy, M. W. Hentze. “Generation of a mouse 
strain with inducible IRP1 overexpression: a new model for understanding iron metabolism 
disorders” International Bioiron Society (IBIS) meeting, June 2009, Porto. Poster presentation. 
 
 
D. Casarrubea, L. Viatte, R. Eisenstein, B. Galy and M.W. Hentze. “A new mouse model 
with gain of IRP function to investigate the in vivo role of the IRP/IRE system in normal and 
pathological iron metabolism. European Iron Club (EIC), Nijmegen 2010. Poster presentation. 
 
 
Daniela Casarrubea, MS, L. Viatte, T. Hallas, A. Vasanthakumar, R. Eisenstein, K. 
Schümann, B. Galy and M.W. Hentze. “A new mouse model with gain of IRP function to 
investigate the in vivo role of the IRP/IRE system”. International Bioiron Society (IBIS) meeting, 
May 2010, Vancouver. Podium presentation. 
 
 
 
7.2 PUBLICATIONS 
 
 
Most results presented in this dissertation are part of a manuscript submitted for publication 
and currently under review process. Some text passages of the submitted manuscript have been 
adopted in this dissertation. 
7. PRESENTATIONS AND PUBLICATIONS
   
 146
 
   
 147
8. ACKNOWLEDGEMENTS 
 
 
 
I want to thank all the people who contributed to the success of this work. 
 
 
First of all, I like to thank Matthias for giving me the possibility to do my PhD in such a great 
research institute as EMBL. In particular, I want to thank him for his faith and great 
encouragement over the last years. 
 
I am especially indebted to Bruno, for his interest in my work, his inspiration, his suggestions and 
the time he took for discussion. 
 
 
Many thanks to Darren Gilmour, François Spitz and Klaus Unsicker, who followed with interest 
the development of my work throughout these years. 
 
I would like to thank Ralf Bartenschlager for kindly taking part to my thesis defense committee. 
 
 
I want to acknowledge the laboratory of animal resources (LAR) and the transgenic service. In 
particular I would like to thank Conny Henkel for taking daily care of our animals and Klaus 
Schmidt for being always so eager to help with mouse experiments. The flow cytometry facility, 
and in particular Alexis, helped a lot for part of this work. 
 
I also want to thank S. Srinivas for donation of the plasmids pBigT and pROSA26PA, as well as 
Maja Vujić and Martina Muckenthaler for the kind gift of the HFE mouse line. 
 
Thanks to our collaborators Rick Eisenstein, Klaus Schuman, the ICS and prof. J.H. Groene for 
sharing their expertise and for their contribution to this work. Also, I want to thank Lydie Viatte 
who started this project before my arrival to the lab. 
 
 
8. ACKNOWLEDGEMENTS
   
 148
If the experimental work was particularly challenging, I was glad that I could always count on 
Dunja for technical assistance and for sharing all her tips and tricks. I would also like to thank 
Sandro, who even from downtown was so open for discussion and help. 
 
 
I am grateful to all the people who proof-read my thesis and gave useful comments, including 
Bruno, Matthias, Elli, Rasti, Suzie, Per, Dunja, Amy, Robert and Rodolfo. In particular, I am 
thankful to Suzie for her critical support during this last intense lap of my PhD, for very useful 
discussion and help. Also, I want to thank Bene for translating the summary of this thesis into this 
evil language (a.k.a. German). 
 
Alongside, I would like to thank all the previous and current members of the Hentze lab, for the 
science they shared but also for the friendship and the great atmosphere they created in the lab. 
Among the previous, I want to especially thank Francesca and Aurelie, and among the current 
ones I cannot fail to mention Alfredo, since he showed me that “he has changed”. Thanks all of 
you for the crazy and fun atmosphere of the “main lab” (V211), and also of the other lab V210 
(now it’s stated in an official document). 
 
My stay in Heidelberg would not have been so enjoyable and unique if I had not met nice people 
with whom I shared friendship, trips, troubles and parties. Among those, I want to especially 
thank my great friends Francesca, Luca, Angelica and Andreas. Also, it was great to share, among 
other things, a passion for swing dance with my friends Erika and Enrico. I want to thank all the 
predocs of my year, for the fun and trips, as well as my dear roomies, Johanna, Esme and Caro, 
for being so incredibly caring and supportive like a real family. 
 
 
These last six months would have been much harder if Per was not next to me, with all his 
affection, great support, patience and encouragement. Thanks so much. 
 
 
Grazie a mia madre, per la sua testarda irragionevolezza nel continuare a credere in me. 
8. ACKNOWLEDGEMENTS
   
 149
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work was partially supported by an EEC FP6 grant (LSHM-CT-2006-037296 Euroiron1) and a Virtual 
Liver Network grant (funding number 315740) to M.W.H.. 
